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"Sight is our most precious sense, and any 
diminution of it is regrettable. Our eyes alone 
save us from perpetual darkness, and they fill 
our lives with all the glory of creation. They 
enable us to scan the vast sweep of the universe 
a million light years away, or examine the minute 
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Inherited retinal degenerative disorders are a common cause of severe yisual 
dysfunction. Retinitis pigmentosa (RP) comprises of a group of retinopathies 
characterised by a progressive loss of photoreceptor and retinal pigment 
epithelium function. Over the past decade numerous RP-causing genes and loci 
have been identified. 
The study of a South Mrican (SA) family with autosomal dominant RP (ADRP) 
fonns the subject of this dissertation. The initial and most ascertainable clinical 
manifestation of the disorder is night-blindness and is usually evident before 10 
years of age. Disease severity correlates with progressive and diffuse retinal 
pigmentation in affected family members. 
Following recruitment and clinical investigation of members of the large family, 
genetic linkage analysis facilitated the localisation of the disease phenotype to a 
23 cM interval on chromosome 17p13 (RP13), the seventh locus identified for 
ADRP. Recruitment of additional members of the family, with a series of 
subsequent Inultipoint linkage analyses and haplotype construction, facilitated 
the fine mapping of RP13 to a 3 cM region between microsatellite markers 
Dl 7S1529 and D17S831 on chrompsome 17p13.3. An additional two RP13­
linked families (from the UK and USA) mapped to this locus in subsequent 
independent studies. Although the families share a common ancestry, the UK 
family does not share the same disease-associated haplotype (the family from 
the USA was not available for testing). 
Five genes which were considered to be functional candidates and which map to 
chromosome 17p, were screened for mutations in members of the RP13-linked 
SA family. The genes investigated were: recoverin (RCV1) retinal guanylate 
cyclase (RETGC-l), phosphatidylinositol transfer protein (PITPN), pigment 
epithelium-derived factor (PEDF) and beta arrestin 2 (ARRB2). These candidates 
were chosen on the basis of map position on chromosome 17p, expression in the 
r~tina and/or involvement in the rod phototransduction cascade. 
Recombination events between the ADRP locus and a microsatellite 
polymorphism in RCVl provided evidence for the exclusion of this gene. Direct 
sequence analysis of the coding regions of RETGC-l and ARRB2 in affected 











1 was excluded based on reported fIndings which, implicated the gene in the 
pathogenesis of Leber's congenital amaurosis (LCA), a condition which mapped 
centromeric to the RP13 interval (Perrault et al., 1996). ARRB2 was placed 
centromeric to the RP13 interval based on radiation hybrid mapping studies as 
shown at the GeneMap98 internet site. Direct DNA sequencing of the coding 
regions of PITPN and PEDF including the intron-exon boundaries revealed no 
potential disease-causing alterations. Genetic mapping strategies did however, 
place these genes into the RP13 critical interval. These fmdings were supported 
by additional data which suggests that PITPN and PEDF reside on a physical 
clone contig within the RP13 critical region. The, results of several mutation 
detection techniques, including direct sequencing suggested that PITPN and 
PEDF are unlikely to be responsible for the ADRP phenotype in the RPl3-linked 
SA family. 
In a further effort to identify the RP13 gene an attempt was made to construct a 
physical map of the deduced 3cM critical region. To this end a megaclone contig 
comprising seven yeast artifIcial chromosomes (YACs) and three PI artifIcial 
chromosomes (PACs) using sequence-tagged-site (STS) content mapping was 
constructed. Furthermore, a partial physical sequence contig comprising eight 
sequence flles were assembled. The m~gaclone and electronic sequence contigs 
provide the valuable tools necessary for the purpose of isolating new genes 
within the RP13 genetic interval. In this regard, the sequence flles were 
interrogated for transcription units within the interval. Sequence comparisons 
were performed between these units and the eye subset of the STACK EST 
databas,e. Using this approach the known retinal genes PEDF and PITPN were 
identifIed, together an additional retinally expressed gene, PRP8, and other novel 
transcripts. 
The fIndings presented in this dissertation will contribute to the increasing 
knowledge on inherited retinal degenerative disorders. Moreover, this 
investigation should provide the basis for further study of the aetiology of RP in 
all families linked to the RP13 locus on chromosome 17p13. The short term 
J 
application of the molecular fIndings is the potential for pre-symptomatic testing 
of at-risk members from the family. In the long term it is possible that the 
fIndings presented will form the foundation for understanding the genetic and :, 
biological causation of disease in the large SA and other RPl3-linked families;' 
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PLAN OF THESIS 

This dissenation is divided into five chapters and the layout is as follows: 
Chapter One provides a background to the anatomy of the eye and the biology of 
vision. It provides a review of hereditary retinal degenerative disorders. focussing 
on retinitis pigmentosa (RP). A synopsis of the development of RP research in 
South Africa is provided, and includes an outline of the aims and objectives of the 
study. 
Chapters Two, Three and Four contains experimental details. Each ofthese 
chapters is divided into four sections i.e. Introduction, Materials & Methods. 
Results and Discussion. Chapter Two describes the genetic linkage study 
undenaken in a large South African family in order to map the gene underlying an 
autosomal dominant form ofRP. Chapter Three outlines the investigative 
approach used to screen the potential and functional candidate genes for RP 13. 
Chapter Four deals with the construction of a physical map of the RP13 locus. In 
addition, this chapter describes the approach used towards the generation of a 
transcription map for this region. 
While the conclusions drawn for each aspect of this study are discussed at the end 
of the relevant Chapter, Chapter Five provides a final comment on each of these 


















1.1. REVIEW OF INHERITED RETINAL 
DEGENERATION 
1.1.1. INTRODUCTION 
Retinal degeneration (RD) leading to either partial or complete blindness, 
is the consequence of a very heterogeneous group of conditions. Early 
family studies revealed that RD could be inherited in dominant, recessive 
and X-linked modes. Later, molecular analysis of these disorders showed 
further genetic heterogeneity existed within each group. A subset of the 
hereditary forms of retinal degeneration, namely, retinitis pigmentosa 
(RP), in the South African context forms the subject of this thesis. 
RP is caused by mutations in several genes, however, because the 
disorder in several families remains unmapped, it is likely that many 
additional genes which cause RP, exist. The identification of the entire 
set of RP-causing genes requires considerable effort. The exercise will 
nevertheless be valuable as the discoveries may represent a valuable step 
towards understanding the pathogenic mechanisms underlying RP. 
Molecular genetic studies will also contribute increasingly to the clinical 
diagnosis, management and treatment of patients with RP, the ulti~ate 











In this introductory chapter the anatomical structures underlying vision, 
the process of visual transduction and the genetics of RP is reviewed in 
order to provide a perspective for the investigations trends in this thesis. 
1.1.2. THE STRUCTURE OF THE EYE 
A description of the general structure of the "eye essentially as outlined in 
Ross and Romrell (1989) is provided as a backdrop to retinal disorders. 
The eye is made up of three separate concentric layers (figure 1. 1.): 
• 	 an outer layer, the corneoscleral coat, which consists of the sclera 
and cornea; 
• 	 a middle layer, the uvea, consisting of the choroid, ciliary body, and 
iris; 
• 	 the innermost layer, the retina, which consists of an outer pigment 
epithelium (PE) and an inner neural retina. 
The eye is a specialised organ of photoreception, a process that involves 
the conversion of light energy into nerve action potentials. The 
photoreceptors consist of two types of nerve cells, the rods and cones. 
These rod and cone receptors and a system of integrating neurons are 
located in the inner layer of the eye, the retina. The remaining structures 
of the eye serve to support the retina. In addition, there are several 
accessory structures, namely the eyelids, lacrimal gland and 
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Figure 1.1 Schematic diagram of the layers of the eye. 











1.1.2.1. The Corneoscleral Coat 
The corneoscleral coat forms a tough fibro-elastic support capsule 
around the eye. The posterior section, the sclera, is opaque and provides 
an anchor for the extra-ocular muscles. The anterior section, the cornea, 
is transparent and is the principle refracting medium of the eye. It 
roughly focuses an image onto the retina. 
1.1.2.2. The Uvea 
The uveal tract is a vascular layer made up of the choroid, ciliary body 
and the iris. The choroid lies between the sclera and the retina in the 
posterior section of the eye. It provides nutritive support for the retina 
and is heavily pigmented in order to absorb light which enters the eye. 
\ 
Anteriorly, the choroid merges with the ciliary body, which is muscular 
and controls the shape of the lens. The iris, which extends in front of 
the lens from the ciliary body, is highly pigmented and adjustable in 
order to regulate the amount of light reaching the retina. 
1.1.2.3. The Retina 
A more detailed review of the structure of the retina is provided since 
this is the primary tissue which is diseased in persons with RP. Nerve 
fibres from the retina converge to form the optic nerve, which leaves the 
eye through a part of the sclera known as the lamina cribrosa. The 
function of the retina is to send appropriate signals to the brain, via the 
optic nerve, in response to light entering the eye. 











distribution of the various cell types of the retina is illustrated in figure 
1.2. There are two layers within the retina: (i) the neural retina, and (ii) 
the retinal pigment epithelium (RPE). 
The neural retina consists of two regions that differ in function, based on 
their response to light (i) a photosensitive and (ii) a non-photosensitive 
region. 
(i)The photosensitive region lines the whole inner surface of the eye, 
(except where it is pierced by the optic nerve) and is composed of 
photoreceptor cells. The rod and cone photoreceptors are specialised 
nerve cells that convert photons into nerve signals (figure 1.3.). Cone 
cells provide colour vision and are most concentrated at the fovea which 
is located at the centre of the macula. Rod cells are more sensitive to 
light than cones, but provide essentially black and white vision. 
Rod cells are long slender bipolar cells, which extend beyond the outer 
limiting membrane (figure 1.3.). Rod cells consist of three parts: 
• 	 The outer segment which is closely associated with projections from 
the adjacent RPE and contains an array of horizontal membranous 
discs. The discs incorporate the pigment rhodopsin, which is involved 
in the first step of the visual pathway. These discs are continuously 
phagocytosed by the cells of the PE at one end of each rod and 
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• 	 The stalk which is a strand of cytoplasm containing nine microtubule 
doublets and joins the inner and outer segments. 
• 	 The inner segment which is associated with a cell actively 
synthesising proteins. This section contains a prominent golgi 
apparatus and many mitochondria. 
Cone cells are similar in basic structure to the rods but differ in several 
respects : 
• 	 The outer segments of cone cells are long conical structures about 
two-thirds the length of a rod . The membranous discs are flatter than 
those in rod cells and are continuous with the plasma membrane so 
that on one side, the spaces between the discs are continuous with 
the extracellular matrix (figure 1.3 .). The discs are not replaced on a 
regular basis . 
• The inner segments are continuous with the bodies of cone cells. 
The outer segments house the photosensitive pigment cells, while inner 
segments contain components for metabolic processes, which provide 
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(ii) The non-photosensitive region lines the inner aspect of the ciliary 
body and the posterior surface of the retina and is composed of the 
following cell types: 
Direct conducting neurones: bipolar cells are the most numerous of the 
direct conducting neurones and in general they make direct connections 
between one or more photoreceptors and one or more optic tract> 
neurones. The cell bodies of the optic tract neurones or ganglion cells 
comprise the ganglion cell layer (figure 1.2.). 
Association and other neurons: horizontal cells are neurons involved in 
processes making connections between adjacent and more distal rods 
and cones. The amacrine cells are neurons, which form connections 
with bipolar and optic tract neurones as well as making occasional 
feedback connections with the ph toreceptors. 
Supporting cells: An elongated support cell extends between inner and 
outer limiting membranes (figure 1.2.). These are called MOller cells 
which have long cytoplasmic processes that embrace and sometimes 
encircle the retinal neurones, filling all the intervening spaces. The 
Muller cells provide structural support and may mediate the transfer of 
metabolites to the retinal neurones. 
The region around the optic nerve (figure 1.1.) is devoid of 
photoreceptors, making it a blind spot in the visual field. In contrast, the 











greatest visual discrimination as the visual elements are concentrated in 
this area. 
The retinal pigment epithelium (PEl is a single layer of hexagon-shaped 
cells resting on Bruch's membrane, which is part of the choroid (figure 
1.1.). Adjacent cells are connected by a junctional complex and are the 
site of the "blood-retinal barrier." Complex cytoplasmic processes, typical 
of cells involved in active transport, project for a short distance between 
the photoreceptors of the rods and cones. The elongated melanin 
granules are the most prominent features of the cells. The pigment cells 
are tallest in the fovea and adjacent area, accounting for the darker 
colour of this region. The RPE has many important functions, namely: 
• 	 absorption of light entering the eye, thereby decreasing light scatter; 
• 	 it is a component of the blood-retina boundary, isolating the retinal 
cells from blood borne substances; 
• 	 it is implicated in the photopigment regeneration process, after their 
response to light. 
The RPE also plays a role in the phagocytosis and disposal of the 











1.1.3. THE PHOTOTRANSDUCTION PATHWAY 
The photoreceptor outer segment is the major location for light 
transduction and it can be the site of extensive pathology. On this basis 
it is possible that any protein involved either in the structure or the 
visual process in the outer segment, could be a candidate for inherited 
retinopathies. Several research groups have investigated this possibility 
by looking at the components of the visual transduction pathway. 
The first step for perception of light is the enzymatic amplification of the 
light signal and occurs in the rod outer segment. In this segment, opsin 
combines with the chromophore 11-cis-retinal to form rhodopsin (RHO), 
a 40-kOa transmembrane protein (Stryer, 1988). Photoisomerisation or 
light activation of the 11-cis-retinal chromophore is both efficient and 
rapid, and is the first step in the visual transduction cascade (Yau, 
1994). The subsequent transmission of the signal is illustrated in figure 
1.4. The photoisomerisation of RHO produces an intermediate compound 
called metarhodopsin II (R") , which is conformationally activated. 
The second step in visual excitation is the activation of transducin by R". 
Transducin (T) is a peripherally expressed membrane protein with three 
subunits: Ta (39kOa), TP (36kO), and Tts (8kOa). The Ta subunit contains 
a binding site for guanosine triphosphate (GTP) and guanosine 
diphosphate (GOP) as well as a catalytic site for the hydrolysis of bound 











associated when GDP is bound (T-GDP, the inactive dark state), and 
separate when GTP is bound (T-GTP, the light-activated state). The 
GTPase activity of transducin is essential for bringing the system back to 
the dark state. Follo\\ring illumination, T-GDP encounters R* in the plane 
of the disc membrane. R' induces the release of GDP from transducin 
and allows GTP to enter. 
R*-T-GTP then dissociates into Ta-GTP, T~H and R*. Ta-GTP carries the 
excitation signal to cGMP phosphodiesterase (PDE) and R* is free to 
catalyse another round of GTP-GDP exchange. Hundreds of transducin 
molecules are activated by a single R* and this is the primary stage of 
amplification in vision. The transducin cycle (figure 1.5.) flows 
unidirectionally where both the formation of Ta-GTP and its hydrolysis 
are essentially irreversible. 
Ta-GTP activates PDE by carrying away its inhibitory subunits. PDE 
consists of three polypeptide chains: a (88kDa), ~ (85kD), and H (9kDa), 
and is a peripherally expressed membrane protein with a subunit 
structure of a~H2. Ta-G;I'P first interacts with the a~H2 holoenzyme and 
removes one of its Hsubunits to form a partially active a~H complex. The 
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Figure 1.4. The visual excitation and recovery pathway (Stryer, 1991). 
Photoactivation of rhodopsin (R) triggers a cascade leading to closure of 
membrane channels, which generates a nerve signal. Channel closure 
also causes a drop in the cytosolic calcium level, which leads to the reopening 
of channels. T-transducin, GTP-guanosine triphosphate, PDE-cGMP­











Fully activated PDE hydrolyses cGMP (bound to the rod photoreceptor 
cGMP-gated channel protein) which leads directly to channel closure. 
Channel closure is a result of the lowering of cytoplasmic cGMP 
concentration. Closure of the channel causes hyperpolarisation of the 
rod cell plasma membrane, which initiates the visual transduction 
signal. 
The channel opens and closes within milliseconds in response to 
changes in the cGMP level. The plasma membrane of the rod outer 
segment is in essence a cGMP electrode as it is gated solely by cGMP. 
Most of the light-induced hyperpolarisation, the excitation signal, comes 
from blockage of Na+ influx. 
Channel reopening depends on the restoration of the cGMP level, which 
requires activation of guanylate cyclase (GC) and inhibition of PDE. 
Deactivation of PDE* requires hydrolysis of Ta-GTP to Ta-GDP (figure 
1.4.). For channel opening, photoexcited rhodopsin (R*) must also be 
deactivated. This shut-off is achieved by the phosphorylation of multiple 
serines and threonines in the carboxyl terminal region of R* by 
rhodopsin kinase, a cytosolic protein. Another cytosolic protein, 
arrestin, then caps multiple phosphorylated R* to prevent it from 
interacting with transducin. Rhodopsin is regenerated minutes later: ~y 











the COOH-terminal phosphates by protein phosphatase 2A (Fmx;les et 
al., 1989). The restoration of the dark state also requires the activation 
of GC. It is thought that recoverin is also involved in the recovery from 
light to dark state. 
R 
hv) ATP AOP A 
l- ~ R".P!.. A-R'­POE; 








Figure 1.5. Light-activated transducin cycle. 
R - Rhodopsin; R* - photoexcited rhodopsin; T ­
transducin; PDEi - inhibited phosphodiesterase; PDE*.­












In the dark, the entry of Ca2'" through the cGMP-gated channel is 
matched by its efflux through an exchanger that is driven by the influx 
of three Na'" and the efflux of one K.... Following illumination, the influx 
of Ca2'" through the cGMP-gated channel ceases,but its export by the 
exchanger continues until the Ca2'" intracellular concentration drops 
markedly. A lowering of Cai stimulates recoverin, which in turn 
activates GC (Shastry, 1997), resulting in a rise in cGMP production 
which reopens the cGMP-gated channel. This process together with the 
~ 
phosphorylation of photoactivated rhodopsin by rhodopsin kinase 
converts the rod cells to the ground state. 
This pathway takes place in both rods and cones. Many of the proteins 
involved, however, exist in either rod-specific or cone-specific versions. 
1.1.4. MOLECULAR GENETICS OF HUMAN INHERITED 
RETINAL DEGENERATION 
Inherited disorders that cause the retina to degenerate lead to either 
partial or total blindness. Much progress has been made in the 
identificationof the genetic defects underlying common inherited retinal 
conditions such as RP, macular degeneration and other rare forms of 
retinal disease, which manifest primarily as degeneration of the 
photoreceptor cells. 











biochemical defects in the cell. If the defect affects rods, visual field loss 
progresses from the periphery towards the centre of the retina. 
Conversely, defects that affect cones have the opposite effect, destroying 
the central region of the retina (the macula) where cones are most 
abundant (Zhang et al., 1995). 
It appears that many factors can initiate RD, and it is possible that 
several different processes are involved. The process leading from 
genetic defect to RD is not well understood. One current theory is that 
regardless of the fundamental genetic defect, apoptosis, a form of 
programmed cell death, is ultimately responsible for RD (Chong et al., 
1999). 
RP, the group of disorders wh~ch forms the subject of this thesis will be 
.discussed in this section. 
1.1.4.1. Retinitis Pigmentosa (RP) 
One group of the degenerative retinopathies, RP, has attracted special 
attention in this decade. The nomenclature encompasses many 
conditions, involving progressive photoreceptor and retinal pigment 
epithelial degeneration in the retina (Bunker et aI., 1984). This group of 
disorders which occur in all popUlation groups is· the most common 
cause of genetic blindness (Inglehearn, 1998) and affects approximately 











The diagnostic criteria for RP are bilateral involvement, loss of 
peripheral vision and abnormal rod responses in the electroretinogram 
(ERG). These criteria reflect rod dysfunction and progressive loss of 
both rod and cone photoreceptor function. The corresponding clinical 
symptoms are: 
• 	 night blindness (nyctalopia); 
• 	 progressive concentric reduction of the visual fields; 
• 	 usually later, signs of macular involvement like loss of reading 
acuity, abnormal colour vision and sensitivity to glare, and 
• in the final stages of the disease, most patients experience blindness. 
Clinical variability is a feature in RP, even within the same family 
(Berson, 1996). In some instances the disorder manifests early, within 
the first decade of life, followed by a rapid progression to blindness. 
Conversely, symptoms may not manifest until the fifth decade or 
beyond, with a more gradual progression of the disorder. Other ocular 
findings include atrophic changes of the RPE followed by the 
appearance of melanin-containing structures in the vascular layer and 
around the MOller cells resulting in the typical bone-spicule-like 
pigmentation, waxy pallor of the optic discs and attenuated retinal 
vessels. Myopia is frequent, with subcapsular posterior cataract and 
destruction of the vitreous usually occurs in patients over 40 years (Gal 
et al., 1997). 











either X-linked (10-15%) (XLRP), autosomal dominant (15-20%) (ADRP), 
autosomal recessive (20-25%) (ARRP), maternal (mitochondrial), or 
digenic inheritance patterns. Besides the genetically classifiable cases, 
however, many families which have been reported cannot be ascribed to 
any genetic form (Phelan and Bok, 2000). Such cases are labelled 
"simplex" and this cohort may account for at least 40% of cases (Jay 
and Jay, 1982). Individuals in the simplex group have no family history 
of the condition. The condition may also appear as part of a syndrome 
where RP presents with additional features (Chong et al., 1999). 
The molecular defects underlying several forms of genetic blindness 
have already been identified. The majority of the genetic categories of RP 
mentioned above are caused by defects in various genes. It has been 
shown that mutations reside not only in genes whose transcription 
products are directly involved in the visual pathway, but may also occur 
in other retinally-expressed genes whose products have an indirect 
effect on the pathway. 
Autosomal dominant retinitis pigmentosa (ADRP): The published 
incidence of the different genetic forms of RP in the USA and UK 
suggests a higher prevalence of the dominant form of the disorder 
compared to the others (Krumpaszky and Klauss, 1996). The evidently 
higher prevalence of ADRP has resulted in a greater effort being 











Clinically, ADRP is classified into two main groups based on differences 
in the relative loss of rod and cone function. Type 1 ADRP refers to an 
early and diffuse loss of rod function followed by a progressive loss of 
cone function (Massof and Finkelstein, 1981). In type 2 ADRP, the 
condition progresses in a more regional fashion, with a concurrent loss 
of both rod and cone function. In comparison with type 1, patients with 
type 2 ADRP usually have a later onset of night blindness and the 
~~: 	 visual fields are better preserved; individuals with the latter type, 
therefore, usually have a more favourable visual prognosis. ADRP types 
1 and 2, described by Massof and Finkelstein (1981) correspond well to 
the D-type and the R-type, respectively, described by Lyness et aI. 
(1985). 
Considerable progress has been made in the understanding of the 
molecular pathology of ADRP resulting in 12 chromosomal loci being 
mapped to date (Clarke et aI., 2000). These ADRP loci reside on 
chromosomes 3q (McWilliam et al., 1989), 6p (Farrar et aI., 1991), 8q 
(Blanton et aI., 1991), 7p (Ingelhearn et aI., 1993), 7q (Jordan et aI., 
1993), 19q13.4 (Al-Maghtheh et aI., 1994), 19q13.3 (Sohocki et aI., 
1998), 17p13.3 (Greenberg et aI., 1994b), 17p13.1 (Perrault et aI., 
1998), 17q (Bardien et aI., 1995), 1q (Xu et aI., 1996) and 14q (Bessant 











Disease-causing mutations have been identified in genes at six of these 
ADRP loci: 
• 	 Rhodopsin (RHO), on chromosome 3q, encodes the visual pigment 
that initiates the phototransduction cascade. This was the first gene 
to be implicated in ADRP (Dryja et al., 1990). Since the first report of 
a mutation in the RHO gene, a variety of other mutations have been 
described in this gene in families manifesting ADRP (AI-Maghtheh et 
aI., 1993). Many of the gene alterations are missense mutations and 
occur only in individual families (Ingleheam, 1998). RHO gene 
mutations account for approximately 20% of ADRP. Interestingly, 
some mutations in the RHO gene are believed to cause ARRP, 
simplex and congenital stationary night blindness (Phelan and Bok, 
2000). 
• 	 Peripherin/ RDS, on chromosome 6p, the second gene implicated in 
ADRP (Dryja and Li, 1995), encodes a membrane protein located in 
the rim of outer segment discs (Molday et al., 1987). The postulated 
function of the protein is the creation of a conformational bend at 
the periphery of disc membranes, or to anchor the discs to the 
cytoskeleton of photoreceptor cells (Arikawa et aI., 1992). In 
addition, the protein is essential for the biogenesis of photoreceptor 
outer segments. Peripherin/ RDS mutations segregate in families with 
the AD and the AR form of RP (Ingleheam, 1998). While the majority 
of peripherin/RDS mutations are believed to cause RP, some are: 











macular dystrophy (Weleber et aI., 1993), vitelliform macular 
dystrophy (Wells et aI., 1993), butterfly macular dystrophy (Nichols 
et aI., 1993), or fundus flavimaculatus (Weleber et aI., 1993). Since 
mutations in the same gene can produce such different phenotypes, 
it is thought that other gene products or environmental factors could 
be associated with these disorders (Phelan and Bok, 2000). 
• 	 RETGC-l, on chromosome 17p, was implicated in the phenotype of 
AD cone-rod dystrophy patients (Perrault et ai., 1998). The cone-rod 
dystrophy group of disorders is a common variant of RP which shows 
the simultaneous involvement of cone and rod photoreceptor 
degeneration (Phelan and Bok, 2000). RETGC-1 is one of two 
isoforms which dimerise to form the functional RETGC. The active 
enzyme is required during the phototransduction cascade to return 
the levels of cG MP to normaL 
• 	 The cone-rod homeobox gene (eRX), on chromosome 19q, encodes a 
photoreceptor-specific transcription factor. The gene was shown to 
underlie a late-onset dominant form of RP (Sohocki et at, 1998). The 
CRX protein regulates the expression of RHO and other outer 
segment proteins genes including rod transducin and arrestin 
(Clarke et aL, 2000). 
• 	 The neural retina-specific leucine zipper gene (NRL), on chromosome 
14q (Yang-Feng and Swaroop, 1992), shown to underlie ADRP 
(Bessant et ai., 1999), encodes a basic motif-leucine zipper protein 











that the mutant NRL protein up-regulates the RHO gene promoter. 
.• 	 The RPl gene, on chromosome 8q, was recently shown to underlie 
the ADRP phenotype (Sullivan et aI., 1999). Several disease-causing 
alterations in RPl have been elucidated in families previously 
mapped to this locus. RPl gene-expression is retina-specific and the 
product is believed to be a protein kinase involved in the 
development and/or maintenance of the neural retina (Sullivan et 
aI., 1999). 
For the remaining six loci, the disease-causing genes have not yet been 
identified. Based on the observation that the disorder in several ADRP 
families has been excluded from the above loci (by linkage analysis) 
suggests that further ADRP loci remain unmapped. 
Autosomal recessive retinitis pigmentosa (ARRP): The clinical 
manifestations of RP are most severe in persons with the autosomal 
recessive form of the condition (Jay and Jay, 1982). ARRP accounts for 
approximately 20% of all cases of RP. However, simplex forms of RP, 
which are presumed to be recessive in most cases, account for a further 
50% (Jay, 1982). ARRP is characterised by allelic and non-allelic 
heterogeneity, and several loci have been identified for this form of the 
disorder, on chromosomes 1p31 (Gu et aI., 1997), 1p21 (Cremers et aI., 
1998), 1q31 (van Soest et aI., 1996), 2p11 (Gu et aI., 1999), 2q31 (Bayes 
et al., 1998), 2q37 (Nakazawa et al., 1998), 3q21 (Rosenfeld et aI., '. 










(Huang et al., 1995), 6p21 (Knowles et al., 1994), 6q15 (Ruiz et al., 
1998), 15q26 (Maw et al., 1997), and 16p12 (Finckh et al., 1998). 
In some instances, specific genes and causative mutations have been 
identified in forms of ARRP: 
• 	 RHO, on chromosome 3q (Rosenfeld et al., 1992); 
• 	 a and ~ PDE, on chromosomes 5q and 4p, respectively (Huang et al., 
1995, McLaughlin et al., 1995, Danciger et al., 1995 and Valverde et 
al., 1996); 
• 	 the a subunit of cGMP-gated channel protein (CNGq, on 
chromosome 4p14 (Dryja et al., 1995); 
• 	 RPE65, on chromosome 1p31 (Gu et al., 1997); 
• 	 RLBP1, on chromosome 15q (Maw et al., 1997); 
• 	 ABCR, on chromosome 1p21 (Martinez-Mir et al., 1998); 
• 	 TULP1, on chromosome 6p (Banerjee et al., 1998 and Hagstrom et 
al., 1998); 
• 	 SAG, on chromosome 2q37 (Nakazawa et al., 1998); and 
• CRB1, on chromosome 1q31 (den Hollander et al., 1999). 
Interestingly, both RPE65 and RLBPl are expressed primarily in the 
RPE, and not the neural retina (Inglehearn, 1998). Each encodes 
proteins involved with the transport of retinoids from the RPE to the 
neural retina. It is believed that RD caused by mutations in these genes 












X-linked retinitis pigmentosa (XLRP): Persons exhibitirl.g the XLRP have 

earlier manifestations compared to individuals with ARRP or ADRP. 

Males are consistently severely affected and never pass the disorder on 

to their male off-spring. Molecular investigations have revealed genetic 

heterogeneity in this form of the condition, where at least six disease 

loci have been identified (Clarke et al., 2000): 

RP2 (Xp 11.3) between markers DXS7 and DXS255 (Teague et al., 1994), 

RP3 (Xp21.1) which is closely linked and distal to DXS7 (Chen et al., 

1989), RP6 (Xp21.3) (Ott et al., 1990, Aldred et al., 1994), RP15, RP23 

(both at Xp22) and RP24 (Xq26) (Clarke et al., 2000). 

Two genes have been cloned, characterised and shown to underlie the 

XLRP disease phenotype: 

• 	 mutations in the RP guanosine triphosphate (GTP)ase regulator gene 
(RPGR) (at the RP3 locus) were found in approximately 20% of XLRP 
patients (Buraczynska et al., 1997), and 
• 	 mutations in the RP2 gene (RP2) are thought to account for 20-30% 
of XLRP cases in European popUlations (Clarke et al., 2000). 
A range of other X-linked retinal phenotypes all map to loci 
overlapping the XLRP interval. These include cone dystrophy (Meire et 
aI., 1994), Norrie's disease (Berger et al., 1992), congential stationary 
night blindness (CSNB) (Hardcastle et al., 1997) and Aland Island eye 











Digenic retinitis pigmentosa: The phenotype segregating in most RP 
families is the result of defects in single genes (monogenic). In 1994, 
however, three families with RP were identified, each with the same 
missense mutation in peripherin/RDS (on 6p) (Kajiwara et al., 1994). 
Each of the three families had a second mutation in ROMI (a gene on 
11q), thereby demonstrating the phenomenon of digenic inheritance. 
Parents of affected individuals were carriers for either the ROMI or the 
peripherin/RDS mutations but did not manifest the condition. 
Peripherin/RDS and ROMI encode the polypeptide subunits of an 
oligomeric transmembrane protein complex present at photoreceptor 
outer segment disc rims (Phelan and Bok, 2000). Goldberg and Molday 
(1996) reported that, when defective, the protein subunits of the 
complex do not assemble correctly. 
Syndromic retinitis pigmentosa: RP is a component of a number of 
genetic diseases. Usher syndrome (USH) is comparatively common, 
comprising RP and genetic deafness. USH is an AR heterogeneous 
condition (Clarke et al., 2000). Three phenotypic variants of USH are 
defined according to the severity of hearing loss and the degree of 
vestibular involvement (Smith et al., 1994). Type 1 USH (USH1) is 
characterised with profound hearing loss with vestibular dysfunctio!l 











90% of all USH cases (Kaplan et al., 1992). USH2 is the most common 
form of the disease. Patients with USH2 present with RP,moderate 
hearing loss and normal vestibular involvement. The condition is not 
congenital. In USH3, the rarest form, the RP and hearing loss is 
progressive and the condition manifests in adulthood (Smith et aI., 
1994). 
The clinical heterogeneity of USH is reflected by the assignment of this 
group of disorders to at least nine loci on chromosomes 1 q (Kimberling 
et aI., 1990), 3p (Hmani et al., 1999), 3q (Sankila et aI., 1995), 5q (Pieke 
Dahl et aI., 2000), 14q (Kaplan et al., 1992), 11 q (Kimberling et aL, 
1992), IIp (Smith et al., 1992), 10q (Wayne et al., 1996) and 21q (Chaib 
et aI., 1997). 
Two USH genes have been characterised (Kimberling et aI., 2000): 
• 	 The myosin VIlA gene (MY07A) has been shown to be causative of 
the USH1 form of the disorder at the 11q locus (Wei! et aI., 1995). 
Reported findings suggest that myosin is required for the transport 
of opsin to the outer segment of photoreceptor cells (Uu et aI., 1998), 
and 
• 	 USH2A, on chromosome 1q41 (Uu et al., 1999). The USH2A protein 
sequence suggests that it may represent a novel class of 
interphotoreceptor cell matrix (IPM) proteins or a cell adhesion 











Bardet-Biedl syndrome is a recessive condition which involves RP, 
polydactyly, obesity, hypogenitalism, mental retardation and renal 
anomalies. Four loci have been associated with the condition through 
linkage analysis, on chromosomes 11q (Leppert et aI., 1994), 16q 
(Kwitek-Black et aI., 1993), 3p (Sheffield et aI., 1994)and 15q (Carmi et 
al., 1995). 
Refsum disease is characterised by RP, peripheral neuropathy, 
cerebellar ataxia and elevated cerebrospinal fluid protein levels (Jansen 
et al., 1997). Defects in the phytanoyl-CoA hydrolase gene on 
chromosome lOp has been shown to underlie this condition (Jansen et 
aI., 1997). 
Congenital stationarY night blindness (CSNB): Individuals with CSNB 
have normal day vision, mediated by the cone cells of the retina. They 
experience night blindness due to the malfunctioning of the rod 
photoreceptors in dim light. The disorder is non-progressive and 
genetically heterogeneous (Hardcastle et aI., 1997). It is believed that 
the genetic colocalisation of CSNB and RP for at least four loci suggests 
that CSNB is a mild, non-progressive form of RP. 
Distinct genetic loci have been reported for the X-linked form of CSNB 
at Xp21.1, one which is allelic to the RP3 gene RPGR (Apfelstedt-Sylla et 











(Aldred et aI., 1992). Furthermore, there is yet another locus for X­
linked CSNB (CSNB4) between the RP2 and RP3 loci on proximal Xp 
(Hardcastle et aI., 1997). A recessively inherited form of CSNB, Oguchi 
disease, results from mutations in SAG (Fuchs et al., 1995) and 
rhodopsin kinase (Yamamoto et al., 1997). Both these genes encode 
proteins which function to restore the resting phase in rods after 
response to light. CSNB is also transmitted in an autosomal dominant 
fashion. Dominant CSNB is associated with mutations in the ex subunit 
of rod transducin, GNATl (Dryja et al., 1996), PDE(3 (Gal et al., 1994) 
and RHO (Gal et al., 1997). 
Macular Degeneration: The phenotype of macular degeneration 
encompasses a heterogeneous group of disorders characterised by a 
progressive loss of central visipn due to the degeneration of the macula 
and the underlying pigment epithelium (Zhang et aI., 1995). Much 
progress has been made in the elucidation of the macular dystrophies, 
with the genes responsible for dominant and recessive forms of the 
. condition being mapped to specific chromosomes. Some of these 'are: 
11q13 - Best macular dystrophy, an autosomal dominantly inherited 
disorder where patients have bilateral macular lesions at a young age 
(Stone et aI., 1992). Funduscopically, features include a yellow 
appearance of the macula. 1p21-p13 - Stargardt macular dystrophy, 
characterised by bilateral atrophic changes in the macula, degeneration 











A recessive form of Stargardt disease maps to chromosome 1 p (Kaplan 
et al., 1993). 6qI4-qI6.2 - Autosomal dominant Stargardt dystrophy 
(Stone et al., 1994). 13q34 - Autosomal dominant Stargardt dystrophy 
(Zhang et al., 1994). 
Specific genes and genetic alterations have been found to underlie some 
forms of macular degeneration: 
• 	 Peripherin/RDS, on chromosome 6p, has been implicated in some 
macular dystrophies (Shastly, 1994). 
• 	 retina-specific ATP-binding cassette transporter (ABCR) gene, on 
chromosome lq, has been shown to be causative of dominant age­
related macular dystrophy (AMD) and recessive Stargardt dystrophy 
(Allikmets et aL, 1997a; b). AMD is the leading cause of blindness in 
the elderly. The condition is characterised by progressive 
degeneration of the retina, the RPE and the choriocapillaris (the 
blood supply to the outer retina). 
• 	 A 7 -kb heteroplasmic deletion of the mitochondrial genome was 
found in a patient with diabetes, deafness, cataract, and 
maculopathy (Souied et al., 1998). This was the first report of a 











1.2. RETINITIS PIGMENTOSA IN SOUTH AFRICA 

SA RP families have been documented in the Department of Human 
Genetics at the University of Cape Town for the past 27 years. A nation­
wide survey of individuals with RP was conducted in 1985 (Oswald et 
aI., 1985). The figures reported at that stage were recognised as being 
incomplete, however, the aim of the study was to provide a perspective 
on the genetics of RP in SA; Sixty three families comprising one 
hundred and thirty affected individuals participated in the survey. The 
results showed that the proportions of the different genetic categories of 
RP were generally in accordance with those found in international 
studies. 
The situation in SA was reviewed again in 1993 (Greenberg et aI., 1993). 
This review took place three years after the establishment of a DNA 
banking centre in the molecular laboratory of the Department of 
Human Genetics, in 1990. By 1994, blood specimens for DNA 
extraction and archiving had been received from 153 affected 
individuals, from 75 families. At the time of the review, none of the 
families had been mapped to any of the candidate loci screened. In the 
first report by Oswald et al. (1985) and in the later report by Greenberg 
et al. (1994a), the apparent small proportion ofXLRP families in SA was 
noted. Oswald also proposed a possible "reverse" founder effect. And in 
1994 it was postulated that each of the SA RP families is likely to have a 











The localisation of the first RP gene locus to the long arm of 
chromosome 3 in 1990, prompted molecular genetic studies aimed at 
identifying disease-associated loci in SA RP families (Greenberg et aI., 
1992). 
1.2.1. CURRENT STATISTICS 
DNA samples from 1501 affected and unaffected individuals from 383 
families with RP had been archived in the molecular laboratory at the 
department of Human Genetics at UeT (as at June 1999). The genetic 
categorisation of 383 families is presented in table 1.1. The proportions 
of the different genetic forms of RP archived continue to be in 
accordance with those published internationally. Families have been 
categorised where pedigree d?tta indicated typical Mendelian patterns of 
inheritance. The term simplex is used to define a single affected 
individual with no family history or consanguinity evident in the 
pedigree. Families with inor~ than one affected individual, but with 
insufficient information to indicate any specific Mendelian pattern of 











Table 1.1. Genetic categorisation of 383 RP families 
Inheritance Pattern No. of 
Families 
No. of Affected 
individuals 
Total no. of 
individuals 
Autosomal dominant 68 211 591 
Autosomal recessive 45 69 173 
X -Linked recessive 17 26 69 
Simplex 31 33 128 
Indeterminate 61 77 91 
Macular dystrophy 40 41 71 
Stargardts disease 68 96 230 
Lebers congenital 
amaurosis 3 3 3 
Other 11 13 25 
Syndromic: 39 51 120 











1.3. AIMS AND OBJECTIVES 

The present study was initiated with the aim of elucidating the 
molecular genetic basis of the RP phenotype segregating in a large SA 
family of British origin. The family is one of the largest pedigrees from 
which DNA is archived in the Department, and the pedigree structure 
and ADRP phenotype will be discussed in detail in chapter t\vo. 
The identification of the gene underlying the phenotype in the family is 
significant, as it will facilitate pre-symptomatic testing and informed 
genetic counselling for at-risk members from this large family. The 
same advantage will be applicable to any other ADRP families linked to 
this gene. 
Findings from a study such as this could lead to an improved 
understanding of the pathogenic pathways which underlie the ADRP 
phenotype. This knowledge will in turn improve our understanding of 
the visual process. In addition, information gleaned from the function of 
the disease-causing gene is necessary for the development of 
appropriate therapeutic measures for the affected family members. 
Furthermore, it is believed that therapeutic modalities will be gene- or 
mutation-specific, therefore, defining the set of ADRP genes in the SA 













LOCALISATION OF THE RP13 GENE 

2.1. INTRODUCTION 
In the study of retinal disease many genes involved in the visual 
phototransduction pathway have either been mapped or cloned. These 
efforts have facilitated the investigation of the possible role of these 
genes in various forms of retinal degenerative disorders, including 
ADRP. The investigation of the reported loci in a large number of 
families with ADRP confirmed the high level of heterogeneity and the 
existence of other loci (Inglehearn, 1998). To date several genes have 
been implicated in the ADRP form of RD. The purpose of the present 
study was to find the location of the genetic defect in a large SA family 
(ADRP-SA1) in which retinitis pigmentosa segregates as an autosomal 
dominant condition. 
At the outset of this investigation, five loci had already been reported to 
be associated with ADRP. The disorder was first shown to be linked to a 
marker, C 17, close to the RHO gene on chromosome 3q21-q24 
(McWilliam et al., 1989). Peripherin-RDS, on chromosome 6p21.1-cen, 
was the other gene shown to be associated with ADRP (Farrar et al., 
1991). The remaining three disease-associated loci represented 
anonymous chromosomal regions. These were, the pericentric region- of 











(7p) (Ingelheam et al., 1993), and the long arm (q) of the same 
chromosome (Jordan et al., 1993). These five confirmed ADRP loci were 
the obvious candidates with which to commence the search for the gene 
underlying the ADRP-SA1 disease phenotype. Additional functionally 
and structurally significant candidate genes, not previously associated 
with RD, were investigated for linkage to ADRP-SA1. These included: 
• 	 cGMP-PDE~, on chromosome 4p (Weber et al., 1991); 
• 	 the interstitial retinal binding protein gene (!RBp), on chromosome 
lOp (Liou et al., 1987); 
• 	 the retinoid binding protein gene (REP), on chromosome 10q (Rocchi 
et al., 1989); 
• 	 the rod outer membrane 1 gene (ROM1), on chromosome 11q, which 
at the time was thought to be involved in ADRP (Bascom et aI., 
1992a', b)', 
• 	 cGMP-PDE a, on chromosome 5q (pittler et al., 1990); 
• 	 the rod a-transducin gene (GNAT1), on chromosome 3p (Ngo et al., 
1993); 
• 	 . the S-antigen gene (SAG), on chromosome 2q (Ngo et al., 1990); and 
• 	 the recoverin gene (ReVl) on chromosome 17p (Wiechmann et al., 
1994a). 
The positional candidate approach was the strategy of choice used to 
test the various loci in the ADRP-SA1 family. This approach involved the 
analysis of polymorphic DNA markers tightly linked to the genes of: 











genotypes were then tested for linkage in the family. The principle of 
linkage is a 	statistical estimate of the tendency of genes or DNA 
sequences at specific loci to be inherited together as a result of their 
physical proximity on a single chromosome (Terwilliger and Ott, 1994). 
2.2. PATIENTS, MATERIALS AND METHODS 
2.2.1. 	 RECRUITMENT OF PATIENTS AND 

ACCUMULATION OF BIOLOGICAL SAMPLES 

A retinal degeneration (RD) research centre was established in the 
Department of Human Genetics in Cape Town, with the goal of 
elucidating the molecular basis of this group of disorders in South 
Africa. The centre archives patient data and biological material from 
individuals and families with all forms of inherited RD (Greenberg et aI., 
1994a, Greenberg and Peters, 1995). 
Patients with RD are recruited through ophthalmologists and the 
support group, Retinal Preservation Foundation of South Africa. Before 
blood samples are taken, patients are counselled and patient data and 
DNA consent forms are completed in the presence of the patient 
(Appendix C, section C.1). The patient signs the form once he/she has a 
clear understanding of its content. The form is distributed to 
Ophthalmologists and genetic centres regionally and nationally, schools 
for the blind, patient support groups for the visually impaired and the 
RP Foundation of SA. In every instance, patients are assured of t~e .. 











samples are sent to the laboratory. Specimens are coded and the 
clinical and personal data captured on computer. The patient data and 
DNA consent forms were filed together with any additional information 
on the family. 
Subjetcs, who were generally affected with RD, or first degree relatives 
of such individuals were evaluated ophthalmologically at the 
Department of Ophthalmology, Groote Schuur Hospital, or by 
ophthalmologists in other centres. Clinical signs and 
electrophysiological information is documented according to a clinical 
data form (Appendix C, section C.2) designed for the consistent 
collection of accurate clinical data. 
Analysis of the genealogical data compiled from each of the families 
archived, revealed a large autosomal dominant RP kindred (Oswald et 
aI., 1985, Greenberg et aI., 1993, Greenberg et aI., 1994a). The family 
was designated, ADRP-SA1. 
2.2.1.1. The ADRP-SAI Family 
ADRP-SA1 (figure 2.1.) was first identified in 1985 (Oswald et aI., 1985) 
through theproband (individual IV-17) and her two affected sons. 
Individual IV-17 was eventually instrumental in tracing 60 South 
African relatives, 24 of whom manifest RP. A genealogical study revealed 
that the progenitor emigrated from England in the early twentieth 
century, with many descendants still resident in South Africa. The 











only affected individual of nine siblings and possibly represents a ne,~; 
mutation. 
The disorder in the ADRP-SAI pedigree showed a clear autosomal 
dominant inheritance pattern (figure 2.1.). Both males and females were 
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o Unaffected female / . deceased affected female ~ deceased unaffected male 
• Affected female o unaffected male / deceased affected male 
Deceased unaffected female. affected male 
Figure 2.1. Pedigree of the ADRP·SAl family showing a clear 












2.2.1.2. Clinical Presentation 
In the ADRP-SAI family the onset of night-blindness was consistently 
around 4 years of age with a diffuse pattern of retinal involvement. 
These clinical signs are indicative of type I ADRP as described by Massof 
and Finkelstein (1981). This diagnosis was confirmed by various 
ophthalmologists who investigated the affected family members. In 
every recorded instance, affected family members experienced night­
blindness followed by characteristic tunnel vision. Affected individuals 
exhibited abnormal ERGs of both the rods and cones, however, the rods 
were predominantly involved. Generally, the diffuse pattern of 
pigmentation (type I ADRP) was observed in the mid-equatorial region of 
the retina before 10 years of age. The RP phenotype was consistent 
within the family and appeared to be fully penetrant with no evidence of 
skipped generations. Bilateral cataracts were commonly observed in 
affected individuals. Minimal clinical details were available regarding 
the retinal defects in the family. 
A detailed ophthalmological report on affected individual VI-l (figure 
2.1.) revealed that at 17 years of age she complained of reduced vision 
in both eyes. On examination, her visual acuity was 6/7.5 and 6/9, 
without correction. She had sight astigmatism and, with a correction, 
the visual acuity could be improved to 6/6. Intra-ocular pressures were 
normal. After dilation very little pigment was observed in the retina. She 
also had a posterior lenticonus, again of little significance. On 
subsequent examination, at 20 years of age, the visual acuity in her 











without, and 6/7.5 with correction. Colour vision, stereo vision and 
intra-ocular pressures were normal. A small central subcapsular 
cataract was present in both eyes. A partially collapsed vitreous and 
signs of severe vitreous floaters were present in both eyes. The retinal 
signs were still typical of RP and the electroretinogram (ERG) showed 
abnormalities of both rod and cone cells, with greater involvement of the 
rods. 
2.2.2. LINKAGE ANALYSES WITH CANDIDATE LOCI 
Several candidate genes and loci were investigated towards localising 
the disease gene in ADRP-SAI. The study was undertaken using linkage 
analysis with markers that were selected because they were either 
intragenic or tightly linked to the genes investigated. 
The object of linkage analysis is the estimation of the recombination 
fraction (El) between two genetic traits and to test whether El is less than 
0.5. The recombination fraction, is therefore the rate of recombination 
between loci, which is taken as a measure of the genetic distance 
between genetic loci. The standard tools for linkage analysis are 
generally genetic markers, which have undergone major developments 
over the past century (Strachan and Read, 1996). During recent years· 
the markers of choice have been microsatellites. Microsatellites are 
small arrays of tandem repeats interspersed throughout the genome of 
which the bulk are (CA)n repeats (Strachan and Read, 1996). These 
arrays of CA repeats are very common in the genome and highly 











during this study. However, as tri- and tetranucleotide repeats produce 
clearer results (genotypes), these replaced dinucleotide repeats as the 
markers of choice over the extended period of this study. 
2.2.2.1. DNA ISOLATION 
Genetic linkage studies were undertaken using genomic DNA which was 
extracted from whole blood, obtained from subjects, using the 
Genomix™ blood scale-up kit [Talent, Italy] (Appendix A, section A.l). 
Peripheral blood (1 Oml) was obtained by venipuncture from 46 family 
members. 
2."2.2.2. Candidate Loci And Polymorphic Markers 
The five known ADRP-causing genes/loci on chromosomes 3q 
(McWilliam et aI., 1989), 6p (Farrar et al., 1991), 8q (Blanton et aI., 
1991), 7p (lngelhearn et aI., 1993), and 7q (Jordan et aI., 1993), were 
chosen as the candidate loci to commence the investigation for linkage 
in ADRP-SA1. The study was subsequently extended to eight other 
functional candidate genes including cGMP-PDE P(4p) (Weber et aI., 
1991), IRBP(10p) (Liou et aI., 1987), RBP(10q) (Rocchi et aI., 1989), 
ROM1 (11 q) (Bascom et al., 1992a), cGMP-PDE a (5q) (Pittler et aI., 
1990), GNATl (3p) (Ngo et aI., 1993), SAG (2q) (Ngo et aI., 1990) and 
ReVl (17p) (Wiechmann et al., 1994a). 
The DNA markers used are listed in tables 2.1. and 2.2. The peR 
markers D4S227 and ID53/54 were the generous gift of Dr Bernard 
Weber (Germany) and D8Sl65 and D8Sl08 of received from Dr Steven 











Table 2.1. List of the microsatellite markers used to test each 









8q Locus D8S165 
D8S87 
7p Locus D7S460 
D7S435 































Table 2.2. List of supplementary RFLP markers used to test 
candidate loci for linkage. 
. . 
Candidate Marker Restriction' Probe 





















from Research Genetics (Huntsville, USA) (Appendix A, section A.3). The 
RFLP genomic probes on chromos me 3 were inserts in the vector, 
Charon 4A and were propagated in bacteriophage lambda (Sambrook et 
al., 1989). The genomic probes, L182, R208 and Ul were polymorphic 
for the restriction enzyme MspI(Donnis-Keller et aI., 1987) and 
purchased from the American Type Culture Collection (ATCC Baltimore, 
USA). The chromosome 2 RFLP probes were obtained from the 
Waardenberg Consortium (Farrar et al., 1992). The Southern blot 












2.2.2.3. Polymerase Chain Reaction 
Microsatellite markers were processed by amplification using the 
polymerase chain reaction (PCR). PCRs contained 0.2~g of genomic 
DNA, as template; 50mM KCl, 10mM Tris-HCI pH8.3, 1.5mM MgC12, 
200~M of dATP, dGTP, dTTP and dCTP; 1~Ci of a-[32P]dCTP; 10-20 
pmol of each primer and 1 unit of Taq polymerase [GibcoBRL, UK], in a 
final volume of 25~1. The samples were generally amplified through 30 
cycles in an Omnigene [Hybaid, UK] thermal cycler denaturing at 95 oC, 
annealing temperatures of 550C to 600C, and extension at 72 0C. PCR 
products were checked for size against a standard 1kb molecular weight 
marker [GibeD, UK] on 2% agarose [Sigma, USA] gels. Twenty ~l of 
formamide loading buffer (Appendix B, section B.3.) was added to each 
react~on after PCR. Samples were denatured for 3 min at 950C and 
chilled on ice for 10 min, followed by electrophoresis through 6% 
denaturing polyacrylamide gels (Appendix B, section 8.4). The gels were 
dried onto 3MM paper [Schleicher and Schuell, Germany] on a slab gel 
drier [Hoefer Scientific Instruments, USA] for 1-2 hrs at 800C and 
exposed to X-ray film [Agfa, Germany] for 16-32 hrs at -70oC. 
2.2.2.4. Calculation or Lod Scores 
In order to establish the likelihood that the ADRP-SA1 disease-causing 
gene locus was linked to the markers tested, two-point analyses were 
performed during the initial test of candidate loci, and mUltipoint 
analyses once an indication of linkage was observed. The latter was" 











map the disease gene with respect to these markers, Analyses \\'ere 
performed using the LINKAGE software package Ver.5.03 (Lathrop and 
Lalouel, 1984). The Genethon map order of microsatellite markers for 
each chromosome was used (Gyapay et al., 1994). In order to facilitate 
processing by the software, the number of alleles for each marker v,'as 
reduced to five, ensuring no loss of informationin the family, The RP 
gene was assumed to be completely penetrant and lod scores bet\.:veen 
the markers and the ADRP locus were calculated using recombination 
fractions from 0.00 to 0.25. A gene frequency of 0.001 was assumed for 
the disease locus. For multipoint analyses, allele freque cies for each of 
the markers were calculated from a number of unaffected unrelated 
control individuals from the population of origin. 
2.2.3. HAPLOTYPE CONSTRUCTION 
The alleles of markers situated close together on a small genomic 
segment tend to be inherited as a set or haplotype through generations 
within a pedigree. Haplotype analysis is powerful in mapping genes 
because it facilitates the identification of recombinant events within the 
genomic segment. These events enable the researcher to pin-point the 
exact region within the segment which harbours the gene of interest. A 
set of eight markers on chromosome 17p which span the RP13 critical 












2.3.1. LINKAGE ANALYSES WITH CANDIDATE LOCI 
2.3.1.1. Exclusion of 11 Candidate Loci 
A range of 34 markers was used to investigate 11 distinct loci as 
candidates underlying the RP phenotype in the ADRP-SA1 family. 
Results from a series of two-point linkage analyses between the disease 
phenotype and test markers. are presented in table 2.3. Significantly 
negative lod scores provided evidence for exclusion of the candidate 
,genes on chromosomes 2q (SAG), 3p (GNATl), 4p (cGMP-PDE ~), 5q 
(cGMP-PDE a), lOp and q (IRBP and RBPj, and 11q (ROMl), and the 
anonymously linked loci on, 7p, 7q and 8q. The genotypes produced for 
the two markers used to test the RHO and peripherin/RDS genes for 
linkage were uninformative, resulting in low positive lod scores in each 
instance. Observed meiotic recombinants were, however, detected 
between the disease phenotype and the intragenic markers (RHO and 
RDS) used at each locus (Greenberg et al., 1993), thereby excluding 
these 2 genes. 
These results provided evidence for exclusion of the five reported 
primary ADRP candidate loci and a further six functional candidate 











Table 2.3. Pairwise lod scores (z) showing exclusion of linkage 
between ADRP and selected marker at 11 candidate loci. 
Marker Recombination Fractioll (8) 





































































-4.96 -2.98 -1.92 -1.25 
-5.90 -3.70 -2.49 -1.69 
-4.93 -3.11 -2.1 -1.43 
-0.34 -0.10 0.01 0.06 
0.98 1.02 0.94 0.80 
0.57 0.45 0.34 0.24 
-2.88 -1.61 -0.97 -0.59 
-LOS -0.37 -0.08 0.06 
-6.17 -3.74 -2.44 -1.59 
-2.39 -1.40 -0.89 -0.59 
-3.22 -2.05 -1.32 -0.79 
-7.56 -4.94 -3.47 -2.49 
-1.12 -0.36 -0.03 0.11 
-7.22 -4.48 -2.99 -2.02 
-3.52 -2.18 -1.46 -1.00 
-1.24 -0.76 -0.49 -0.32 
-2.57 -1.34 -0.74 -0.39 
-1.76 1.00 -0.62 -0.39 
-1.80 -1.00 -0.58 -0.33 
-4.21 -2.59 -1.73 -1.18 
-5.93 -3.69 -2.48 1.68 
-7.84 -4.84 -3.22 -2.17 
-5.73 -3.38 -2.15 -1.39 
-1.45 -0.74 -0.41 -0.22 
-1.37 -0.88 -0.63 -0.48 
-3.42 -2.29 -1.66 1.23 
-4.11 -2.65 -1.84 -1.30 
-3.48 -2.13 -1.39 -0.92 
-5.12 -3.23 -2.20 -1.53 
-4.03 -2.34 -1.44 -0.87 
-5.02 -2.97 -1.92 -1.29 
-3.58 -2.27 -1.58 -1.14 
-2.54 -1.65 -1.16 -0.83 













































2.3.1.2. Linkage To Chromosome 17p 
Evidence for linkage was first noted on visual examination of the 
genotypes produced with the set of markers (D17S849, D17S938 and 
D17S796) used to test the candidate gene, recoverin (ReV1), on 
chromosome 17p for linkage to the phenotype in ADRP-SA1 (figure 2.2). 
Significantly positive two-point lod scores of 3.60, 5.43 and 4.82 were 
subsequently obtained for markers D17S849, D17S938 and D17S796, 
respectively (all at e =0.10). In order to further investigate these 
preliminary findings, the DNA from subjects in the family was 
genotyped with six additional markers (D17S926, D17S960, D17S578, 
D17D786, D17S804 and TP53) spanning a genetic distance of 23cM 
within the 17p13 chromosomal region. Two-point lod scores between 
the phenotype and the initial three markers used to test the locus and 
each of the six additional markers are shown in table 2.4. The gene 
underlying the phenotype in ADRP-SA1 was most closely linked to 
D 17S938, which produced the highest lod score at lowest e value (lod 
score of 5.43, at e= 0.10), between markers D17S849 and D17S796 
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Figure 2.2. Representation of the segregation of the genotypes for 
markers D17S849 (five alleles), D17S938 (eight alleles) 











Table 2.4. Pair-wise lod scores between ADRP and nine polymorphic 
DNA markers on chromosome 17p. 
Recombination Fraction (9) 
Marker 0.00 ···0.05 0.10 0.20 0.30 0.40 
D17S926 .co 0.07 1.09 1.51 1.15 0.45 
D17S849 .00 3.35 3.60 3.14 2.17 0.97 
D17S938 _00 5.07 5.43 4.82 3.49 1.78 
D17S796 _co 4.72 4.82 4.01 2.69 1.19 
D17S960 _00 3.09 3.16 2.62 1.76 0.77 
D17S578 .00 2.83 3.29 2.93 1.97 0.83 
D17S786 _00 3.26 3.55 3.14 2.24 1.11 
D17S804 .00 -0.47 0.14 0.47 0.41 0.22 
TP53 _00 3.34 3.55 2.95 1.89 0.74 .
The bold numbers mdicate the highest lod score at the corresponding (e) value 
obtained for each marker 
2.3.1.3. Fine Mapping The RP13 Locus 
Further genetic mapping studies were carried out to establish the 
smallest possible interval harbouring the RP13 locus and to facilitate 
the identification of the disease-causing gene. 
To establish which interval between the nine markers should be 
exploited to fine map the RP13 locus, a series of three-point analyses 
were undertaken using two markers (from the initial nine) and the 
disease phenotype in subjects from the ADRP-SAI family. The highest 











and D17S938. DNA from family members was genotyped with five 
markers (D17S1529, D17S1528, D17S831, D17S829 and D17S1353) 
within the lScM interval between D17S849 and D17S938 (figure 2.3.). 
Two point lod scores obtained between the disease locus and each of 
these markers are shown in table 2.S. Marker D17S1528 showed no 
recombination events and produced a lod score of7.19 (0 = 0.00). 
Markers D17S1529 and D17S831, located on either side of D17S1528 
also showed significantly positive lod scores of S.64 and 6.66 
respectively, at 0 = O.OS. 
In order to confirm the order of markers on the genetic map of 
chromosome 17p, another set of multipoint analyses was performed, 
using 10 markers, starting at the telomeric marker, D17S849, and 
ending at the centromeric marker, D17S804. The multipoint analysis 
results illustrated in figure 2.4., show that a peak lod score of 8.4 was 
obtained between D17S1529 and D17S1528, indicating that this was 
the most likely interval to contain the disease gene. The l-unit-of-Iod­
score support interval (an estimation of a two-point recombination 
fraction) only encompasses the region between D17S1529 and 
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Figure 2.3. Ideogram of human chromosome 17, with an expanded 
genetic map of the region to which the ADRP-SAI 
phenotypelocaUsed. 
Table 2.5. Pair-wise lod scores between microsatellite markers and 
the ADRP-SAI disease phenotype. 
Recombination fraction (8) 
Marker 0 0.05 .0.1 
.. 
0.2 ·0.3 0.4 
D17S849 -"" 3.35 3.60 3.14 2.17 0.97 
D17S1529 2.12 5.64 5.21 3.95 2.43 0.88 
D17S1528 7.19 6.70 6.10 4.71 3.12 1.43 
D17S831 2.97 6.66 6.22 4.93 3.35 1.57 
D17S829 -9.15 0.92 0.92 0.64 0.27 0.00 
D17S1353 -5.13 2.40 2.72 2.39 1.63 0.73 
D17S938 _00 5.07 5.43 4.82 3.49 1.78 
The bold numbers indicate the higheSt lad score at the corresponding (8) value 
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Figure 2.4. Results or multipoint analyses or the ADRP phenotype 












2.3.2. HAPLOTYPE ANALYSIS 
Towards confirming and further narrowing the RP13 genetic interval, 
haplotypes comprising 8 markers ranging from D17S926 to D17S938 
were constructed. The support interval as defined by genetic mapping 
studies was confirmed by observed meiotic recombinants on haplotype 
analysis (figure 2.5.). It would appear that affected individual III-2 is 
recombinant for the markers D17S926 through to D17S1529. The 
recombinant chromosome was transmitted to all the affected individuals 
in her branch of the pedigree through three generations, except to 
individual VI-I. It is evident that in individual VI-I the paternally 
inherited chromosome had recombined between markers D17S1528 
and D17S831. Individual VI-I is unequivocally affected with ADRP. She 
is currently aged 26 years and fundal examination revealed typical 
features of RP (Ophthalmologist's report in section 2.2.1.2., page 41). 
The recombination events (in individuals III-2 and VI-I) provide 
conclusive evidence that the RP13 gene maps proximal to D17S1529 
and distal to D 17S831. 
The two-point, multipoint linkage and haplotype data presented support 
the fine localisation of RP 13 from a 15cM to a 3cM interval between 
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Figure 2.5. ADRP-SAI pedigree showing the segregation of the 
affected haplotype'in red and critical recombination 













This study reports the identification of the ADRP locus (RP13) which 
occurs on chromosome 17p in a large SA family (ADRP-SAl), during a 
positional candidate-based linkage approach (Greenberg et aL, 1994b). 
The subsequent fine mapping of the disease locus placed it on the 
17p13.3 chromosomal band, within a 3cM interval between markers 
D17S1529 and D17S1528 (Goliath et al., 1995). 
The positional candidate approach used in the search for the ADRP-SA1 
disease-causing gene consisted of two phases. The first phase involved 
screening the five extantly known ADRP loci for linkage to the ADRP­
SAl RP phenotype. The disease locus was excluded from each of the five 
disease loci: The RHO and RDS intragenic microsatellite markers at the 
RHO and peripherin/RDS genes, respectively, proved to be mostly 
uninformative, hence the low positive lod scores obtained (table 2.3.). 
These genes were, however, excluded due to the recombination events 
observed between the disease locus and alleles of the respective 
intragenic markers used. The ADRP loci on chromosomes 8q, 7p and 7q 
were excluded based on linkage analyses which produced lod scores of 
less than -0.20, at a recombination fraction of 0.05, the generally 
accepted value for significant exclusion (Lester et al., 1990). Exclusion 
of ADRP-SA 1 from the known loci was not surprising as genetic 












Exclusion of the five known disease loci directed the mapping efforts 
into the second phase of the positional candidate gene screen. This 
phase involved screening markers associated with retinally-expressed 
genes not previously reported to be associated with ADRP. Candidate 
genes cGMP-PDE a and ~, GNAT1, SAG and RCVl on chromosomes 5q, 
4p, 3p, 2q, and 17p, respectively, were chosen because of the 
established function of each gene product in the visual 
phototransduction cascade (chapter1, section 1.1.3., page 11). IRBP and 
RBP on chromosome 10 were chosen because of the important 
transport functions of each gene product in photoreceptor cells. IRBP 
binds hydrophobic ligands of both retinoids and analogs in the 
interphotoreceptor space preventing the degradation of these molecules 
(Nickerson et al., 1998). RBP is involved with the transport of vitamin A 
to target cells (Naylor et al., 1999). ROM-1 is a transmembrane protein 
present at photoreceptor outer segment disc rims (Goldberg and 
Molday, 1996). 
It was during the second phase of the study that evidence for linkage 

was observed with markers flanking the RCVl gene locus (D17S849, 

. D17S938 and D17S796J. This result was confirmed by genotyping DNA 
from family members with a range of markers spanning a genetic 
distance of 23 eM. The data presented strongly suggested that the 
causative gene for ADRP in ADRP-SA1, maps to the short arm of 
chromosome 17 (RP13) (Greenberg et aI., 1994b). Based on further· : 
genetic fine mapping studies, the interval was eventually reduced to a 











1995). Haplotype analysis using eight markers spanning the 
chromosomal region confIrmed this support interval. The haplotypes 
revealed meiotic recombinants in two affected individuals with markers 
(D17S1529 and D17S831) on either side of the critical interva1. 
RP13 represented the seventh locus for ADRP assigned by linkage 
analysis. It is not yet known what proportion of patients with RP have 
mutations in the corresponding gene on chromosome 17p. Literature 
reviews suggest that mutations of RHO and peripherin/RDS account for 
approximately 25% and 5% of all ADRP cases, respectively (Inglehearn, 
1998). The recently identifIed RPl gene appears to account for at least 
7% of ADRP (Bowne et a1., 1999). In contrast, the majority of the 
remaining seven ADRP loci have each been assigned in a single family 
or have been detected in just a few families (Greenberg et a1., 1994b, 
Ingelhearn et a1., 1993, Jordan et al., 1993, Bardien et al., 1995, AI­
Maghtheh et a1., 1994, Blanton et al., 1991 and Xu et a1., 1996). The 
RP13 locus has been excluded in at least three large SA ADRP families 
in which the disease locus has been excluded from all known loci 
(unpublished results). This observation is suggestive of the existence of 
at least one other ADRP locus. 
Amongst the three anonymous ADRP loci tested for linkage (7p, 7q and 
8q) in the ADRP-SA1 family, only the gene on chromosome 8q (RP1) has 
since been identifIed (Bowne et a1., 1999). Several pathogenic alterations 
in RPl were elucidated in families previously mapped to this locus. 











and the product may be a protein kinase involved in the development or 
maintenance of the neural retina (Sullivan et aL, 1999). An additional 
three ADRP loci have been mapped to chromosomes 19q (AI-Maghtheh 
et al., 1994), 17q (Bardien et al., 1995) and 1q (Xu et al., 1996). 
Furthermore, ADRP-associated defects have been identified in an 
additional three genes (NRLJ CRXand RETGC-l) (Bessant et al., 1999, 
Sohocki et aI., 1998, Perrault et aI., 1998). The previously described 
retina-specific gene, NRL (on chromosome 14q) (Yang-Feng et aL, 1992) 
encodes a transcription factor which has been shown to regulate the 
expression of the photopigment, rhodopsin, in vivo (Kumar et al., 1996). 
The gene, CRX (on chromosome 19q) encodes another transcription 
factor, which regulates rhodopsin (Sohocki et at, 1998). The RETGC-l 
gene (on chromosome 17p) product is required during the 
phototransduction cascade to return the levels of cGMP to normal. 
Taken together, to date these findings bring the totaI number of ADRP­
causing genes/loci to 12. 
Of the eight additional non-disease associated candidate genes 
investigated in this study, six have since been implicated in various 
forms of retinal disease. Defects in SAG, on chromosome 2q have been 
identified to be causative of Oguchi disease, a rare autosomal recessive 
form of congenital stationary night blindness (Fuchs et at, 1995). The 
GNATl gene, on chromosome 3p was implicated in an autosomal 
dominant form of congenital stationary night blindness termed 
Nougaret disease (Dryja et al., 1996). The cGMP-PDE p gene on 4p' . 











congenital stationary night blindness (Gal et aI., 1994). cGMP-PDE a 
and !RBP on 5q and lOp, respectively, were shO\vn to be causative of 
ARRP (Huang et al., 1995; Valverde et aI., 1998), and ROM-1 on 
chromosome 11q together with peripherin/RDS (6p) was shown to 
underlie the digenic form of RP (Kajiwara et aI., 1994). 
The localisation of the chromosome 17p ADRP locus (RP13) in this 
study allowed for the mapping of two additional families to this locus, 
one from the USA (of British origin) (Kojis et aI., 1996) and the other 
from the UK (Tartellin et aI., 1996). Other large SA families, however, 
have been excluded from the RP13 locus. It was interesting to note that 
the three RP13-linked families (Greenberg et aI., 1994b, 'Kojis et aI., 
1996; Tartellin et al., 1996) were each of British origin. The possibility 
that the separate families were part of a common genealogy. 
Genealogical data, however, indicated that the immigrant progenitor of 
the ADRP-SA1 family was the only visually impaired individual of nine 
siblings with no furth r family history of disease. Furthermore, 
haplotype analysis of each of the SA and UK families refuted the 
possibility that they were related (unpublished data). Two distinct 
chromosomal haplotypes segregated with the disorder in the two 
families. These findings suggested that the families were not related. 
The USA family was not available for testing. The critical genetic 
intervals as defined by the three studies are illustrated in figure 2.6. 












• 	 Leber's congenital amaurosis (LCA1), is an autosomal recessive 
condition responsible for severe congenital visual impairment. The 
disorder maps to a 1cM genetic interval ben1,:een D17S938 and 
D17S1353 (Camuzat et al., 1995; 1996). 
• 	 LCA4, presents with the same clinical picture as LCA1, together \yith 
keratoconus. The combined phenotype maps to a distinct locus on 
chromosome 17p13 (Hameed et aI., 2000). 
• 	 Autosomal dominant progressive cone degeneration (CORD5) is 
closely linked to marker D 17S796 in a single large family from the 
USA (Small et aI., 1996). A Swedish family with apparently the same 
clinical picture mapped to the same chromosome 17p region 
(Balciuniene et aI., 1995). 
• 	 Central areolar choroidal dystrophy (CACD) a rare autosomal 
dominant condition maps close to marker D17S938 (Lotery et aI., 
1996). 
• 	 Sjogren-Larsson syndrome (SLS) is an autosomal recessive disorder 
where about 20-30% of patients develop chorioretinitis with macular 
and perimacular pigmentary degeneration. SLS maps close to 
marker D17S805 (Rogers et aI., 1995). Three mutations in the fatty 
aldehyde dehydrogenase gene, which maps to chromosome 17p11.2, 
were identified in three unrelated SLS patients. 
• 	 Cone-rod dystrophy is a severe retinal degenerative condition which 
maps to an 8cM interval between the markers D17S796/D17S938 
and D17S954 (Kelsell et aI., 1997) (CORD6). 











number of retina-specific genes map to the same chromosomal region 
(chapter 3). The phenotypic variation between the disorders that map to 
chromosome 17p, may be due to allelic heterogeneity as is the case with 
peripherin/RDS where one or more of the retinal dystrophies may result 
from mutations in the same gene at the 17p13 locus. Furthermore, the 
phenomenon of epistasis cannot be ruled out. Varied phenotypic 
expressions could also be the result of alterations in the same gene 
which in turn cause changes in the amounts and pattern of gene 
expression. The identification of the disease-causing genes and the 
elucidation of the molecular pathology of these disorders will clarify 
these questions. 
Localising the RP13 locus relied heavily upon the use of the available 
genetic marker maps which consist of highly polymorphic microsatellite 
DNA markers. It has been the goal of researchers internationally to 
establish a genetic map of the genome where these "landmarks" are 
spaced approximately 1cM apart. The increased density of markers 
facilitates and expedites the mapping of disease genes with a high level 
of confidence. During the past decade the use of these powerful tools 
have allowed for the mapping of several disease-causing genes. Indeed 
several of the ADRP genes and/or loci have been localised in this way. 
The recent surge of interest in single nucleotide polymorphisms (SNPs), 
an abundant form of genome variation, distinguished from rare 
variations by a requirement for the least abundant allele to have a­
frequency of 1% (Brookes, 1999), is now set to benefit a wide range of 











expected concentration in or near to transcribed sequences (Brookes et 
al., 2000) is set to revolutionise mapping stategies in the third 
millenium. For these reasons there is considerable interest in the 
discovery and characterization of SNPs to enable the analysis of the 
potential relationships between human genotype and phenotype 
(Picoult-Newberg et al., 1999). Analysis of human genetic variation 
around candidate genes can shed light on the problem of the genetic 
basis of complex disorders. The complete elucidation of SNPs in 
candidate genes will enable further association studies on panels of 
affected and unaffected individuals. 
The mapping of the RP13 locus by linkage analyses has contributed to 
the world-wide endeavour in the development of a gene map of the 
genome. As this research initiative progresses, it becomes an 
increasingly powerful tool in assigning disease loci to chromosomes or 
smaller sub-regions, as described in this chapter. When specific genes 
are presumed candidates of a disorder, the tool of linkage provides a 
rapid, standard approach to investigate the locus. In this way linkage 
provides a valuable diagnostic tool as well as a handle for unravelling 
the molecular basis of a disease. 
Although ADRP is rare, linkage to chromosome 17p in ADRP-SA1 is 
important not only in relation to the disease, but also as it highlights 
genes (that map to the same chromosomal region) which may be 















































I INVESTIGATION OF CANDIDATE GENES 

i I AT THE RP13 LOCUS 
I 
3.1. INTRODUCTION 
Once the neighbourhood of a gene of interest has been identified, 
several strategies can be used to find the gene itself. Because of a 
potentially large number of genes in a specific interval, it is reasonable 
to establish a priority scale in further investigations. One way of 
ranking candidate genes in order of priority involves the expression of 
that gene in the tissue of interest, e.g., a gene responsible for kidney 
disease is likely to be expressed in the kidney and probably less likely in 
other tissues or organs. This strategy will limit the search to one or a 
few genes. A gene that is potentially involved has to be compared 
between unaffected and affected subjects. DNA variation within a 
candidate gene, between unaffected and affected subjects and its 
absence in a significant number of a population of matched control 
individuals, will suggest that the gene of interest has been found. 
Since the initial identification of the RP13 locus on the telomeric end of 
chromosome 17p (Greenberg et aI., 1994b), this genomic region has 
been intensively tested for co-localisation of phenotypically distinct 
retinal disorders. This gross region has proven to be relatively fruit~ul in 











(Camuzat et aI., 1995; 1996), CORD5 (Ba1ciumiene et ai., 1995), CACD 
(Lotery et aI., 1996), SLS (Rogers et at, 1995) and CORD6 (Kelsell et al., 
1997). Furthermore, several retinal genes which are functionally 
significant map to the same chromosomal region, including reco\'erin 
(ReV1) (Wiechmann et aL, 1994a), retinal guanylate cyclase-l (RETGC­
1) (Oliveira et aI., 1994), phosphatidylinositol transfer protein (PITPN) 
(Fitzgibbon et aI., 1994), ~-arrestin 2 (ARRB2) (Calabrese et aI., 1994) 
and pigment epithelium-derived factor (PED}) (Tombran-Tink et al., 
1994). Although any gene which co-localises with a disease phenoty-pe 
is a candidate, those which are functionally tissue-specific assume a 
higher priority for further investigation. Based on map position and 
function, the RCV1, RETGC-1, PITPN, ARRB2 and PEDFgenes were 
ranked as significant candidates for the disorder in the ADRP-SAI 
family. The following is a compilation of the functionally significant 
candidates, which were considered for further investigation. 
Recoverin (ReVl): In moving from darkness into bright light, a state of 
temporary blindness is experienced by the subject. Photoreceptor cells 
within the retina subsequently, are able to rapidly adapt to the influx of 
photons of light into the eye and vision is reinstated. The ca1cium­
binding protein, RCVl, is believed to playa role in this "recovery" 
process by affecting the termination of the phototransduction pathway 
(Hurley et al., 1993). RCVl alters the ability of rhodopsin kinase to 
phosphorylate activated "rhodopsin (chapter 1, page 11). 











(Murakami et al., 1992). The RCV1 gene (RCVl) is expressed in the 
photoreceptors as well as in the bipolar and ganglion cell layers of the 
retina (Wiechmann and Hammarback, 1993) and has been localised to 
chromosome 17p12-13 by in situ hybridisation (Wiechmann et al., 
1994a). 
RCV1 is encoded by a 9kh single-copy gene with the entire coding 
sequence contained within three exons (Murakami et al., 1992). Exons 
1, 2 and 3 are 568bp, 113bp and 493bp, respectively. The three 
calcium-binding regions are all contained within exon 1. This is 
unusual as other gene sequences that contain calcium-binding domains 
are usually separated by introns (Xiang et al., 1991). 
The function, expression and genetic mapping of RCVl rendered it a 
good candidate for retinal degenerative disorders that mapped to 
chromosome 17p. 
Retinal guanylate cyclase (RETGC): RETGC is a critical component of 
the visual transduction pathway and is involved in the recovery from 
the light to dark state in the retina. Light activation leads to a drop in 
the calcium levels within rod photoreceptor cells. The drop in calcium 
levels in turn leads to a stimulation of membrane-bound RETGC 
production via the activation of guanylate cyclase-activating proteins 
(Dizhoor et a1., 1994). Activated RETGC, in turn, catalyses the 
conversion of guanosine triphosphate to cyclic 3',5'-guanosine 











genes, RETGC-l and RETGC-2, exist (Yang et a1., 1995). The n\"o 
isoforms dimerise to form the active cyclase (Yang et al., 1996). 
RETGC is a membrane-associated retinal enzyme \\'ith a high 
concentration in the outer segments of photoreceptor cells (Shyjan et 
al., 1992). The prominent expression of RETGC transcripts in only 
photoreceptors in itself implies that the enzyme has a very specialised 
function in these cells. 
The gene encoding RETGC-1 maps to chromosome 17p13.1 (Oliveira et 
al., 1994). The autosomal recessive condition, LCA, which also maps to 
chromosome 17p, was genetically fine mapped to the interval between 
markers D1781353 and D178838 (Perrault et aL, 1996). Three 
mutations, one in exon 8 and two in exon 2 of RETGC-1, were identified 
in affected individuals from three LCA families. Subsequently, 
additional LCA-related mutations were identified in RETGC-1 (Loyer et 
aL, 1998). Mutations of RETGC-1 were also shown to underlie the AD 
cone-rod dystrophy (CORD6) phenotype which maps to the same 
chromosomal region (Kelsell et aL, 1998). 
The human RETGC-1 gene is 16kb long, contains 20 exons, encodes a 
protein of 1101 amino acids with a molecular weight of 119,274, and is 
conserved between species (Shyjan et al., 1992). The localisation of 
RETGC-1 to chromosome 17p raised the possibility that a defect in this 












Phosphatidylinositol transfer protein (PITPN): Unlike the previous 
two candidates discussed, PITPN is not directly involved in the visual 
transduction cascade (as outlined in chapter 1). Instead, PITPN is 
involved with the regulation of membrane transport within 
photoreceptor cells (Vihtelic et al., 1993). A working model for the 
proposed function of PITPN was established with rdg8, the Drosophila 
homologue (figure 3.1). It has been proposed that rdg8 is required to 
transport proteins involved in phototransduction from the 
subrhabdomeric cisternae (SRC) to the photosensitive rhabdomeric 
membra·nes. PITPN is believed to stimulate membrane transport from 
the Golgi. The protein is membrane-bound (with six transmembrane 
domains) and possesses calcium-binding properties. 
The PITPN gene is expressed in a variety of sensory and neuronal cells 
(Vihtelic et aI., 1993) and is highly conserved between species. The 
human PITPN eDNA is 1368bp long (Gen8ank accession No. M73704) 
and, to date, no genomic DNA sequence of the gene has been published. 
It is known, however, that the gene contains an intron of about 1kb in 
its 3' untranslated region (personal communication with Dr David Hunt, 
London, UK). 
PITPN maps to human chromosomal band 17p13.3 (Fitzgibbon et aI., 
1994). A mutation identified in the Drosophila rdg8 gene (rdgB 
mutation) causes mutant flies to undergo photoreceptor degeneratron 











conditions for phototransduction between the SRC and the 
rhabdomeres is not established in rdgB mutants (Vihtelic et al., 1993). 
Studies have indicated that the SRC degenerates before the 
rhabdomeres, which suggests that the rhabdomeres are gradually lost 
as a result of inadequate maintenance by the SRC (Matsumoto-Suzuki 
et al., 1989). 
In view of the postulated function of the PITPN protein as well as the 
existence of a retinal degeneration homologue in Drosophila, it is 
conceivable that defects in PITPN (and hence in the membrane transfer 
process), could be involved in human retinal diseases. The possible 
involvement of the PITPN gene in the pathology of the ADRP-SA1 
phenotype was therefore investigated. 
Pigment epithelium-derived factor (PEDF): PEDF is believed to 
influence the development and maintenance of the neural retina (NR) 
(Tombran-Tink et al., 1995). The gene (PEDF) is, however, expressed in 
the RPE. PEDF is a major secretory product of human RPE cells into 
the interphotoreceptor matrix (IPM). In the IPM, the'PEDF protein 
possesses both neurotrophic and neuronal survival activities. Its loss 
may produce cell senescence (Tombran-Tink and Johnson, 1989). 
Although most of the cellular PEDF protein product is secreted into the 
IPM, it is also found to be associated with cytoskeletal structures. It co­
localises with actin, suggesting that PEDF could be involved in the. 





















Figure 3.1. Working model of the function of the rdgb protein in 
the photoreceptor cell. 
(a) 	 A Drosophila photoreceptor cell showing various subcellular stnlctures. The 
subrhabdomeric cisteITlae (SRC) is often connected to the rough endoplasmic 
reticulum by tubules. It is believed that integral membrane proteins such as 
rhodopsin pass through the SRC en-route to the rhabdomeric membranes. 
(b) 	 An expanded view of the interface between the SRC and the rhabdomeric 
membranes. The rdgB protein is situated within the SRC membrane with the PITP 
and acidic (calcium-binding) domains within the cytoplasm. The PITP and acidic 
domains are at these positions to respond to visual transduction triggers such as 
intracellular calcium levels. This subcellular localisation suggests that the rdgB 
protein regulates membrane transport from the SRC to replenish rhabdomeric 












PEDF was localised to the short arm of chromosome 17 by fluorescent 
in situ hybridisation (FISH) analysis (Tombran-Tink et aI., 1994). The 
gene is conserved between higher vertebrate species, is expressed in 
almost all human cel1ty"J:>es and belongs to the serpine gene family 
(Steele et aI., 1993). The serpines are a group of serine protease 
inhibitors. The PEDF reactive site, however, has a low sequence' 
homology to the reactive sites of other proteases. It is therefore not 
thought to behave as a classical antiprotease. 
The PEDF gene consists of eight exons which are transcribed into a 
1.5Kb long mRNA sequence. The mRNA, in turn, is translated into a 
50kDa protein of which several isoforms exist. The presence of these 
isoforms indicate, that different post-translational modifications take 
place within different cell typ.es. Furthermore, the various isoforms 
could be associated with the different proposed functions of the PEDF 
protein (Tombran-Tink et al., 1995). 
The proposed wide range of functions of PEDF in retinal cells, together 
with the location of the coding sequence on chromosome 17p, renders 
this a good candidate for the disorder segregating in the ADRP-SA1 
family. It may be postulated that a disruption of the RPE-NR 
relationship could cause photoreceptor degeneration. PEDF was 












~-arrestin 2 (ARRB2): ~-adrenergic receptor kinase (~ARK) and its 
cofactor ~-arrestin play an important role in determining homologous 
desensitisation of G-coupled receptors (Calabrese et al., 1994). ~­
arrestin quenches phosphorylated ~-2-adrenergic receptors. 
Both ~ARK and ~-arrestin are members of multigene families. To date, 
three members belonging to the arrestin/~-arrestin gene family have 
been identified: arrestin (SAG), ~-arrestin 1 (ARRB1) and ~-arrestin 2 
(ARRB2) (Wilson and Applebury, 1993). The gene, ARRB2, has been 
mapped to chromosome 17p13 by fluorescent in situ hybridisation 
(Calabrese et at, 1994). 
Although ARRB 1 and ARRB2 are localised predominantly in neuronal 
tissues and in the spleen (Attramadal et al., 1992), they have also been 
shown to be expressed in a wide range of tissues (Calabrese et at, 
1994). However, studies have shown that the ~-arrestins act in concert 
with ~ARK to regulate G protein-coupled neurotransmitter receptors 
(Attramadal et at, 1992), of which rhodopsin is a member. 
The genomic structure of ARRB2 has not yet been elucidated, however, 
it encodes a eDNA sequence of approximately 1.2kb (GenBank 
AF106941). The proposed function of ARRB2 and the localisation of its 
coding sequence to the short arm of chromosome 17 validated the 
investigation of the gene as a candidate for the ADRP phenotype 











A comprehensive range of techniques was used to investigate the 
candidates described. 
3.2. MATERIALS AND METHODS 
The RP13 disease-causing gene was localised to chromosome 17p 
(Greenberg et al., 1994b). Various genes mapping to the same 
chromosomal region were investigated using a range of PCR-based 
techniques to test their candidacy for involvement in the RP13 
phenotype in ADRP-SAl. 
3.2.1. POLYMERASE CHAIN REACTION 
Peripheral blood (10ml) was obtained from family members by 
venipuncture and genomic DNA was extracted using the Genomix™ 
blood scale-up kit [Talent, Italy] (Appendix A, section A.1). 
PCR amplifications were performed in reactions containing 0.211g of 
genomic DNA as templates; 50mM KCI, 10mM Tris-HCI pH8.3, 1.5mM 
MgCI2, 200l1M of dATP, dGTP, dTTP and dCTP; 111Ci of a-[32P]dCTP (for 
amplification of microsatellite markers and omitted for single-stranded 
conformational polymorphism (SSCP) analysis); 10-20 pmol of each 
primer and 1 unit of Taq polymerase [GibcoBRL, UK], in a final volume 
of 25111. Amplifications were carried out at 940 C for 3 min, followed by 
30 cycles at 940 C for 30 seconds, 550 C to 600 C for 30 seconds, 720 C 
for 40 seconds and a final extension of 5 min at 720 C in an Omn.igene 











PCRs to which radioactivity was incorporated, 20 ).11 of formamide 
loading buffer (Appendix B, section B.3) was added to each reaction 
after amplification. Samples were denatured for 3 min at 95DC and 
chilled on ice for 10 min, followed by electrophoresis through 6% 
denaturing polyacrylamide gels (Appendix B, section BA). The gels were 
dried onto 3MM paper [Schleicher and Schuell, Germany] on a slab gel 
drier [Hoefer Scientific Instruments, USA] for 1-2 hrs at 80DC and 
exposed to X-ray [Agfa, Germany] for 16-32 hrs at -70DC. Non­
radioactive products were used for SSCP analyses (section 3.2.3.). 
3.2.2. LINKAGE ANALYSIS 
Where intragenic microsatellite markers or SSCPs were available or 
identified, two-point linkage analyses were performed between the 
marker alleles and the RP13 disease locus. In order to produce a 
composite genetic map of flanking markers and the candidate genes, 
multipoint linkage analyses were performed between the tested 
intragenic and flanking markers using the LINKAGE software package 
Ver.5.03 (Lathrop and Lalouel, 1984). To conform to the number of 
alleles accommodated by the software, the number of alleles for each 
marker was reduced to five, ensuring no loss of information in the 
family. Lod scores between the markers and the ADRP locus were 
calculated using recombination fractions from 0.00 to 0.25 and the RP . 
gene was assumed to be completely penetrant. A gene frequency of 











3.2.3. INVESTIGATION OF RCVl 
3.2.3.1. SSCP Screening 
DNA from members of ADRP-SA1 was screened for a pathogenic 
mutation in the three exons of RCVl by SSCP analysis (Appendix A, 
section A.5). Genomic DNA was extracted from blood samples and the 
exons and flanking sequences amplified using oligonucleotide primers 
received from Dr Carol Freund (Baltimore, USA) (table 3.1.). Exon 1 was 
investigated using two overlapping PCR fragments because of its large 
size and to accommodate the size limitation for SSCP analysis of 200­
300bp (Grompe, 1993). 
SSCP loading buffer (Appendix B, section B.5) was added to each PCR 
product in a 1: 1 ratio. The samples were denatured for 2 min at 950 C 
and then chilled on ice for 5 minutes. Ten JlI of the denatured sample 
was electrophoresed through a non-denaturing 0.5% MDETM gel matrix 
[FMC BioProducts, USA] at 5-12W for 16-18 hrs followed by silver 
staining to visualise the DNA banding patterns [Lohmann et al., 1992] 
(Appendix A, section A.5.3). 
Table 3.1. Primer sequences used to amplify the three ReVl exons. 




































3.2.3.2. Microsatellite PCR 
The microsatellite marker D17S945 was reported to be located \\'ithin 
the 3' untranslated region of RCV1 (Wiechmann et aI., 1994b). To 
ascertain whether RCV1 segregates with the ADRP disease phenotype, 
DNA from family members of ADRP-SA1 were genotyped with this 
intragenic marker. Two point lod scores were calculated as described 
(section 3.2.2.). 
In order to refine the genetic localisation of RCV1, DNA from family 
members was genotyped with an additional 12 genetically ordered 
microsatellite markers spanning the RP13 chromosomal region. The 
order of the markers on the chromosome 17p genetic map was reported 
to be: tel- D17S926- D17S849- D17S1529- D17S1528- D17S831­
D17S829- D17S1353- D17S938- D17S796- D17S960- D17S786­
D17S804- cen (Gyapay et aI., 1994). A series of two point lod scores 
were calculated between each of the 12 microsatellite markers and the 
RCVl intragenic marker, D17S945. 
3.2.4. INVESTIGATION OF RETGC·l 
3.2.4.1. Direct PCR Sequencing 
A 675bp genomic DNA fragment isolated during the initial 
characterisation of RETGC-1 (Oliveira et aI., 1994), contained two 
complete and two partial exons of the gene. This candidate genomic 
fragment was assessed for DNA alterations between affected and . 
unaffected members of ADRP-SAI using direct peR sequencing 











5'cggtcaacaccgcctcgcgcatg3' and R - 5'cgggtgggatctcctgcaggctg3') used to 
amplify the fragment were the generous gift of Dr Steven Pittler 
(Alabama, USA). PCR fragments were electrophoresed through 2% 
agarose [Sigma, USA] gels, the bands were excised and purified using 
,the QIAquick protocol and sequenced, using the Sequenase version 2.0 
DNA sequencing kit (Appendix A, section A.6) as recommended by the 
manufacturer [USB, USA]. Sequencing reaction products were analysed 
on 6% PAGE gels and visualised by autoradiography. Fragments were 
compared between unaffected and affected individuals. 
Investigation of RETGC-J using the direct PCR sequencing approach 
was extended to the entire coding sequence of the gene. In order to 
facilitate this analysis three pairs of oligonucleotide primers were 
designed from the cDNA sequence of the gene (GC 1, GC2 and GC3) 
(table 3.2). 
Peripheral blood (10ml) was obtained from affected and unaffected 
family members by venipuncture and the lymphocytes, separated by 
centrifugation, were then transformed with Epstein-Bar virus (EBV). 
Total RNA was extracted from the transformed lymphoblasts (Appendix 
A, section A.2). The RNA was reverse transcribed using RT PCR 
(Appendix A, section A.2.1) followed by amplification of the overlapping 
RETGC-J cDNA fragments. The fragments were directly sequenced in 











Table 3.2. Primer sequences used to amplify and screen RETGC~l. 
Fragment peR Priln~rs 
5'-3' 



















3.2.5. INVESTIGATION OF PITPN 
3.2.5.1. MicrosateWte Analysis 
As a first step towards considering the possible involvement of PlTPN in 
the ADRP-SA 1 disease phenotype, DNA from affected and unaffected 
subjects in the family was genotyped with the marker D17SS, at the 
PlTPN gene locus (personal communication with Dr David Hunt, 
London, UK). PCRs were carried out with the incorporation of 
radioactively labelled dCTP (as described in section 3.2.1) and two-point 
lod scores were calculated from the resultant genotypes on 
autoradiographs (section 3.2.2). 
3.2.5.2. Restriction Fragment Length Polymorphism (RFLP) 
Analysis 
The genomic DNA from the ADRP-SA 1 family was tested for significant 
rearrangements within the PlTPN gene. Genomic DNA from a subset of 
affected and unaffected individuals was restricted with a battery of nine 
restriction endonuclease enzymes (AZul, BgZII, Csp4Sl, Dral, Haem, Mspl, 











hybond N+ nitrocellulose filters (Amersham, South Africa) using the 
conventional Southern blot method (Appendix A, section A.4.1). The 
filters were probed with a PITPN cDNA PCR probe which was amplified 
using a pair of primers (PITPN-F /PITPN-R) (table 3.3.) designed to 
amplify the 1.5kb cDNA fragment. Southern blot membranes were 
prepared, according to protocols in Appendix A, section A.4 (Vandenplas 
et al., 1984). The membranes were hybridised overnight at 65°C with 
the [a32PjdCTP-Iabelled probe (Appendix A, section A.4.2), washed at a 
final stringency of 0.6X SSC; 0.3% SDS at 65°C and exposed to Agfa 
Curix X-ray film at -70°C, overnight. 
3.2.5.3. Direct peR Sequencing 
,In order to screen for pathogenic mutations in PITPN, oligonucleotide 
primers (PITPN-F /PITPN-R) were designed to amplify the 1.5kb cDNA 
sequence (table 3.3). The resulting PCR fragment was sequenced 
directly, from both ends. In order to expedite the analysis, additional 
nested primers (table 3.3.) were used to amplify the gene (Lotery et al., 
1996). These facilitated the amplification of smaller fragments within 
the 1.5kb fragment for sequence analysis. 
Total RNA was extracted from Epstein-Barr virus-transformed 
lymphoblasts of an affected and an unaffected member from ADRP-SAI 
(Appendix A, section A.2). The RNA was reverse transcribed and 
fragments of the PITPN cDNA were amplified by PCR using nested 
primers. The amplified fragments were sequenced in order to screep for 











Table 3.3. Oligonucleotide primers used to amplify and sequence 
PITPNcDNA. 




PITPN-F 5 '-agcagagcacgacgaagac-3' 















3.2.5.4. Characterisation of The Intron-Exon Boundaries of 
PITPN for SSCP Analysis 
Towards characterising the genomic structure of PrFPN for further 
mutation analysis of the intron/exon boundaries, sequence 
comparisons were performed between the cDNA gene sequence 
(M73704) and data emerging from the high through-put genome 
sequence (htgs) database, using the BLAST function at the National 
Institute of Biotechnology Information (NCBJ) world wide web (www) 
site. 
3.2.6. INVESTIGATION OF PEDF 
3.2.6.1. RFLP Analysis 
A RsaI RFLP in PEDF had previously been reported with a 3.5kb 
polymorphic band, and three additional constant bands at 1.7kb, 
1.3kb, and l.Okb (Tombran-Tink et al., 1994). DNA from subjects 











conventional Southern blot method and radioactively labelled probe 
hybridisation (Appendix A, section A.4). The 1.5kb cDNA PCR product, 
amplified using oligonucleotide primers PI /499 (5'­
cctcagtgtgcaggcttagag-3' and 5'-ttgtatgcattgaaaccttacagg-3'), was used 
to probe the filters. The variant 3.5kb allele was seen in several 
individuals thereby facilitating analysis of the pattern of allele 
segregation within the family. 
In order to test for any significant rearrangements within the PEDF 
gene, genomic DNA from a subset of affected and unaffected ADRP-SAI 
individuals was restricted with a battery of nine restriction 
endonuclease enzymes (AZul, BgUI, Csp45I, DraI, RaeIII, MspI, Taql, XhoI 
and PvuIl). The digestion products were transferred onto Hybond N+ 
nitrocellulose filters (Amersham, South Africa) using the conventional 
Southern blot method. The radioactively labelled 1.5kb cDNA PCR 
product, was used to probe the filters (as described in section 3.2.5.2). 
3.2.6.2. SSCP Analysis 
The eight exons of PEDFwere screened for the pathogenic alteration 
segregating in ADRP-SAI using SSCP analysis (section 3.2.3.1). Eight 
pairs of oligonucleotide primers (table 3.4.) received from Drs Gerald 
Chader and Joyce Tombran-Tink (Washington, USA), were used to 
amplify the exons of the gene. The reSUlting PCR fragments included the 
intron-exon boundaries. In the initial screen of the PCR fragments, a 
section of ADRP-SAI was investigated for altered SSCP banding 
patterns. Where SSCP alterations were observed, the investigation 'was 











exhibiting alterations were sequenced directly (as described in section 
3.2.4.1.) in order to establish the precise DNA sequence change 
underlying the SSCP alteration. 
In order to assess whether DNA sequence alterations effected changes 
at the protein level, nucleotide database comparisons were performed 
against all available non-redundant protein data sets at the NCBI using 
BLAST (Altschul et al., 1990). 
Two point lod score's were calculated, as described in section 3.2.2. 
between the ADRP locus and the SSCP alterations observed in PEDF. 
The putative promoter region was screened for a pathogenic mutation 
using SSCP analysis. Five pairs of oligonucleotide primers were 
designed to produce overlapping PCR fragments spanning the 1.0kb 
length of the PEDF promoter region (table 3.5.). 
3.2.6.3. Refining The PEDF Map Position 
A series of two- and multipoint linkage analyses were performed 
towards fine mapping PEDF using the SSCP polymorphism in exon 4 as 
a fixed marker for the gene. The genetic order of the microsatellite 
markers in the region, as published by Genethon (Gyapay et al., 1994) 
and confirmed during this investigation (chapter 2), are as follows: cen ­
D17S829 - D17S831 - D17S1528 - D17S1529 - D17S849 - D17S926 ­
tel. The RP13 critical interval as defined by multipoint genetic linkage 












Table 3.4. OUgonucleotide primer pairs used to amplify the exons 
of PEDF. 






























Table 3.5. OUgonucleotide primers used to amplify the promoter 
region of PEDF. 
<AnnealingFragment PCR primers I Product 
Temp (OC,5'-3'. size (bp) 
Tl ggatcacctgaggtcagga 220 55 
ttaaaccttaggtcaatgt 




T4 247 55ctgcctcagactcccaagta 
aagaccagcctggccaa 












Multipoint linkage analyses were carried out where the SSCP in PEDF 
exon 4 was moved up to and between the 3 fIxed markers D17S849, 
D17S1529 and D17S831. A e value of 0.5 was used as the starting point 
away from D17S849 and then 4 equal increment values were used to 
move in on the fIxed marker loci. 
3.2.6.4. peR Sequencing 
Considering the fact that SSCP analysis has a sensitivity of 80-85% 
(Grompe, 1993), it is conceivable that the technique had failed to resolve 
a potential disease-causing DNA aberration in ADRP-SA1. In light of 
this reservation together with the genetic fIne mapping of PEDF, which 
deemed the gene an excellent candidate at the RP13 locus, the entire 
cDNA was sequenced directly, as previously described. The PEDF cDNA 
was sequenced using two pairs of nested oligonucleotide PCR primers 
(table 3.6). 
Total RNA was extract d from Epstein-Barr virus-transformed 
lymphoblasts of both an affected and an unaffected member from 
ADRP-SA1, as previously described in section 3.2.4.1. The RNA was 
reverse transcribed with a reverse transcriptase and PEDF cDNA was 
amplifIed by PCR and directly sequenced in order to screen for 
potentially pathogenic mutations. 
The intron-exon boundaries of the PEDF were also sequenced from· the 
eight genomic DNA fragments amplifIed during the SSCP screening of 











Table 3.6. Oligonucleotide primers used to analyse the cDNA 















3.2.7. INVESTIGATION OF ARRB2 
3.2.7.1. Sequencing of ARRB2 cDNA 
In order to screen for pathogenic mutations in ARRB2, oligonucleotide 
primers were designed to amplify and sequence the 1160bp of cDNA. 
The primers used were ARRB2-F 5'tcttcaagaagtcgagcc 3' and ARRB2-R 
5'agtcgtcatccttcatcc 3'. 
Total RNA was extracted from Epstein-Barr virus-transformed 
lymphoblasts of both an affected and an unaffected member of ADRP-
SAl (Appendix A, section A.2). The RNA was reverse transcribed and 
ARRB2 cDNA was amplified by peR and directly sequenced in order to 












3.3.1. ANALYSIS OF RCVl 
SSCP analysis: SSCP analysis of the four PCR-amplified fragments 
used to screen the exonic regions of ReVl revealed no altered DNA 
banding patterns between affected and unaffected subjects within a 
nuclear section of the ADRP-SAI family. 
Microsatellite analysis: To further investigate ReVl as the possible 
causal gene, DNA from members of the ADRP-SA 1 family was genotyped 
with the intragenic micro satellite marker, D17S945. Two-point linkage 
analysis between the marker and the ADRP-SA 1 disease phenotype 
produced a maximum lod score of 1.64 at e = 0.10 (table 3.7.). This 
result excludes a 10cM genetic distance on either side of ReVl. 
Table 3.7. 	 Pair-wise lod scores between D17S945 and the ADRP­
SAl phenotype. 
Recombination fraction (6) 
0 0.05 0.1 0.2 0.3 0.4 
D17S945 -0. 1.43 1.64 1.42 0.85 0.24 
In order to fine map ReVl and facilitate more accurate future 
investigations at the ReVl locus, a series of two-point linkage analyses 
was performed between D17S94$ and 12 genetically ordered DNA 











results obtained (table 3.8.) indicated that RCV1 was most closely 
linked to the markers D 17S796 and D 17S938. The findings placed 
RCV1 9 cM centromeric to the RP13 critical interval. These results 
confirmed and substantiated the exclusion of RCV1 from being 
causative of the ADRP-SA1 disease phenotype. 
Table 3.S. Pair-wise lod scores between D17S945 at the RCVl gene 
locus and chromosome 17p microsatellite markers. 
Recombination fraction (8) 
D17S945 vs 0 0.05 0.1 0.2 0.3 0.4 
D17S926 -a -3.21 -1.48 -0.26 0.02 0.02 
D17S849 -a -0.50 0.32 0.66 0.47 0.17 
D17S1529 -a 1.14 1.48 1.41 0.91 0.31 
D17S1528 -a 0.92 1.34 1.19 0.63 0.13 
D17S831 -a -0.29 0.63 0.88 0.51 0.11 
D17S829 -a 1.24 1.39 1.11 0.61 0.17 
D17S1353 3.22 3.28 2.98 2.08 1.07 0.28 
D17S938 5.04 5.05 4.69 3.53 2.08 0.66 
D17S796 4.97 4.52 3.98 2.80 1.63 0.57 
D17S960 2.28 2.25 2.09 1.53 0.80 0.18 
D17S786 4.75 4.27 3.74 2.60 1.46 0049 
D17S804 3.02 2.81 2.54 1.87 1.11 0040 
3.3.2. ANALYSIS OF RETGC-l 
PCR sequencing: A 675bp genomic peR fragment (isolated during the 
initial characterisation of RETGC-1), was sequenced in order to screen 
for the pathogenic alteration in the DNA of affected family members. 
Sequence analysis of the fragment revealed no sequence variations 











As no intragenic variants were detected with which to track the gene in 
the family, the entire coding sequence of the gene was sequenced (after 
subsequent characterisation of the cDNA) using overlapping peR 
fragments, No sequence variations were detected between the DNA of 
affected and unaffected subjects in the ADRP-SAl family. 
3.3.3. ANALYSIS OF PITPN 
MicrosatelZite analysis: In order to test PlTPN for linkage to the ADRP­
SAl phenotype, DNA from family members was genotyped with the 
marker D 17S5 which is closely linked to the gene'. While the disorder 
tracked consistently with one of the marker alleles, most of the meioses 
were uninformative. Two-point linkage analysis between the marker and 
the disease phenotype produced a very low positive lod score of 0.9 at e 
= 0.00. The gene could not be excluded on this basis. 
Southern blot analYSis: In the absence of other known tightly linked 
markers, the PlTPN gene sequence was tested for gross rearrangements 
or polymorphisms in the DNA of affected individuals using Southern 
blotting and hybridisation to a labelled probe. The banding patterns 
observed using the nine restriction endonuclease enzymes listed in 
section 3.2.5.2 were consistent between affected and unaffected 
individuals. The results indicated that there were no major detectable 












peR sequencing: As PITPN could not be excluded as the ADRP-SAl 
disease gene, the entire 1.5kb cDNA was sequenced. A C ~ T 
substitution at position 1127 of the cDNA sequence in an unaffected 
unrelated control individual was observed using oligonucleotide primers 
listed in table 3.3. The sequence change resulted in the creation ofa 
Puullrestriction enzyme site. The change was not detected in the DNA 
from family members on restriction enzyme analysis. No other sequence 
variations were observed between affected and unaffected subjects. 
The genomic structure of PITPN and SSCP analysis: The genomic 
structure of PITPN was elucidated by performing database comparisons. 
The PITPN cDNA sequence (M3704) was found to be homologous to a 
large genomic sequence file (accession number AC006405). The 
AC006405 sequence of 164kb contained almost all of the PITPN cDNA 
sequence, except for the first 236bp at the 5' end and 68bp at the 3' end 
of the sequence. The genomic sequence file is incomplete and this would 
therefore account for the gaps in the sequence. Eight exons were 
distinguishable (table 3.9.). Following the identification of 8 intronjexon 
boundaries, mutation analysis was performed by SSCP analysis. 
Oligonucleotide primers derived from the intronic sequences flanking 
the exonic fragments were designed to amplify the exons of the gene 












Table 3.9. The intron-exon boundaries of PITPN. 
Exon 5' Boundary .3' Boundary Size (bp) 
1 caactatgagagaaaa acatctactccattcag 50 
2 gacaggaaatcatagt ggacgtctccatacgcc 145 
3 ggggcgatatcgtttca cgtcttggccactcacg 93 
4 aagaaggtcttactcat ctcttacactcatcatc 84 
5 aagggtgtccacgtatt agtcgttccatcctagg 83 
6 taaagagagtcctaat ggttaaccttccatggt 78 
7 aaagattacgtcgttct gtaggtattccattcatc 112 
8 ggaaagatatcgttctc gacctacttcattcacc 124 
The bases U1 bold represent the 5' and 3' ends of each exon. 
Table 3.10. Oligonucleotide primers designed to amplify the 
PITPNexons from genomic DNA. 





































3.3.4. ANALYSIS OF PEDF 
RFLP analysis: The RsaI RFLP within PEDF was genotyped in the 
ADRP-SA1 family to test for linkage as described in section 3.2.6.1. On 
visual examination of the resulting allele segregation pattern, no 
recombinant meioses were observed, however, the genotypes were 
mostly uninformative. It was therefore not possible to conclude whether 
an association between the disease phenotype and the gene existed. As 
linkage results did not conform to the exclusion criteria for linkage 
analysis, the genomic DNA of affected individuals was tested for any 
significant rearrangement within PEDF using a battery of restriction 
endonuclease enzymes (section 3.2.6.1). No gross rearrangements of 
banding patterns were observed between affected and unaffected 
individuals. 
SSCP analysis: The exons and intron/exon boundaries of the PEDF 
gene were screened for SSCP alterations in the DNA of affected and 
unaffected members of ADRP-SA1. SSCP variants were detected in four 
of the eight PCR fragments analysed (table 3.11.). SSCP analysis of the' 
extended ADRP-SA1 family proved that each of the four fragments 
segregated in a Mendelian fashion with no observed recombinant 
events. Direct PCR sequence analysis of the variant fragments revealed 












Table 3.11. Base substitutions identified in PEDF 
on SSCP analysis of the exons. 












tga ~ tca 
ccc ~ cgc 
act ~ acc 
tac ~ tat 
Database searches suggested that while the substitutions in exons 3, 4 
and 7 reside in the coding region of the tested PCR fragments, they do 
not incur amino acid changes at the peptide level. These findings 
indicated that the changes in these exons are not disease-causing, but 
are non-deleterious polymorphisms. The base substitution underlying 
the SSCP change observed in the exon 1 PCR fragment proved to be 
located 16 bases into intron 1. In order to ascertain whether this 
substitution was disease-causing, 56 unaffected unrelated control 
chromosomes were tested for its presence using SSCP analysis. The 
intron 1 base change was identified in 15 of the chromosomes tested 
(figure 3.2.). 
The SSCP polymorphisms identified were further analysed to ascertain 
their usefulness in testing for linkage between the ADRP phenotype and 
PEDF. Visual examination of the allele segregation of the SSCPs in PEDF 













Figure 3.2. Silver stained SSCP gels showing (a) the Mendelian 
inheritance of t h e PEDF exon 1 polymorphism in a 
small branch of the ADRP-SAI family and (b) the same 












most polymorphic and exhibited no recombinant meioses. Interestingly. 
the recombinant meioses that defined the critical genetic interval 
harboring the ADRP-SA1 disease gene (in individual VI-I, chapter 2, 
figure 2.5.), was informative and not recombinant for the exon 1 
polymorphism. Two-point linkage analysis between the disease locus 
and the polymorphisms in exon 1 and 4 produced maximum lod scores 
of 4 and 7.1 respectively, at a 8 = 0.00. These findings strongly 
suggested that the PEDFgene lies within the RP13 genetic interval. 
SSCP analysis of the five overlapping fragments spanning the promoter 
region of the gene did not show any altered banding patterns. 
Genetic mapping ofPEDF: To confirm and substantiate preliminary 
results which suggested that PEDF lies within the RP13 critical interval, 
the gene was fine mapped with respect to previously ordered markers in 
the region. Two-point linkage analyses between the SSCP polymorphism 
in exon 4 of PEDF and the markers, D17S1529, D17S1528 and 
D17S831, produced maximum lod scores of 6.53,6.26 and 5.36, 
respectively (each at 8 = 0.00). The pooled results obtained from a series 
of multipoint linkage analyses are presented in figure 3.3. PEDF was 
estimated to be closest to marker D17S1529, with a maximum lod score 
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Figure 3.3. 	(a) Mendelian pattern of inheritance of the PEDF e.."{on 
4 SSCP polymorphism. (b) Multipoint map illustrating 
the pooled multipoint linkage results using the exon 











Sequence Analysis: In order to exclude PEDF from the disease 
phenotype with a high level of confidence, the entire cDNA sequence 
and intron/ exon boundaries were sequenced directly. Except for the 
polymorphic sequence variations identified during SSCP analysis of the 
exons (which were amplified from genomic DNA), no additional 
variations were observed. In terestingly, affected individual IV-17 was 
consistently heterozygous for the polymorphism in exon 4 (as revealed 
on genomic DNA as well as cDNA sequence analysis) (figure 3.4) . This 
finding confirms that both alleles were sequenced during the cDNA 
sequence analysis and reflects expression of both alleles. 
















Figure 3.4. 	Diagram showing heterozygosity in the cDNA sequence 












3.3.5. ANALYSIS OF ARRB2 

peR sequencing: Since the intron-exon boundaries of ARRB2 have yet 
to be established, the cDNA was sequenced in an ADRP patient and an 
unaffected family member from ADRP-SAI in order to screen for 
J . 
pathogenic mutations. In total, 800bp of the 1160bp cDNA was 
sequenced but no pathogenic sequence variations were detected. 
During the sequencing of the ARRB2 cDNA, according to a then newly 
published radiation hybrid map of 17p13.3; the gene was shown to map 
between the microsatellite markers D17S1828 and D17S796. This 
interval lies 4cM proximal to the refined RP13 locus, thus excluding 













Recently, substantial progress has been made in determining the 
genetic basis of monogenic retinal disorders. Mutations are identified on 
a regular basis in new genes responsible for some form of retinal 
degeneration. To date, in the ADRP form of human RDs alone, 12 genes 
have been localised to various chromosomal regions (chapter 1). 
Molecular genetic studies have identified disease-causing mutations 
associated with ADRP in 6 genes, while the remaining 6 genes which 
have been mapped, have yet to be identified 
(http:www.sph.uth.tmc.edujRetNetj). The first two genes which were 
identified encode the membrane proteins, RHO and peripherin/RDS 
(McWilliam et aL, 1989, Farrar et al., 1991). RHO initiates the 
phototransduction cascade (Yau, 1994) and peripherinjRDS plays an 
important role in maintaining the structural integrity of the 
photoreceptor discs (Kemp et al., 1992). More recently, an additional 
four genes were shown to be associated with ADRP. These include, (i) 
the transcription factor gene, NRL (14q), which is involved in the 
regulation of photoreceptor genes (Bessant et aL, 1999), (ii) the gene 
underlying the RP 1 phenotype (RP1) at the chromosome 8q locus 
(Sullivan et al., 1999), a retina-specific gene which regulates RHO 
expression, (iii) RETGC-1 on chromosome 17p which was shown to 
underlie a dominant cone-rod dystrophy, which is a common variant of 
RP (Perrault et al., 1998), and (iv) CRX (on 19q), which encodes a 
photoreceptor-specific transcription factor that regulates RHO 











have only been mapped to date. Among the latter anonymous loci, is 
RP13, which resides in a 3cM genetic interval on chromosome 17p13.3 
(described in chapter 2) (Goliath et al., 1995). 
In an attempt to identify the disease-causing gene at the RP13 locus, 
the 17p13.3 encompassing chromosomal region was interrogated for 
functionally significant genes. Genes which were located on 17p13 
included; RCV1, RETGC-l, PITPN, PEDFand ARRB2. Comprehensive 
investigation of the candidate genes suggest that aberrations in these 
were unlikely to be responsible for the ADRP phenotype in ADRP-SAl. It 
was worth noting, however, that the inability to detect a pathogenic 
alteration could be due to one of several reasons, e.g. the unsuccessful 
selection of the right candidate genes for the analysis, the methods 
employed, or both. The most recently mapped retinal gene chromosome 
17p13, AlPL1, (Sohocki et al., 1999) was excluded as a possible 
candidate, because ofits reported map position centromeric to the RP13 
critical interval (Sohocki et al., 1999). 
RCVl was excluded with a high level of confidence based on the 
observation of two recombinant meioses between an intragenic marker 
(D17S945) and the disease phenotype. As both recombinants were 
observed in individuals affected by RP, phenotypic misclassification due 
to reduced penetrance could be rejected. Furthermore, additional 
linkage analyses facilitated the genetic mapping of RCVl to a 
chromosomal region centromeric to the RP13 critical interval. This'work 











17p, which was done by in situ hybridisation analysis (Bayes et al., 
1995). The genetic mapping of RCVl corroborated the negative linkage 
results. It is interesting to note, that despite its key role in the 
phototransduction pathway, ReV1 has not yet been implicated in a 
human hereditary retinal disease. A number of possible explanations 
exist. The RCVl gene could have a mutation rate so low that the form of 
RD due to a defect in this gene would occur very rarely. A second 
possibility is that ReV1 is functionally redundant, where another 
protein has the same function. If this is the case, then individuals with 
RCVl mutations would not manifest a recognisable disease phenotype. 
Since RETGC-1 had not been fully characterised, direct sequence 
comparison analysis of the cDNA of an affected and unaffected member 
of ADRP-SA1 was carried out. Results did not reveal any pathogenic 
alterations. These findings suggested that RETGC-l was not the gene 
responsible for the disease phenotype in the family. Further evidence 
against RETGC-1 involvement was subsequently provided by a group 
investigating Leber's congenital amaurosis (LeAl), a form of retinal 
degeneration. The LeAl gene was genetically fine mapped to a lcM 
critical interval (9cM centromeric to the RP13 critical interval) between 
markers Dl7S938 and Dl7Sl353 defined by three critical recombinant 
events (Camuzat et al., 1996). The identification of RETGC-l mutations 
associated with the LCAl disease phenotype placed the gene into that 
same critical interval. Although unequivocal proof of exclusion was .not 
found in the current study, the localisation data indicated a low 











mutation in RETGC-l. 
As the PITPN gene sequence had not been fully characterised, the cDNA 
sequence of the gene was investigated using direct sequence analysis. 
No disease-causing variants in affected individuals from the ADRP-SA1 
family were detected. A genomic clone (AC006405) identified to be 
homologous to the PITPN cDNA sequence facilitated the characterisation 
of eight intron-exon boundaries. SSCP analysis of each exon and intron­
exon boundary revealed no pathogenic sequence changes in the DNA of 
affected members of the ADRP-SA1 family. Even though a Drosophila 
homologue exists, where mutations have been shown to underlie 
photoreceptor degeneration (Hotta and Benzer, 1970), no human 
disease association has been reported to date. 
In the search for the pathogenic alteration segregating in ADRP-SA1, 
PCR-SSCP analysis of the eight exons of PEDF elucidated five 
polymorphic alterations. These variants facilitated allele segregation 
analysis in the family as well as the genetic fine mapping of PEDF with 
respect to genetic markers which had been ordered at the RP13 locus 
(Goliath et al., 1996). No recombinant events were observed between the 
disease and an SSCP in exon 4. The observation that the disease gene 
and PEDFwere tightly linked, was confirmed with a series of multipoint 
analyses, which placed PEDF close to the telomeric RP13-flanking 
marker, D17S1529.. Based on the compelling linkage data presented in 
this chapter, PEDF was the most promising of the candidate genes' 











investigation, a disease-associated mutation was not identified in the 
PEDF gene. The possibility that a pathogenic mutation may result in a 
null allele, was an obvious concern. cDNA analyses for mutations is 
limiting in such cases since only the non-mutated allele may be present 
in the emerging sequence data. This theory was rejected when an 
individual heterozygous for the SSCP in exon 4 of genomic DNA, was 
shown to remain heterozygous for the same polymorphism on cDNA 
sequence analysis (figure 3.4.). This finding indicated that the promoter 
region of both alleles was functional. It was concluded that although 
PEDF is a prime candidate for the RP13 locus, the molecular genetic 
techniques utilised were unable to reveal any disease-associated DNA 
alteration. 
No mutation was detected upon direct sequencing of the ARRB2 cDNA. 
Furthermore, radiation hybrid mapping data obtained at Genemap98 at 
the NCBI, subsequently placed ARRB2 out of the RP13 critical interval. 
For these reasons the gene was not investigated any further. 
Although the five candidate genes discussed in this chapter have been 
screened extensively using a combination of molecular genetic 
techniques, no pathogenic genetic changes were found. Each one of 
them, however, remains a candidate for the other forms of RD localised 
to chromosome 17p. RETGC-l already has been reported to underlie 
LCA1 (Perrault et al., 1996) and CORD6 (Kelsell et al., 1998; Gregory­
Evans et at, 2000). 











• 	 the genetic fine mapping of the genes RCVl, and PED?, 
• 	 the elucidation of polymorphic variants within the PEDF and PITPN 
genes; and 
• the characterisation of the intron-exon boundaries of PITPN. 
These findings will assist in future investigations into disorders 
involving RD and RPE dysfunction linked to chromosome 17p. 
Methods for the identification of new candidate disease genes are being 
developed and should generate additional candidates at the RP13 locus. 
The first two ADRP genes identified RHO and peripherin/RDS were 
obvious candidates for retinal degeneration because of their function in 
the visual phototransduction cascade. It is now becoming clear though, 
that any gene that co-localises with a disease phenotype could be a 
candidate for that disorder. Researchers around the world are 
characterising genes from cDNA libraries from various tissues and 
mapping them to specific chromosomes using techniques such as FISH 
and RH mapping. In many instances the function of these genes are 
unknown. Hence the candidacy of these genes when localised to the 
same chromosomal region as a disease phenotype, cannot be ruled out. 
Hence, the assumption that only retinal specific genes will underlie the 
various forms of retinal degeneration has been discarded. Examples 
include the ubiquitously expressed RPGR gene which has been reported 
to be associated with XLRP (Meindl et al., 1996), and the ABCR gene 
causative of Stargardt macular dystrophy, which is expressed in ro~ 
cells while the disorder affects mainly cone cells (Allikmets et al., ' 











strategies have been developed towards identifying potential candidate 
genes for inherited retinal disorders. A method based on the use of 
subtractive and differential hybridizations from RD mouse retina, has 
been used in the identification of several retinal disease genes (Bowes et 
al., 1989). When mapped onto mouse chromosomes, these genes 
become candidates for retinal disease mapping to syntenic human 
chromosomal regions. Examples of genes identified in this way include 
cGMP-PDE P(Bowes et al., 1990) which led to the identification of 
defects in the human homologue shown to underlie ARRP (McLaughlin 
et al., 1993), peripherin/RDS (Travis et al., 1989) and rULPl (Hagstrom 
et al., 1998). The most recent RD gene identified using this method was 
the RP1 gene (RP1) (Sullivan et al., 1999). Another advantage of 
comparing human-mouse syntenic regions is that the animal model 
allows for the functional investigation of the encoded protein. 
In conclusion, 118 retinal disease loci have been identified and at least 
55 of the genes at these loci with defects responsible for various forms 
of retinal disease involving photoreceptor loss have been identified 
(Clarke et al., 2000). Several of the genes were first considered as 
candidates for study because of their involvement in murine retinal 
disease, others because of their chromosomal location and other novel 
genes were characterised by positional cloning techniques. Based on 
reports of disease loci for which no gene has yet been found, more than 
twice as many genes remain to be identified in this genetically 
heterogeneous group of diseases. It has been predicted that in the' 











choice in the search for disease-causing genes (Strachan and Read, 
1996). Hence, in the search for the RP13 causal gene, further screening 
of positional candidates should be continued. 
The fact that a mutation was not detected in the functionally significant 
genes investigated, led to the exploration of the physical map of the 
17p13.3 chromosomal region and more detailed interrogation of the 
interval. Towards this end, and because there was no evidence of 
existing contigs, it was necessary to extend the project into physically 












PHYSICAL MAP SPANNING THE RP13 
. LOCUS Iii 
4.1. INTRODUCTION 
Following the mapping of the RP13 locus to chromosome 17p13.3, the 
positional cloning approach was attempted in an effort to identify the 
defective gene. An initial step in this approach involved the construction 
of a physical map for the 3cM critical interval containing RP 13. 
Genetic maps define markers along each chromosome, and hence are 
invaluable tools to the molecular biologist providing the means to 
localise and identify disease genes. The work presented in chapter two 
of this thesis relied upon genetic marker maps for linkage analyses, and 
chapter three on genomic gene maps. Genetic maps are constructed 
using statistical analyses based upon a particular data set. Gene maps 
are constructed using a combination of mapping techniques ego FISH 
analyses for gross localisation as was done for the PEDF gene, prior to 
this study, (Tombran-Tink et al., 1994), and linkage analyses, as 
described for the PEDF gene and the RP13 locus in this study (Goliath 
et al., 1996). While these maps are invaluable in localising and fine 
mapping genes which cause disease, they are labile, in that the order of 
information on these maps is in flux. Physical maps which include 
clone and sequence contig maps, however, consist of a linked library of 
small overlapping clones or sequences representing a complete 













available for chromosome 17p has been exhausted in the search for the 
disease gene in family ADRP-SA 1. This chapter presents work carried 
out towards constructing a physical map at the RP13 locus with a 
combination of in vitro and in silico analyses. 
In vitro analysis involves the construction of physical maps of genomic 
DNA fragments cloned into vectors that are maintained in yeast cells as. 
artificial chromosomes (YACs) (Burke et al., 1987). One of the major 
advantages of these vectors is their ability to contain large segments of 
genomic DNA. The ordered fragments form contiguous DNA blocks 
called contigs. Significant time and effort has been invested in 
establishing genomic libraries that cover the entire genome in relatively 
small overlapping fragments. Currently, the resulting library of available 
human YAC libraries comprise of clones containing insert DNA which 
varies in size from 10,000 bp to 1 Mb. The physical clone contig 
covering a critical interval, is an important tool for the identification and 
cloning of genes causative of inherited disorders. There are some 
problems, however, that need to be considered when working with YAC 
clones. One disadvantage is that YACs (40-60%) may be chimaeric i.e. 
the clones may contain two or more fragments derived from non­
contiguous segments of human insert DNA. A second problem is that 
some clones are unstable and rearrangements may result in the 
deletion of internal regions of the insert fragment (which could be 
counter productive in gene isolation experiments or in the construction 











In order to overcome these problems, several alternative cloning vectors 
have been developed e.g. bacterial artificial chromosomes (BACs), Pl­
derived artificial chromosomes (PACs) and cosmids (containing a 
bacteriophage lambda cos site) which contain smaller insert sizes. 
One of the goals of the Human Genome Project has been to determine 
the sequence of the 3 billion bases that make up the human genome, to 
store this information in databases and to develop tools for analysis of 
the data (http:j jwww.ornl.govjhgmisjprojectjabout.html). Cloned 
human genomic fragments are sequenced in a shot-gun approach 
resulting in an array of sequences for each clone. The arrays are 
ordered on completion of the sequencing of the cloned fragment. The 
sequence information is then stored in electronic files and placed in 
databases. Each sequence file may not be complete and may consist of 
an array of unordered sequence fragments of a specific clone. The in 
silico analysis of the sequence files encompasses the field of 
bioinfomatics which involves the creation, development, and operation 
of databases and other computing tools to collect, organize, and 
interpret data. To date, a vast range of bioinformatics utilities have been 
developed to analyse and arrange the sequence files into ordered 
sequence contigs. The networked information of searchable databases of 
genetic data has become a powerful resource in the field of molecular 
genetics. Establishing the sequence of the entire genome in the form of 













4.2. MATERIALS AND METHODS 
4.2.1. INVESTIGATIONS IN VITRO 
4.2.1.1. Detection of YACS by STS Screening of Pooled 
Libraries 
In order to generate a physical map of the RP13 region, YAC libraries of 
the Imperial Chemical Industries (ICI), Imperial Cancer Research Fund 
(ICRF) and Centre d'Etude du Polymorphisme Humain (CEPH) were 
screened using standard PCR protocols with microsatellite markers 
around the critical interval namely D17S1529, D17S1528, D17S831, 
D17S1798 and D17S5 (chapter 2). The ICI and ICRF pooled YAC 
libraries were obtained through the HGMP Resource Centre (Hixton, 
UK), and the CEPH mega-YAC library from the Jean Dausset CEPH 
(Paris, France). PCR products were checked for size by comparison with 
a lkb molecular weight marker [GibeD, UK] on 2% agarose [Sigma, USA] 
gels. The YAC clones which proved positive for one or more of the 
microsatellite markers were streaked on YEPD [GibeD, UK] plates 
(Appendix A, section A.7.1) with IJ.tI/ml ampicillin and incubated for 2 
days at 30oC. Single colonies of each YAC were tested for their sequence 
tagged site (STS) content by performing colony PCRs in order to test for 
clonal rearrangement during cell division before YAC DNA extraction. 
Sterile toothpicks were used to pick the colonies, followed by inserting 
the toothpick into standard PCR reaction mixes for direct PCR. YAC 
DNA of positive colonies was extracted into solution for further 
manipulations, and into agarose plugs in order to maintain the integrity 
of the DNA (Appendix A, section A.7.2). The YACs were retested for their 












4.2.1.2. Isolation of YAC Ends 
In order to establish the end sequences of the clones identified, YAC end 
sequences were generated by the vectorette and fragment isolation 
method adapted from Riley et al. (1990). The cloned DNA was digested 
with a range of restriction enzymes (Alul, EcoRV, PuuII and Rsal) and 
ligated with a blunt-end vectorette cassette, as described. The resulting 
four vectorette libraries were used as templates and PCR was performed 
with a universal vectorette primer and either the SP6 or T7 primers to 
amplify the terminal sequences. The oligonucleotides and primers used 
are detailed in table 4.1. 
Table 4.1. Oligonucleotides used in vectorette PCR. 
Primer 













4.2.1.3. YAC Contig Construction 
In order to arrange the YACs identified by pooled library screening into 
an ordered contig, a series of PCR-based STS content mapping tests 
were carried out. Standard PCR protocols were used. The YACs were 











D17SS and D17S1798; the EST, PEDF3; and the YAC end sequences 
3SBES-L, 3SBES-R, 25BH6-L and 25BH6-R (Stack et al., 1995) (table 
4.2.). 
Table 4.2. Details if STSs used in YAC contig construction. 





























4.2.2. INVESTIGATIONS IN slueo 
The increasing number and size of sequence databases available on the 
www facilitates the creation of sequence contigs across regions of 
interest. A series of bioinformatic applications were used in an effort to 
establish a sequence contig, the ultimate physical map, across the RP13 
chromosomal region. 
4.2.2.1. Database Searches and Sequence Comparisons 
Sequence files which map to the RP13 chromosomal region were 
identified by performing homology searches against the nucleotide 
databases outlined in table 4.3., using the basic local alignment search 












(NCBI). The nucleotide sequence databases were BLAST searched with 
the markers surrounding the RP13 interval, as well as with expressed 
sequence tagged sites (ESTs) and STSs placed into the interval by 
radiation hybrid mapping as outlined at GeneMap98 (NCBI). End 
sequences of homologous files were used to search the same databases 
for overlapping sequence files. 
The STS content of the genomic files was tested by performing homology 
searches using the BLAST 2 SEQUENCES utility at the NCBL Files were 
retrieved using the sequence retrieval utilities at EMBL and Genbank. 
Table 4.4. lists the universal resource locators (URLs) for the 
bioinformatics utilities used most frequently in the in silico analyses of 
the RP13 chromosomal region. 
Table 4.3. Nucleotide databases used in in silica analyses. 
", 
Database Abbreviation: 
Genome survey sequences 
High through-put genome sequences 
Non-redundant nucleotide sequences 
Sequence tagged site database 
Expressed sequence tagged site database 



























BLAST 2 sequences 











http://www.ncbLn1m.nih.govIgenemap981 map.cgi?CHR= 17 
http://www.ncbLn1m.nih.gov/genome/seqj 
http://ziggy·sanbi.ac.za/stack/stacksearch.html 
4.2.2.2. Identification of Retinal ESTs Mapping To The RP13 
Interval 
In order to identuy any retinal ESTs within the critical interval, a 
database of the RP13 sequence files was created and compared with the 
eye subset of the STACK EST database using the STACKsearcher utility 
at the South African National Bioinformatics Institute (SANBI). The 
STACKsearcher allows you to perform a BLAST search of your query 
sequencejs against the STACK database. The STACK EST database 
consists of groups of aligned ESTs organised via tissue subdivisions as 
well as a whole body index. 
4.2.2.3. Identification of New Microsatellite Markers 
The identification of new polymorphic markers within a region of 
interest could prove useful in reducing the critical interval. Towards this 
end the RP13 sequence contig was searched with arbitrary sequences of 












4.3.1. PHYSICAL MAPPING IN VITRO 
Identification ofYAC clones mapping to the RP13 region: To 
identify clones residing in the RP13 chromosomal region three pooled 
YAC libraries (ICI, ICRF and CEPH) were screened using microsatellite 
markers bracketing the interval. A total of 4 YACs were identified as 
containing at least one of the genetic markers from the RP13 region. 
YAC clones 4X70-B3, 4X127-H12 and 4X54-A9 were identified from the 
ICRF library with markers D17S1528, D17S831 and D17S1798 
respectively, and clone 341-B6 from the ICI YAC library with marker 
D17S1529 (table 4.5). In addition YACs 441D8, 38BE8, 416F9 and 
21 FH 10 which map to the region around the marker D 17S5, were 
obtained from Dr C. Inglehearn (London, UK) (table 4.5.). 
YAC contig constnLction by STS content and integration of genetic 
and physical mapping data: In order to organise the 4 YACs 
identified by pool screening (4X70-B3, 4X127-H12, 4X54-A9 and 341­
B6) into an ordered contig, a series of PCR-based STS content mapping 
tests were carried out. The same strategy was used to integrate these 4 
YACs with the 4 YACs around the marker D17S5 (441D8, 38BE8, 
416F9 and 21FH10). The D17S5YACs form part ofa small contig, 
constructed by Stack et al. (1995). Details of the STS content mapping 
of the 8 YAC clones are presented in table 4.5. and illustrated in figure 
4.1. YACs 416F9 and 38BE8 are each homologous for the non- ." 











The marker, D17S1528, is present in YAC 38BE8 but not in 416F9. The 
markers D17S5, D17S831 and D17S1528 are present in 441D8 while 
this YAC does not contain the STS 38BE8-L. The STSs PEDF2 and 
PEDF3 (second and third exon of the PEDF gene) were present in 4X70­
B3 alone, thereby specifying the physical orientation of the markers. No 
further Y ACs could be identified to close the gap between the YAC 
4X70-B3 and 34I-B6, by screening the pooled YAC libraries. The UK 
group, headed by Dr Chris Ingelhearn was, however, able to close the 
gap with three PAC clones 268-A16, 300-H3 and 222-B19 (figure 4.1). 















' PEDF3YAC SOURCE SIZE D1781529 ])17S1S2838BE8·R 25BH6.L D17S831 1)i7S5 2S8H6.R 38BE8·L· D17S1798.' (KB) 
34I-B6 ICI 225 + 0 0 0 0 0 0 0 0 0 
4X70-B3 ICRF 0-1000 + + + + + + 0 0 0 
4X127-H12 ICRF 365 0 0 0 00 + + 0 0 0 
4X54-A9 NAICRF 0 0 0 0 0 0 0 0 0 + 
. 
441D8 530CEPH 0 0 0 + + + + 0 0 0 
416F9 CEPH NA 0 0 0 0 0 0 + + + 0 
38BE8 Zeneca 265 0 0 + 0+ 0 + + + 0 
21FH10 Zeneca 200 0 0 0 +0 0 + 0 0 0 
Markers are listed in their most likely physical order from the telomere to centromere. Clone sizes of the last four YACs were taken from Stack et al. 1995 












25BH6RA D17S5 25BH6LA 38BE8RA PIIPN D17S1529 











! I 300H3 I-r--:_­
4X12f7H12 _J_:!:~!2_ 
Figure 4.1. An STS content physical clone contig spanning the 
RP13 chromosomal region. 
The red arrow and markers represent the RP13 interval 
and bracketing markers. End clones are represented by 
black squares. Black and purple lines represent YAC and 











4.3.2. PHYSICAL MAPPING IN SILICO 
Identification of sequence files mapping to the RP13 region: In 
order to compliment and enhance the physical clone contig at the RP13 
interval, construction of a physical sequence contig of the region v.as 
initiated. Sequence databases were BLAST searched with markers 
bracketing the RP13 interval to identify sequence files residing in the 
same chromosomal region. A total of 8 genomic sequence files were 
identified in the nucleotide databases as containing at least one of the 
genetic markers from the RP13 region (table 4.6.). Six of the sequence 
files identified were incomplete, each consisting of several unordered 
fragments (AC006435, AC0021705, AC007873, AC006405,AC002093, 
AC015884). The remaining 2 sequence files are completely sequenced 
(AC002316 and AC005696). 
Sequence assembly construction by STS content and integration 
of genetic and physical mapping data: In order to organise the 9 
sequence files identified in the R13 chromosomal region into sequence 
contigs, a series of sequence comparisons and EST/STS content 
investigations were carried out between files. 
Using the technique of radiation hybrid (RH) mapping many ESTs and 
genes have been mapped to various chromosomal regions 
(http://www.ncbLnlm.nih.gov/genemap98j).This technique involves 
the use of a panel of somatic cell hybrids, with each cell line containing 
a random set of fragments of irradiated human genomic DNA in a ' 











interval which includes the RP13 critical region (figure 4.2). Sequence 
comparisons between the RP13 sequence files and each of these 
candidate ESTs were carried out. The sequence alignment results 
placed several of these ESTs onto the RP13 sequence files as well as 
several STSs and genes (table 4.7). Sequence files AC002316 and 
AC005696 form a small sequence assembly which overlaps by 15 
633bp. Distal to this assembly, sequence files AC002093 and 
AC006405 also overlap. Figure 4.3. illustrates the sequence contig 
placed against the genetic and clone contig maps of the region as 
discovered during the course of this study. Sequence file, AC005696, 
contains the markers D17S1845 and D17S1798, 146.433kb apart on 
the sequence contig and lcM on the genetic map. 
Table 4.6. Sequence f"ues identified in the RP13 chromosomal 
region. 
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j ACOO~17051 I 

ACqo7873-"­
Figure 4.2. A partial STS content physical sequence contig 
and expression map of the RP 13 chromosomal 
region. 
The ESTs are unordered within the interval. 
AC002316 = 88 071bp 
AC005696 = 177 411bp 
AC006435 = 135 363bp 
AC0021705 = 190765bp 
AC007873 = 214 644bp 
AC006405 = 163 035bp 
AC002093 = 133 687bp 












Table 4.7. Genes/ESTs/STSs placed on the sequence contig in this 
study. 
GeneI EST/STS Seauence f'lle 































Retinal ESTs mapping to the RP13 sequence contig: The retinal 
ESTs identified in the STACK EST database are detailed in table 4.8. 





" 1',­ . '. 
.... FILE.,,'. '. 
GENE.'·, 
. .' 
AA318345 ACOO6405 PlTPN 
AA317269 ACOO6405 PlTPN 
T30609 ACOO2093 PRPB 
AA317401 ACOO5696 Miller-Dieker 
lissencephaly 
disease gene 
W22489 ACOO5696 Human retina 
cDNA 
Microsatellite markers identified: A (CA)n repeat was identified in the 
region of overlap between sequence flIes AC006405 and AC002093. A 
sequence comparison performed between the two sequence fues showed 
that the dinucleotide repeat was polymorphic between them. BLAST 
searching the STS database with the repeat, including the flanking 
region, proved that the repeat had not been previously identified. PCR 
primers designed on either side of the repeat region (RPTI-F 
5'gacctgttcccaggaatgtg 3', RPTI-R 5'aaaaggcaacaaggcatttg 31 were used 
to amplify the region and to genotype the subjects within the ADRP-SAI 
family. Five alleles were observed with the same allele segregation 
pattern as that of the telomeric bracketing marker D17S1529 (figure 
. 

2.6., chapter 2). Hence, the RP13 interval could not be genetically 












The AD form of retinitis pigmentosa was mapped to chromosome 17p 
(chapter 2) within the interval defined by markers, D17S1529 and· 
D17S831 (Goliath et aI., 1995). This chapter described the construction 
of a physical map of the RP13 chromosomal region using a combination 
of in vitro and in silica analyses. 
Physical maps are used to isolate and characterise individual genes and 
other DNA regions of interest and provide the substrate for DNA 
sequencing. The lowest- resolution physical map is the chromosomal or 
cytogenetic map and the more detailed YAC or cosmid contig map 
represents the order of overlapping DNA fragments spanning the 
genome. The ultimate physical map of the human genome, however, is 
the complete DNA sequence. 
The physical clone contig constructed across the RP13 interval 
comprises 7 YACs and 3 PACs. The contig confirms the reported order 
of loci on the genetic map and allows for the placement of markers 
relative to each other that had not been resolved previously. The order 
of STSs highlights which of the genes are positional candidates and 
which are not. Ultimately, according to this study the PEDF and PITPN 
genes remain candidates at the RP13 locus. 
Much progress has been made towards sequencing the entire human 











Examination of these sequence databases for large-scale comparative 
analysis of genome sequence data is becoming the most important 
application of bioinformatics for the characterisation of candidate 
disease genes. Using these bioinformatics utilities to interrogate the 
sequence databases, a partial sequence contig of the RP13 
chromosomal region was constructed. The sequence contigs confirm 
corresponding areas on the physical clone contig. Two of the original 
candidate genes investigated at the RP13 locus have been placed onto 
the electronic sequence contig (PITPN and PEDF). Although no disease­
causing mutations were identified in either of these genes, (chapter 
3.3.3. and 3.3.4.), their precise physical mapping should facilitate the 
molecular genetic investigations of other retinal disorders mapping to 
the same chromosomal region. An additional candidate gene, PRP8, was 
identified by in silica mapping (chapter 4.3.2.). The gene is retinally 
expressed and resides on the sequence contig constructed within the 
RP13 critical interval. Several other ESTs that were previously 
unmapped were placed on.to the contig. 
The sequence databases provide DNA fragments that can be screened 
not only for markers known to be in a region of interest, but also for 
additional polymorphisms. The identification of new polymorphisms 
improves the genetic map of the region with the possibility of further 
refining the gene location. Indeed, a (CA)n repeat region was identified 
within two overlapping sequence files at the RP13 locus. Comparison of 
the repeat regions between the two sequence files showed that the' 











AC006405 was two (CA) units longer than that in sequence file, 
AC002093. Following the design of primers on either side, the repeat 
was amplified and the subjects within the ADRP-SA1 family genotyped 
(chapter 4.3.2.). The allele segregation pattern of the marker proved to 
be the same as seen for the telomeric flanking marker, D17S1529. This 
result therefore, did not facilitate the narrowing of the RP13 interval. 
It is known that telomeric chromosomal regions are the most gene-rich 
areas of the genome (Lese et al., 1999). Consequently, closing the gaps 
in the physical maps of these regions has received much attention. It is 
also believed that genetic maps of telomeric chromosomal regions are 
expanded with respect to the corresponding physical maps. The RP13 
interval covers a genetic distance of 3cM (chapter 2) at the telomeric 
region of chromosome 17p. In genetic terms this should extrapolate to a 
physical distance of approximately 3 megabases. However, a genetic 
distance of 1cM (lmegabase) separates the DNA markers D17S1845 
and D17S1798 at the centromeric end of the RP13 interval on the 
genetic map of the region. In this study these markers were both placed 
onto the sequence file AC005696 (which was completely sequenced) 
with a physical distance of about 150kb between them. This observation 
of apparent enhanced recombination at the telomeric end of 
chromosome 17p confirms a previous study suggesting the same 
phenomenon (Martens et aI., 1998). In this previous reported study it 
was shown that terminal regions of human chromosomes are 
characterised by a series of T2AG3 repeats and that the number of' 











average telomere length (Martens et aI., 1998). Taken together these 
findings may indicate that the 3cM RP13 interval which, in general 
genetic terms, should extrapolate to a physical distance of 
approximately 3 megabases, could actually traverse a much smaller 
physical distance. If this is the case then it would be foreseeable that 
with the current release of draft sequences of the entire genomic 
sequence, that the RPI3 interval could be completely sequenced in the 
not too distant future. 
The YAC I PAC contig, together with the partial sequence-contig, forms a 
solid foundation for the elucidation of the RPI3 disease-causing gene. 
The establishment of a transcriptional (EST) map of the region 
commenced in this study further facilitates this goal. The identification 
of candidate ESTs and genes on the physical contigs of the RPI3 
interval will highlight new candidate genes for ADRP, and other genetic 
disorders that map to this region of chromosome 17pI3.3. The PITPN 
and PEDF genes were placed in the RPI3 interval both genetically 
(chapter 3) and physically (chapter 4). Intense investigation of these 
genes, however, revealed no pathogenic alterations in the ADRP-SAI 
family. Furthermore, according to the GeneMap98 database at the 
NCBI, other genes in the RP13 interval include the PRP8, human 
phosphatidylinositol (4,5) biphosphate, myosin-l beta, alpha-2-plasmin 
inhibitor and the replication protein Al genes. Although these genes are 
expressed in several tissues their candidacy for the RPI3 gene has. pot 
been excluded. As discussed in chapter 3, the tendency to study ohly 











gradually being abandoned. This shift in focus, is due to the elucidation 
of disease-associated alterations in genes either with an unknown 
function or no clear functional significance to the disorder being 
studied. Examples include the ubiquitously expressed RPGR gene 
reported to be associated with XLRP (Meindl et al., 1996) and TIMP3, a 
member of the TIMP gene family, has been shown to be causative of 
Sorsby fundus dystrophy (Weber et al. 1994). 
Clearly the rapidly expanding genome sequencing projects generate 
enough data with which to overwhelm researchers. Fortunately, the 
bioinformatics tools available create an excellent environment for 
searching and exploring this ever expanding "sequence universe." In the 
future, the complete integration of the sequence and clone contigs 
presented here will be useful aids in identifying new candidate genes 















Identification of the disease-causing genes is an important step toward 
understanding inherited retinal degenerative diseases. Currently, in the 
field of inherited RD, major progress has been made in identifying the 
underlying causal genes. With subsequent molecular and cell biological 
investigation yielding insights into the pathogenic mechanisms 
underlying this group of disorders, it is likely that this perspective in 
disease aetiology, will facilitate the development of therapeutic 
measures. The rate at which these genes are being identified continues 
to increase with the constantly improving genetic and physical maps. 
• 
This dissertation describes the progress towards identifying the disease­
causing gene segregating in one of the largest ADRP families recorded in 
South Africa. Using the positional candidate approach, the causal gene 
was localised to the short arm of chromosome 17 (17p13.1) (Greenberg 
et aI., 1994b). The successful mapping followed the exclusion of large 
chromosomal regions which were previously reported to be either linked 
to ADRP, or which contained other functionally significant candidate 
genes. The novel, and at that stage, unique South African locus, 
designated RP13, was the first to be identified amongst a large cohort of 











identification of RP13 confirms that the positional candidate approach 
is a powerful method for mapping disease genes. The same approach 
was subsequently used in the mapping of another novel SA ADRP gene 
to the long arm of chromosome 17 (RP17) (Bardien et aI., 1995). 
Following initial genetic mapping between markers situated 23cM apart" 
the RP13 locus was fine mapped to a 3cM critical interval between the 
microsatellite markers, D17S1529 and D17S831, within the telomeric 
chromosomal band, 17p13.3, (Goliath et a1., 1995). The genetic interval 
could not be reduced any further due to the lack of additional 
microsatellite markers within the RP13 critical region on the genetic 
map and no additional meioses being available for investigation. 
Following the localisation of RP13 in the SA family, the disorder was 
reported in two additional ADRP families (from the USA and UK, 
respectively) and was mapped to the same locus at 17p13.3 (Kojis et al., 
1996; Tarttelin et al., 1996). The disorder in all three families is 
characterised by an early onset form of ADRP. Furthermore, the 
common British ancestry of both the SA and USA RP 13-linked families 
led to the hypothesis that the disease in all three families was due to a 
founder mutation. Genetic analysis, however, comparing linkage data in 
the SA and UK families revealed distinct disease-associated haplotypes 
(the family from the USA was not available for testing). This finding 
indicates that the phenotype in the disparate families might be a re.sult 
of different pathogenic mutations. However, it is possible that the . 











underlying pathogenic mutation where recombination events over many 
generations might have increased the likelihood of tightly linked 
markers being separated. The eventual identification of the disease­
causing gene/ s and pathogenic mutation/ s will clarify this issue. 
It is possible that the molecular demography underlying inherited RD in 
SA may be different to that in other geographic regions of the world. 
This theory is proposed because, of the entire cohort of SA RP families 
being investigated, two novel loci have been reported to date; RP13 
(Greenberg et aI., 1994) and RP17 (Bardien et aI., 1995). Furthermore, 
the disorder in only a minor number of families has been shown to map 
to each of these loci (three at each locus). In addition, although 
international findings suggest that rhodopsin gene mutations account 
for 20% of ADRP, subjects which form part of the research cohort in the 
laboratory of Human Genetics at VCT exhibit a decreased incidence of 
rhodopsin gene mutations as reported by Roberts et al. (2000). 
Subsequent to the identification of the RP13 locus on chromosome 
17p13, several other retinal disorders have been reported to map to the 
same chromosomal region, but to distinct loci. These include LCA 1 
(Camuzat et aI., 1995), CORD5 (Balciumiene et aI., 1995), SLS (Rogers 
et aI., 1995), CACD (Lotery et aI., 1996), CORD6 (Kelsell et aI., 1997), 
and LCA2 (Hameed et aI., 2000) (chapter 2). The specific defect in the 
RETGC-l gene has since been identified for LCA1 and CORD6 (Perrault 
et aI., 1996, Kelsell et aI., 1998) and for SLS in the fatty aldehyde 











Six functionally significant retinal genes map to the short arm of 
chromosome 17 (RCVl, RETGC-l, PITPN, PEDF, ARRB2 and AILPl). The 
retinally expressed gene AILPl J which was most recently mapped to 
chromosome 17p was not considered a candidate for the RP13 disease 
gene due to its map position being outside of the critical interval 
(Sohocki et al., 1999). The first five genes were tested as possible 
disease-causing candidates in the ADRP-SA1 family. The molecular 
genetic techniques used did not reveal potentially pathogenic mutations 
in any of these genes. In addition, the RCVl gene was excluded on the 
basis of recombinant events between the disease phenotype and an 
intragenic polymorphic marker. The RETGC-l and ARRB2 genes were 
further excluded by the subsequent genetic fine mapping of these 
genes, which placed them into a different genetic interval to that of the 
RP13 locus (Camuzat et aI., 1996 and GeneMap98). Although the 
remaining two candidate genes, PITPN and PEDF, map to the RP13 
critical interval, extensive interrogation of these genes did not reveal 
any pathogenic alterations. The data emerging from the analysis of the 
genes, markers and loci, collectively used during this study, contributed 
significantly to,the integrity of the genetic map of the 17p13 
chromosomal region. Furthermore, the identification of intragenic 
polymorphisms in certain instances has and will in the future, allow for 
the rapid investigation of these genes in other retinal disorders that 











The various retinal phenotypes linked to the chromosome 1 7 P region 
could be the result of mutations in one or several of the 17p13 retinally­
expressed genes. The absence of a potential pathogenic alteration in the 
functionally significant positional candidate genes investigated in this 
study so far, suggests that the causal gene is likely to be an as yet 
unknown retinally-significant gene on chromosome 17p. 
The RP13 critical interval spans a genetic distance of 3cM, which may 
initially appear to be too large for the application of conventional 
positional cloning techniques. However, the locus resides at the 
telomeric end of chromosome 17p, a condensed physical region with 
respect to the corresponding genetic map (Martens et al., 1998). In light 
of this, physical mapping strategies were deemed feasible across the 
3cM interval towards identifying the novel gene. A physical clone contig 
i 
that spans the RP13 region was constructed with YAC and PAC clones. 
This contig consists of overlapping clones and contains both flanking 
markers (D17S1529 and D17S831),that define the RP13 critical 
interval. The contig provides the scaffolding upon which new genes can 
now be localised and identified. 
In conjunction with the physical mapping strategies using cloned DNA 
(in vitro analysis), bioinformatics techniques (in silico analysis) were also 
applied in this study. Together with the physical clone contig, a partial 
physical sequence contig was constructed with large sequence files. 
retrieved from various substantial sequence databases available on the 











databases were undertaken in an attempt to generate a transcription 
map of the interval. This approach was also carried out using an eye 
cDNA database (STACK). The findings emerging from the partial 
sequence contig confirms and extends information obtained in areas of 
the clone contig. Using this strategy a number of retinal ESTs and 
cDNAs were identified which are now potential disease-causing genes 
for RP13. A future extension of this study would be the investigation of 
the newly identified retinal candidate genes at the RP13 locus. 
Furthermore, both the physical clone and sequence contigs of the RP13 
interval require intensive investigation. As bioinformatics has become 
widely used in the characterisation of candidate and disease genes, 
both in vitro and in silico technologies need to be undertaken during 
further investigations towards identifying the RP13 disease-causing 
gene. 
The establishment of the disease-associated haplotype has several 
implications for the ADRP-SA1 family. In SA, over the past twenty 
years, increased public awareness of genetic disorders and research has 
led to an increased need for informed genetic counselling. This type of 
service requires a clearly defined diagnosis and detailed knowledge of 
the molecular genetics of a known inherited condition. In particular, 
accurate assessment of presymptomatic individuals in families with RD 
is becoming available for a range of retinal dystrophies (Jay and Evans, 
1996) allowing for more informed counselling and educated decisions to 
be made by patients, guardians and caregivers, respectively. The 











be used in the development of a predictive test for at-risk individuals. 
Using linkage analysis with the conserved dise.ase-associated haplotype, 
asymptomatic individuals could be offered the opportunity to be 
informed of their risk for developing the condition. Since such a 
proposed test would be performed using linkage analysis and not be 
based on the precise disease-causing mutation, an increased or 
decreased relative risk would be inferred. A presymptomatic testing 
programme of this nature would only be established after wide 
consultation, ethical debate and under very specific guidelines 
(Greenberg et aI., 1996). In the first instance, the age and psychological 
status of the individual would need to be considered. Furthermore, a 
psychological support mechanism would need be put in place in order 
to facilitate adaptation to the possible outcome of the test. Of utmost 
importance with presymptomatic testing, is the presence of thorough 
pre- and post-test counselling which WOUld, amongst other things, 
endeavour to ensure that the individual understands the test and is 
prepared for the implications thereof, as fully as possible. Undoubtedly, 
an adult subject -based presymptomatic testing programme would 
assist those concerned in decision making and development of 
particular life skills and career training. The potential for prenatal 
testing also exists, upon request, should the need arise. This would, 
however, require greater deliberation and decision making. 
Initially it was thought that only retina-specific genes would underlie 
retinal disease. An observation which emerged was that the genes· . 











abnormalities in genes encoding the visual cascade proteins, for 
example, RHO, GNATl and a- and ~-PDE, (2) abnormalities in genes 
encoding retinal structural components, such as peripherin/RDS and 
ROMl, each members of the tetraspanin gene family (Phelan and Bok, 
2000), and (3) abnormalities in genes expressed in the RPE which 
include ABCR, TULPl and CRX (chapter 1). Defects from each category 
result in a pathogenic effect in the photoreceptor layer of the retina. 
However, as the effort of finding RD disease-causing genes progresses, 
it is interesting to note that a number of these preconceived ideas about 
the types of genes which could be involved in RD have to be revisited. 
Recent reports have disproved the theory of only retina-specific genes 
underlying RD; for example Sorsby fundus dystrophy was found to be 
associated with TIMP3, a ubiquitously expressed gene. This observation 
therefore indicates that future research efforts would need to be broad 
based, making as few assumptions as possible. Although some genes 
involved in retinal disorders do not show expression that is restricted to 
the visual process and supporting anatomical structures, it seems likely 
that the highly specialised function of the retina must require a large 
number of retina-specifically expressed genes. Therefore, several studies 
are currently underway with the specific goal to isolate retina- and RPE­
specific genes (Sohocki et aI., 1999). Retinal gene isolation studies such 












The study of animal models of retinal dystrophies has provided several 
candidate genes for investigation of RP in humans. This powerful field 
of research has also led to the identification of new genes and even new 
gene families. The identification of the gene defects responsible for tvw 
mouse models of RD, the RD (rd) mouse and the RD slow (rds) mouse, 
led to the screening of the human gene homologues ~-PDE and 
peripherin/RDS. This in tum led to the identification of a number of ~­
PDE and peripherin/RDS disease-causing mutations in humans with 
retinal dystrophies. In addition to the spontaneous dystrophies, 
laboratory mice offer the opportunity for genetic manipulation and 
experimentation through the introduction of a foreign gene (transgenic 
animals) or by the targeted disruption of an endogenous gene (gene 
'knock-out). The study of animal models of human dystrophies 
therefore offers many obvious benefits. In addition to those already 
described, detailed histopathological, molecular and electrophysiological 
studies not possible in human subjects can be undertaken in animal 
models. Any significant findings that emerge will contribute to the 
overall understanding of disease mechanisms in the retina. Hence this 
method of identifying disease-causing genes has been and will continue 
to be widely used. 
Present and future therapeutic modalities: Characterisation of the 
underlying genetic basis for disease is leading to new concepts of 
pathogenesis at the molecular and cellular levels. The correspond~n·g 











interest in the development of therapeutic strategies. Although no 
satisfactory treatment for most inherited retinal dystrophies exists, 
several processes are currently being intensively investigated towards 
this end. 
The manipulation of apoptosis: A particular dilemma in the development 
of therapy is the evidence which suggests that the metabolic defect 
caused by the underlying mutation does not cause photoreceptor cell 
death directly. Investigation. of animal models of RD has revealed that 
photoreceptor cell death occurs by a common mechanism known as 
apoptosis or programmed cell death (Chong and Bird, 1999). The 
significance of this discovery is that this process of premature cell 
death, instead of being the primary underlying genetic defect, may be 
amenable to therapeutic manipulation. Apoptosis, which is an 
important part of embryonic development, is the genetically encoded 
potential of all cells and governs cell turnover. This process is activated, 
for example, for the removal of cells infected by viruses or those 
harbouring disease-causing mutations (Wyllie et al., 1980). 
It has been observed that injection of growth factors into the eye 
reduces the rate of apoptosis in degenerating retina which results in 
long term survival of photoreceptors (Faktorovich et al., 1990). Studies 
have shown that the more effective growth factors are those which have 
a relatively specific influence on neural tissue, for example the 
neurotrophin growth factors (Borhani et al., 1993). The ciliary 











degeneration in rd mice and transgenic mice carrying a mutated 
rhodopsin gene (LaVail et al., 1998). This form of treatment of RD i.e. 
manipulation of the apoptotic process, has the advantage that it may be 
effective in diseases with unknown genetic mutations. 
Gene therapy: Another therapeutic approach being investigated in the 
field of RD, is that of gene therapy. The aim of this type of therapy is the 
replacement of the defective gene with genes that express normally. 
Some promising observations in the field of RD therapy research have 
been noted. Photoreceptor cell death has been shown to be delayed in 
RD mice (with a ~-PDE defect) with the use of subretinal injection of a 
recombinant replication defective adenovirus that contains the murine 
cDNA for the normal ~-PDE (Bennett et aI., 1996). More recently, 
subretinal injection of recombinant adeno-associated virus (AAV) 
encoding a peripherin/rds transgene into the rds mouse resulted in the 
stable generation of outer segment structures and formation of new 
stacks of discs containing both perpherin/rds and rhodopsin (Ali et aI., 
2000). This re-establishment of the structural integrity of the 
photoreceptor layer also results in electrophysiological correction. This 
study demonstrates for the first time that a complex ultrastructural cell 
defect can be corrected both morphologically and functionally by in vivo 
gene transfer. The longevity of transgene expression, however, requires 
further manipulation and investigation. 
Artificial vision: The avenue of artificial vision in the management of 











vision is based on the fact that in the retina of RP patients, 
photoreceptors at the periphery are damaged but the inner retina 
remains healthy. The particular application of this technology, if 
successfully developed, will be in restoration of vision in individuals in 
whom the photoreceptor cells have degenerated, as occurs in all RD 
patients with time. The intact inner retina is thus subjected to electrical 
stimulation in order to effect a visual sensation (Humayun et al., 1994). 
Various "prosthetic devices" are currently being investigated in 
Germany and in the USA, with evidence of minimal perception of light 
stimulus. It is likely that the enormous strides in research and 
development in the field of robotics, wil1lead to a better understanding 
of the interface between biology and electronics, which in turn, will 
improve this very promising area of visual restoration. Using this 
strategy no viable eye tissue is required, however, methods for 
permanent implantation of electrical devices may pose major technical 
problems. 
Retinal cell transplantation: Research in the field of transplantation 
involves the replacement of lost photoreceptors or RPE cells with 
healthy ones. In early experiments fetal retinal tissue was shown to 
survive and differentiate, but failed to show a normal orientation in the 
retina (Aramant et al., 1988). RPE cell transplantation into the 
subretinal space delayed photoreceptor loss and retinal function in rats 
(Sheedlo et al., 1989). Although no visual improvements were recor.ded, 











Research efforts in the fields of ophthalmology, genetics and biology in 
general as well as biotechnology hold promising prospects for sufferers 
of RD and their descendants who may be at risk. Initially, the 
administration of an easily deliverable gene construct before any 
detectable signs of disease, may be a preferable means of avoiding 
manifestation of the disorder. Ultimately, the successful manipulation 
of damaged cells will restore the visual process but the cause of the 
degenerative process in the individual will need to be known if this is to 
be accomplished effectively. Therapies may therefore have to be tailored 
to each individual or family of individuals even with the same genetic 
cause of RD. 
5.1. CONCLUDING REMARKS 
The main findings resulting from this investigation are: 
• 	 Mapping of the disease locus in a large family with ADRP to a 3cM 
region on chromosome 17p13.3 (chapter 2), 
• 	 construction of a complete clone and partial sequence contig across 
the critical interval (chapter 4), 
• 	 exclusion of three candidate genes RCVl, RETGC, and ARRB2 
(chapter 3), 
• 	 genetic fine mapping of RCVl and PEDF (chapter 3), 
• 	 the physical placement of PITPN and PEDF on the physical contigs 
(chapter 4), 











• 	 the characterisation of intron-exon boundaries of PITPN (chapter 3). 
and 
• 	 preparation for the establishment of a potential presymptomatic test 
for at risk individuals in the family concerned. 
These findings have far reaching implications for molecular research 
involving retinal genes on chromosome 17p. The definition of the RP13 
locus has and may in the future, facilitate the localisation of the 
disorder in other previously unmapped families using the genetic 
markers shown to be tightly linked to the disease-causing gene. 
The physical contigs provide a valuable resource for the cloning of the 
RP13 causal gene as well as other genes in this region. With the entire 
genome sequence being documented in electronic databases, it is 
possible that the field of biotechnology may be the investigative 
approach of choice towards characterising the disease-causing gene, 
with these contigs as the foundation. 
In the search for disease-causing genes in the future, the positional 
candidate gene approach will very likely be the method of choice 
(Strachen and Read, 1996). To this end, the precise genetic localisation 
of the retinal genes in this study, will assist in establishing possible 
candidates in the investigation of retinal disorders fine mapped to the 
corresponding genetic intervals on chromosome 17p. In addition, the 
elucidation of intragenic SNPs within PEDF and PITPN as well as the 











facilitate the future investigation of these candidates as possible causal 
genes underlying the chromosome 17p-linked retinal disorders. 
Once the RP13 disease-causing mutation has been identified, the 
question of treatment for the RP13-linked families can be addressed. An 
animal model would then be useful to determine the exact mechanism 
of cell death in this form of RP. The work presented in this dissertation 
provides the foundation for future research such as this, which will 
have the potential to eventually contribute towards the development of 
a form of therapy for this large SA ADRP-SA 1 family which formed the 
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A.I DNA ISOLATION FROM LYMPHOCYTES 
DNA was isolated using a modified version of the Genomix kit (Talent, Italy) as 
described below: 
• 	 10 m1 of frozen venous blood was thawed at 37°C and added to 2 ml of 
Blood Washing Solution (BWS). Mter centrifugation at 7000 rpm for 15 
min at room temperature, the pellet was resuspended in 5 ml of BWS. The 
centrifugation step was repeated. 
• 	 The pellet was resuspended by vortexing in a mixture of 1 m1 BWS and 1 
mlofwater. 
• 	 Mter addition of 4 m1 of Lysing solution, the mixture was incubated at 
68°C for 7 min. 
• 	 The lysate was transferred to a 14 ml gel barrier tube and chloroform was 
added with vigorous mixing in order to mix the two phases. The phases 
were separated by centrifugation at 5 000 rpm at 4°C for 30 min. The 
upper aqueous phase was poured into a 30 m1 Corex glass tube, which had 
previously been treated with diethyl pyrocarbonate. 
• 	 7 ml of Precipitating solution was added and mixed gently by slow 
inversion until a filamentous DNA precipitate was visible. 
• 	 Mter removal of the liquid phase, the precipitate was resuspended in 4 m1 
of Ionic Exchange solution and left 0 IN at RT. 
• 	 The following day, 8 ml of ethanol was added and the DNA precipitate was 
washed twice in 5 m1 of 70% Ethanol and transferred to a 1.5 JlI Eppendorf 
tube. Following centrifugation at 13 000 rpm for 1 min, all the supernatant 
was removed and the DNA pellet was air-dried. Finally, the DNA was 
resuspended in 200 Jll of water and the concentration was calculated from 












A.2 RNA ISOLATION FROM TRANSFORMED LYMPHOBLASTS 
Where appropriate all the reagents and equipment used in this protocol were 
treated with diethyl pyrocarbonate (DEPC) prior to use. 
• 	 10 m1 of EBV-transfonned lymphoblasts were centrifuged in a 
polypropylene tube at 2000 rpm for 5 min and the pellet was washed in 1 
m1 of phosphate buffered saline (PBS). 
• 	 The following solutions were added sequentially, with vortexing after each 
addition: 

Solution D 1 m1 

2M Na Acetate (pH 4) 0.1 ml 

water saturated phenol 1 m1 

chlorofonn:isoamyl alcohol (49: 1) 0.2m1 

• 	 The reaction was incubated on ice for 15 min and then centrifuged at 10 
000 g for 20 min at 4°C. 
• 	 The RNA is in the top aqueous phase and 750 J.l.I of this layer was removed 
to a microfuge tube, 750 J.l.I of isopropanol was added and the RNA was 
precipitated 0 IN at -20°C. 
• 	 The following day, the RNA was pelleted by centrifugation at 10000 g for 
10 min, washed with 70% ethanol, air-dried and fmally resuspended in 20­
50 J.l.I distilled water. 
A.2.1 First strand eDNA synthesis 
2.5 J.l.g of RNA was reverse transcribed with AMV reverse transcriptase 
(Promega, USA) using oligo dT as a primer. The reaction was incubated for 1 
hour at 42°C and in order to yield sufficient cDNA, 3 cycles of linear 
amplification of the RNA were perfonned. 
The reverse transcribed RNA was PCR amplified using the appropriate primers 











A.3 DNA OLIGONUCLEOTIDES 
All DNA oligonucleotides used in this study as primers for PCR or as probes in 
Southern blot analysis were obtained from the following sources: 
• Research Genetics (USA) 
• GIBCO IBRL (USA) 
• Department of Biochemistry at UCT 

• overseas collaborators 

A.4· SOUTHERN BLOT ANALYSIS 
7.5 ~gof genomic DNA was digested to completion with the appropriate 
restriction enzyme and separated by electrophoresis on 0.6% agarose gels 0 IN 
at 45 W. 
A.4.1 Transfer to nylon membranes 
The DNA was transferred O/N from the gel to Hybond N+ membranes 
(Amersham, UK) using 0.4 M NaOH. 
A.4.2 Hybrldisation 
[a32PldCTP- labelled probes were prepared by one of two methods: 
(i) The Multiprime DNA labelling system (Amersham, UK) 
(ii) The Rediprime DNA labelling system (Amersham, UK) 
These protocols were performed according to the manufacturers' instructions. 
The blots were first pre-blocked in a hybridisation solution containing Salmon 
Sperm (Appendix B) and then hybridised to the denatured probes 0 IN at 
65°C. The following day, the membranes were washed over three stages: 
• 3X SSC at RT for 10 min 
• 3X SSC I 01% SDS at 65°C for 30 min 
• 0.6X SSCI 0.3% SDS at 65°C for 30 min 
A.4.3 Autoradiography 
Autoradiographs were obtained by exposure of the membrane to X-ray film 












A.S 	 SINGLE STRAND CONFORMATION POLYMORPHISM 
ANALYSIS (SSCP) 
The exonic sequences of genes were PCR amplified in 200-300 bp fragments. 
An equal volume of SSCP loading dye was added and the samples were loaded 
on MDE gels: 
A.S.I 	Gel matrix 
The gels consisted of 0.5X MDE matrix (FMC BioProducts, USA), 0.6X TBE 
and either with or without 10% glyceroL The glass plates used for the gels 
were 380 cm long and 300 cm wide; and the combs and spaces were 0.375 
mm thick. 
A.S.2 	Electrophoresis conditions 
PCR products were denatured at 95°C for 5 min, chilled on ice for 10 min and 
loaded on the MDE gels. The gels were electrophoresed O/N at 2 to 6 W 
(depending on fragment size) on an in-house gel tank system with 0.6X TBE 
running buffer. 
A.S.3 	Silver staining 
In order to visualise the bands the gels were stained over three stages in: 
• O. 1 % Silver Nitrate for 20 min 
• 1.5% NaOHI 0.15% formaldehyde for 10 min 
• 0.75% Sodium Carbonate for 10 min 














A.6 DNA SEQUENCING 
Direct DNA sequencing was performed by one of three different methods: 
• 	 The Sequenase II sequencing Kit (Amersham, USA) 
• 	 The SequiTherm EXCEL II DNA Sequencing Kit (Epicentre Technologies, 
USA) 
• 	 ABI PRISM Dye Primer Cycle Sequencing Ready Reaction Kit (Perkin-
Elmer, USA). 
In each case, the protocols were followed according to the manufacturer's 
instructions. In the first two methods, [a,32P]dCTP was incorporated into the 
sequencing reactions which were subsequently electrophoresed on 6% 
denaturing polyacrylamide gels at 
60 W in IX TBE. Mter the run, the gels were dried at 80°C and 
autoradiographed at 
-70°C. For the ABI Kit, the sequencing reactions were separated by automated 
capillary electrophoresis and analysed by an ABI PRISM Genetic Analyser 
(Perkin Elmer, USA). 
A.7 YAC DNA ANALYSIS 
A.7.1 YAC DNA ISOLATION 
• 	 10 ml cultures were grown overnight in YEPD media containing Ampicillen 
(100 J,lg/ml). 
• 	 100 ml broths were inoculated with 0.2 ml of the overnight cultures and 
grown 2 days at 30°C. 
• 	 The cells were pelleted at 3000 rpm for 5 min at 20°C and resuspended in 
5 ml of solution 1. 
• 	 20 J,ll of lyticase enzyme (10mg/ml) was added to the peilets and incubated 
for 1 hour at 37°C, shaking. 
• 	 The cells were pelleted gently at 1000 rpm for 10 min and the supernatent 
removed. 
• 	 The pellet was resuspended in 5 ml of solution 2 at 65°C for 10 min. 
• 	 The DNA was allowed to cool to room temperature and an equal volume of 
ethanol was added. 
• 	 The DNA was peileted at 2000 rpm for 10 min. 












• 	 20 III of Rnase (lOllg/ml) was added to the DNA suspension and incubated 
at 37°C for 30 min. 
• 	 40 III of proteinase K (lOllg/ml) was added and the mixture incubated at 
65°C for 1 hour and allowed to cool to room temperature for about 15 min. 
• 	 The DNA was extracted 3x with phenol/chloroform and then once \-vith 
chloroform. 
• 	 The DNA was precipitated with 1/10 sodium acetate and 2x ethanol, 
pelleted, dried and resuspended in 250 IllofTE. 
A.7.2 YAC AGAROSE PLUGS 
• 	 50 ml cultures were grown for 2 days in YEPD media containing Ampicillen 
(100 Ilg/ml). 
• 	 The cells were pelleted at 3000 rpm for 5 min, washed with distilled water 
and recentrifuged. 
• 	 The pellet was resuspended in 1 ml SCE and 7 III beta-mercaptoethanol 
(BME) and incubated at 50°C. 
• 	 3 ml of 2% InCert agarose (FMC BioProducts, USA) containing 0.01 g/ml 
yeast lytic enzyme (ICN) in SCE was prepared and added to the cell mixture 
at 50°C. 
• 	 This mixture was quickly dispensed into the slots of a plug mould (Biorad, 
USA) and allowed to set at 4°C for 25 min. 
• 	 The plugs were washed in: 
(i) 20 ml SCE, 140 III BME and 10 mg/ml YLE at 37°C for 5 hrs. 

(ill 10 ml lysis solution and 1 mg/ml proteinase K at 50°C 0/N. 

• 	 The following day, the plugs were washed 3X in TE with gentle shaking at 
room temperature for 15min. 
• 	 The plugs were stored in 0.05 M EDTA at 4°C and were stable for up to a 














Media, Buffers and Solutions: 
B.1 agarose loading buffer 

B.2 TBE (IX) 

B.3 formamide loading buffer 

B.4 6% denaturing polyacrylamide gels 

B.S SSCP loading buffer 




B.8 lysis solution 

B.9 Solution D 

B.10 Solution 1 


















B.I Agarose loading buffer 




B.2 TBE (IX) 
0.089 M Tris 
0.089 M Bone acid 
0.002 M EDTA (pH 8.0) 
B.3 Formamide loading buffer 
80% formamide 
10 mM EDTA (pH 8.0) 
0.1% xylene cyanol 
0.1% bromophenol blue 
B.4 .6% denaturing polyacrylamide gels 
5.7% acrylamide 
0.3% bis-acylamide 
7.65 M urea 
lXTBE 
D.S SSCP loading buffer 
95% formamide 
20 mM EDTA (pH 8.0) 
10 mM NaOH 
0.02% xylene cyanol 











B.6 Hybridisation solution for Southern blots 
1 M NaCI 
1% SDS 
5 % Dextran sulphate 
10% PEG 6000 
100 Ilg per ml denatured Salmon Sperm 
B.7 SeE 
1 M sorbitol 
0.01 M sodium citrate 
0.06 M EDTA (pH 7.0) 
B.B Lysis solution 
10 mM Tris 
1 % n-Lauroyl sarcosine 
0.45 M EDTA (pH 7.8) 
B.9 Solution D 
Stock solution: Guanidium thiocyanate 50 g 
Distilled water 58.6 ml 
0.75 M Na Citrate (pH 7) 3.5 ml 
10% Sarkosyl 5.3 ml 
Solution D working solution: Add 72 III beta-mercaptoethanol to 10 ml 
stock 
B.IO Solution I 
0.9M sorbitol 
20mM EDTA 















0.05% sarkosyl, pH 8 
B.12 TE 
10mM Tris HCL 

















C.l Department of Human Genetics DNA consent fonn 














CONSENT FOR DNA ANALYSIS AND STORAGE 
I, Mr / Ms / Mrs / request that 
an attempt be made to assess the probability that I, my children or my unborn child 
might have inherited the gene for: 
I understand that the DNA for analysis is to be obtained from: 
a) 	 blood cells =-, b) skin sample ::::, c) other :::: 
The methods and risks of obtaining the specimens have been explained to me. 
I also understand that: 
1. 	The test procedure is specific to the genetic condition mentioned above and cannot 
detennine the complete genetic makeup of an individual. 
2. 	Lack of co-operation by key relatives in providing blood samples may decrease the 
accuracy of the test result for linkage analysis and/ or ability to perfonn the test. 
3. 	Sometimes the genetic pattern in a family renders the test results "uninfonnative" 
(not clarifying the point in question). 
4. 	Even under the best conditions, current technology of this type is imperfect and 
may lead to incorrect results. 
5. I may withdraw my consent at any time without giving a reason and without this 
affecting my future medical care. 
6. 	The DNA bank is under an obligation to respect medical confidentiality. 
7. 	The DNA bank may request relevant clinical details from my doctors 
A portion of the DNA obtained may be stored to enable later 
testing. The following conditions apply to my DNA that is being 
stored: (circle any and all that you wish) 
• 	 To be used for linkage analysis for members of my immediate family. 
• 	 To be used for research purposes without my or my family member's knowledge, at 
the discretion of the Head of Human Genetics, UCT, provided that any infonnation 
from such research will remain confidential. 
• 	 To be used without any restrictions. 
• 	 Other: 
I understand that I may change my mind and withdraw my consent for DNA 
banking at any time. 
ALL OF THE ABOVE HAS BEEN EXPLAINED TO ME IN A LANGUAGE THAT I 
UNDERSTAND AND MY QUESTIONS ANSWERED BY: 
_____________________________DATE: 	 19_______ 














CONSENT FOR PARTICIPATION IN RESEARCH 





DEPARTMENT OF HUMAN GENETICS 
FIRST FLOOR, ANATOMY BUILDING, 
UNIVERSITY OF CAPE TOWN MEDICAL SCHOOL. 
OBSERVATORY, 7925 
(Please read both sections and sign BOTH if you agree with the conditions) 
1. Information for Research Database 
Patients with retinal degenerative disorders are likely to benefit from local and 
international research aimed at defining the cause of their condition. To facilitate 
treatments that will emerge from these research efforts, in the future, it is essential to 
establish and maintain a comprehensive database (a computer record) of all patients 
with these diseases. Should a treatment become available it can then be offered in a 
targeted manner to patients through the database. The treatments are likely to be 
very specific so we require as much detail as possible about your particular disease to 
enable us to keep useful infonnation. You can be assured that patient confidentiality 
is a major concern and your infonnation will only be available to research workers in 
this field. Your name will not be divulged. The purpose of the database is to assist 
the researchers in assessing the magnitude and biology of the problem in our country 
and to enable them to contact and counsel patients quickly should treatment be 
available. 
Consent 
I agree that my details may be released to researchers and authorise mv doctor to release 
medical details to the Department of Human Genetics at the Universitv of Cape Town 
provided that any infonnation from such research will remain confidential. 
Signature................................. Print Name.................................. 

2. 	 Working together with the Retinal Preservation Foundation of 
South Africa (RP Foundation, 
The RP Foundation has played an active role in assisting with research into many 
retinal eye diseases and continues to do so. The Foundation provides many services 
including counselling and provision of infonnation to the patients and their families. 
The Foundation would like to keep the names and contact details of all patients with 
retinal degeneration in South Africa and offer you their services free of charge. 
Consent 
I agree that the attached details also be given to the RP Foundation provided that the 
infonnation remains confidential 













DNA SCREENING PROGRAMME OF RETINAL ,.. 
DEGENERATIVE DISORDERS 
,.J' ,;....."., , 
" "-,,
DEPARTMENT OF HUMAN GENETICS 
FIRST FLOOR, ANATOMY BmLDING, MEDICAL SCHOOL, UNIVERSITY OF 
CAPETOWN, OBSERVATORY, 7925 
TELEPHONE: (021) 406·6467 FACSIMILE: (021) 448-0906 
PATIENTS SURNAME ............................ ............ FIRST NAME 

DATE OF BIRTH .................. TELEPHONE ........................ FACSIMILE 

ADDRESS: ................................................................................................................ 
-SEX: M 0 F 0 ETHNIC GROUP: BLACK 0 CAUCASIAN 0 INDIAN 0 
I MIXED ANCESTRY 0 OTHER 0 
IN MY OPINION THE PATIENT HAS ONE OF THE FOLLOWING 
CONDITIONS: 
RETINITIS PIGMENTOSA Retinal degeneration would appear to be: 
The diffuse form 0 
Sectoral (regional) form 0 
USHER SYNDROME 	 Retinitis Pigmentosa and Congenital Hearing Loss: 
TYPE 1 (profound deafness) 0 
TYPE 11 (mUd to severe deafness) 0 
MACULAR DEGENERATION BEST DISEASE 0 
FUNDUSFLAVIMACULATUS 0 
PATTERN DYSTROPHY 0 
SORSBY FUNDUS DYSTROPHY 0 
STARGARDT DISEASE 0 
FAMILIAL OR EARLY ONSET (under 55yrs) 
AGE RELATED MD Wet 0 
Dry 0 
CONE & ROD DYSTROPHY o 
OTHER RETINAL DISORDERS (SPECIFY) ....................... ......... ...... 0 
MODE OF INHERITANCE 
Dominant Inheritance 0 Recessive Inheritance 0 Unknown but FamUial 0 
X-Linked Inheritance 0 Isolated Case 0 
Number of famUy members affected: .......................... 
AGE OF ONSET .............. (years) VISUAL ACmTY: Left ......... Right ...... 

PROGRESSION OF DISEASE: .................... ...... ...... ......... .................. ...... ..... ". 
















ERG o Colour Fundus Photographs o 
Visual Acuity o Fluorescein angiogram o 
Visual Fields o DNA Screening Programme o 




LENS: Yes / No Pseudophakic Cataract: / Aphakic: Yes / No 
DISC: 	 Normal ••.••••••••• Waxy Pallor 000.0 •• 0.. Other 0 ••••••••••••••••• 
VESSELS: 	 Normal •.....••.••• Attenuated .••••....••Other •••••••••••••••••• 
-MACULA: Comments 
Exudates Yes o No o 
Epiretinal membrane Yes o No o 





Bone spicule: Yes 0 No 0 Distribution: ••.••.•.•..•.........• 

Quality and distribution of pigment: 

Pigment: ............... Depigmentation: ................... 

White dots ............... 

Quadmnt .•••.•••••••••• Periphery 

VITREOUS: 	 Normal Yes 0 No o 
Cellularity Yes 0 No o 
Vitreous Floaters Yes 0 No o 
I**LEFT EYij 
LENS: Cataract Yes/No Pseudoaphakic/Aphakic Yes/no 
DISC: Normal ••••••.•• Waxy Pallor........ Other ••••••••••••••••.•..... 
VESSELS: Nor:rllal .........Attenuated ........... Other ......... .. ........... . 
MACULA: 	 Comment: 
Exudates Yes o No o 
Epiretinal membrane Yes o No o 
Granularity Yes o No o 





Bone spicule: Yes 0 No 0 Distribution: .................. 
Quality and distribution of pigment: 
Pigment: ....... ........ Depigmentation: ................ 

White dots ................ .. 

Quadrant .................. Periphery 

VITREOUS: 	 Normal Yes 0 No o 
Cellularity Yes 0 No o 
Vitreous Floaters Yes 0 No o 
NAME OF DOCTOR: (Please Print) ............................SIGNATURE:...................:......... 

















Aldred MA, Dry KL, Sharp DM, Van Dorp DB, Brown J, Hardwick W, 
Lester DH, Pryde FE, Teague PW, Jay M, et al. (1992): Linkage 
analysis in X-linked congenital stationary night blindness. 
Genomics 14: 99-104. 
Aldred MA, Teague PW, Jay M, Bundey S, Redmond RM, Jay B, Bird 
AC, Bhattacharya SS, Wright AF (1994): Retinitis pigmentosa 
families showing apparent X linked inheritance but unlinked to 
the RP2 or RP3 loci. J Med Genet 31 (11): 848-52. 
Allikmets R, Shroyer NF, Singh N, Seddon JM, Lewis RA, Bernstein PS, 
Peiffer A, Zabriskie NA, Li Y, Hutchinson A, et al. (1997a): 
Mutation of the Stargardt disease gene (ABCR) in age-related 
macular degeneration. Science 277(5333): 1805-1807. 
Allikmets R, Singh N, Sun H, Shroyer NF, Hutchinson A, Chidambaram 
A, Gerrard B, Baird L, Stauffer D, Peiffer A, et al. (1997b): A 
photoreceptor cell-specific ATP-binding transporter gene (ABCR) 
is mutated in recessive Stargardt macular dystrophy. Nat Genet 
15: 236-246. 
AI-Maghtheh M, Gregory C, Inglehearn C, Hardcastle A, Bhattacharya 
SS (1993): Rhodopsin mutations in autosomal dominant retinitis 
pigmentosa. Hum Mutation 2: 249-255. 
AI-Maghtheh M, Inglehearn CF, Keen TJ, Evans K, Moore AT, Jay M, 
Bird AC, Bhattacharya SS (1994): Identification of a sixth locus 
for autosomal dominant retinitis pigmentosa on chromosome 19. 
Hum Mol Genet 3(2): 351-354. 
Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990): Basic 











Apfelstedt-Sylla E, Meitinger T, Meindl A, Hermann B, Brandau 0, 
Wissinger B, Engel C, Zrenner E (1996): RPGR missense mutation 
in congential stationary night blindness (CSNB). Invest 
Ophthalmol Vis Sci 38: 3702. 
Aramant RB, Seiler MJ, Turner JE (1988): Donar age influences on the 
success of retinal transplants to adult rat retina. Invest 
Ophthamol Vis Sci 29: 498-503. 
Arikawa K, Molday LL, Molday RS, Williams DS (1992): Localization of 
peripherinjrds in the disk membranes of cone and rod 
photoreceptors: relationship to disk membrane morphogenesis 
and retinal degeneration. J Cell BioI 116(3): 659-667. 
Attramadal H, Arriza JL, Aoki C, Dawson TM, Codina J, Kwatra MM, 
Snyder SH, Caron MG, Lefkowitz RJ (1992): Beta-arrestin2, a 
novel member of the arrestinjbeta-arr stin gene family. J BioI 
Chem 267(25): 17882-17890. 
Balciuniene J, Johansson K, Sandgren 0, Wachtmeister L, Holmgren G, 
Forsman K (1995): A gene for autosomal dominant progressive 
cone dystrophy (CORDS) maps to chromosome 17p12-p13. 
Genomics 30(2): 281-286. 
Banerjee P, Kleyn PW, Knowles JA, Lewis CA, Ross BM, Parano E, 
Kovats SG, Lee JJ, Penchaszadeh GK, Ott J, Jacobson SG, 
Gilliam TC (1998): TULP1 mutation in two extended Dominican 
kindreds with autosomal recessive retinitis pigmentosa. Nat 
Genet 18(2): 177-179. 
Bardien S, Ebenezer N, Greenberg J, Inglehearn CF, Bartmann L, 
Goliath R, Beighton P, Ramesar R, Bhattacharya SS (1995): An 
eighth locus for autosomal dominant retinitis pigmentosa is' 











Bascom RA, Manara S, Colins L, Molday RS, Kalnins VI, Mcinnes RR 
(1992a): Cloning of the cDNA for a novel photoreceptor membrane 
protein (ROM 1) identifies a disc rim protein family implicated in 
human retinopathies. Neuron 8: 1171-1184. 
Bascom RA, Garcia-Heras J, Hsieh C, Gerhard OS, Jones C, Francke U, 
Willard HF, Ledbetter DH, McLnnes RR (1992b): Localization of 
the photoreceptor gene ROM 1 to human chromosome 11 and 
mouse chromosome 19: sublocalization to human l1q13 between 
PGA and PYGM. Am. J. Hum. Genet. 51: 1028-1035. 
Bayes M, Valverde D, Balcells S, Grinberg D, Vilageliu L, Benitez J, 
Ayuso C, Beneyto M, Baiget M, Gonzalez-Duarte R (1995): 
Evidence against involvement of recoverin in autosomal recessive 
retinitis pigmentosa in 42 Spanish families. Hum Genet 96(1): 
89-94. 
Bayes M, Goldaracena B, Martinez-Mir A, Iragui-Madoz MI, Solans T, 
Chivelet P, Bussaglia E, Ramos-Arroyo MA, Baiget M, Vilageliu L, 
Ba1cells S, Gonzalez-Duarte R, Grinberg D( 1998): A new 
autosomal recessive retinitis pigmentosa locus maps on 
chromosome 2q31-q33. J Med Genet 35(2): 141-145. 
Bennett J, Tanabe T, Sun 0, Zeng Y, Kjeldbye H, Gouras P, Maguire AM 
(1996): Photoreceptor cell rescue in retinal degeneration (rd) mice 
by in vivo gene therapy. Nat Med 2: 649-654. 
Berger W, Meindl A, van de Pol TJ, Cremers FP, Ropers HH, Doerner C, 
Monaco A, Bergen AA, Lebo R, Warburgh M, et al (1992): Isolation 
of a candidate gene for Norrie disease by positional cloning. Nat 













Berson EL (1996): Retinitis pigmentosa: unfolding its mystery. Proc Nati 
Acad Sci USA 93: 4526-4528. 
.... 
Bessant DAR, Payne AM, Mitton KP, Wang Q, Swain PK, Plant C, Bird 
AC, Zack DJ, Swaroop A, Bhattacharya S (1999): A mutation in 
NRL is as'sociated with autosomal dominant retinitis pigmentosa. 
Nat Genet 21: 355-356. 
Blanton SH, Heckenlively JR, Cottingham AW, Friedman J, Sadler LA, 
Wagner M, Friedman LH, Daiger SP (1991): Linkage mapping of 
autosomal dominant retinitis pigmentosa (RP1) to the pericentric 
region of human chromosome 8. Genomics 11: 857-869. 
Borhani H, Peyman GA, Rahimy MH, Beuerman RW (1993): 
Vitreoretinal toxicity of basic fibroblast growth factor. Int 
Ophthalmol 17: 195-199. 
Bowes C, Danciger M, Kozak CA, Farber DB (1989): Isolation of a 
candidate cDNA for the gene causing retinal degeneration in the 
rd mouse. Proc Natl Acad Sci 86(24): 9722-9726. 
Bowes C, Li T, Danciger M, Baxter LC, Applebury ML, Farber DB (1990): 
Retinal degeneration in the rd mouse is caused by a defect in the 
beta subunit of rod cGMP-phosphodiesterase. Nature 347(6294): 
677-680. 
Bowne SJ, Daiger SP, Hims MM, Sohocki MM, Malone KA, McKie AB, 
Heckenlively JR, Birch DG, Inglehearn CF, Bhattacharya SS, Bird 
A, Sullivan LS (1999): Mutations in the RP1 gene causing 
autosomal dominant retinitis pigmentosa. Hum Mol Genet 8(11): 
2121-2128. 











Brookes AJ, Lehvaslaiho H, Siegfried M, Boehm JG, Yuan YP, Sarkar 
CM, Bork P, Ortigao F (2000): HGBASE: a database of SNPs and 
other variations in and around human genes. Nucleic Acids Res 
28( 1): 356-360. 
Bunker CH, Berson BL, Bromley WC, Hayes RP, Roderick TH (1984): 
Prevalence of Retinitis Pigmentosa in Maine. Am. J. Ophthalmol. 
97: 357-365. 
Buraczynska M, Wu W, Fujita R, Buraczynska K, Phelps E, Andreasson 
S, Bennett J, Birch DG, Fishman GA, Hoffman DR, Inana G, 
Jacobson SG, Musarella MA, Sieving PA, Swaroop A (1997): 
Spectrum of mutations in the RPGR gene that are identified in 
~ 
20% of families with X-linked retinitis pigmentosa. Am J Hum 
Genet 61(6): 1287-1292. 
Burke DT, Carle GF, Olson MV (1987): Cloning oflarge segments of 
~xogenous DNA into yeast by means of artificial chromosome 
vectors. Science 236: 806-812. 
Calabrese G, Sallese M, Stornaiuolo A, Stuppia L, Palka G, De Blasi A 
(1994): Chromosome mapping of the human arrestin (SAG), beta­
arrestin 2 (ARRB2), and beta-adrenergic receptor kinase 2 
(ADRBK2) genes. Genomics 23(1): 286-288. 
Camuzat A, Dollfus H, Rozet JM, Gerber S, Bonneau D, Bonnemaison 
M, Briard ML, Dufier JL, Ghazi I, Leowski C, et al (1995): A gene 
for Leber's congenital amaurosis maps to chromosome 17p. Hum 
Mol Genet 4(8):1447-1452. 
Camuzat A, Rozet JM, Dollfus H, Gerber S, Perrault I, Weissenbach J, 
Munnich A, Kaplan J HUm (1996): Evidence of genetic 
heterogeneity of Leber's congenital amaurosis (LCA) and mapping 











Carmi R, Rokhlina T, Kwitek-Black AE, Elbedour K, Nishimura D, Stone 
EM, Sheffield VC (1995): Use of a DNA pooling strategy to identify 
a human obesity syndrome locus on chromosome 15. Hum Mol 
Genet 4: 9-13. 
Chaib H, Kaplan J, Gerber S, Vincent C, Ayadi H, Slim R, Munnich A, 
Weissenbach J, Petit C (1997): A newly identified locus for Usher 
syndrome type I, USH IE, maps to chromosome 21q21. 
Hum Mol Genet 6(1): 27-31. 
Chen JD, Halliday F, Keith G, Sheffield L, Dickinson P, Gray R, 
Constable I, Denton M (1989): Linkage heterogeneity between X­
linked retintis pigmentosa and a map of 10 RFLP loci. Am J Hum 
Genet 45: 401-411. 
Chong NHV, Bird AC (1999): Management of inherited outer retinal 
'dystrophies: present and future. Br J Ophthalmol 83: 120-122. 
Clarke G, Heon E, McInnes RR (2000): Recent advances in the 
molecular basis of inherited photoreceptor degeneration. Clin 
Genet 57: 313-329. 
Cremers FP, van de Pol DJ, van Driel M, den Hollander AI, van Haren 
FJ, Knoers NV, Tijmes N, Bergen AA, Rohrschneider K, 
Blankenagel A, et al. (1998): Autosomal recessive retinitis 
pigmentosa and cone-rod dystrophy caused by splice site 
mutations in the Stargardt's disease gene ABCR. Hum Mol Genet 
7(3): 355-362. 
Danciger M, Blaney J, Gao YQ, Zhao DY, Heckenlively JR, Jacobson 
SG, Farber DB (1995): Mutations in the PDEB gene in autosomal 











den Hollander AI, ten Brink JB, de Kok YJ, van Soest S, van den Born 
LI, van Driel MA, van de Pol DJ, Payne AM, Bhattacharya SS, 
Kellner U, Hoyng CB, Westerveld A, Brunner HG, Bleeker­
Wagemakers EM, Deutman AF, Heckenlively JR, Cremers FP, 
Bergen AA (1999): Mutations in a human homologue of 
Drosophila crumbs cause retinitis pigmentosa (RP12). Nat Genet 
23(2): 217-221. 
Dizhoor AM, LoweDG, Olshevskaya EV, Laura RP, Hurley JB (1994): 
The human photoreceptor membrane guanylyl cyclase, RetGC, is 
present in outer segments and is regulated by calcium and a 
soluble activator. Neuron 12(6): 1345-52. 
Donnis-Keller H, Green P, Helms C, Cartinhour S, Weiffenbach B, 
Stephens K, Keith TP, Bowden DW, Smith DR, Lander ES, et al. 
(1987): A genetic linkage map of the human genome. Cell 51: 
319-337. 
Dryja TP, McGee TL, Reichel E, Hahn LB, Cowley GS, Yandell DW, 
Sandberg MA, Berson EL (1990): A point mutation of the 
rhodopsin gene in one form of retinitis pigmentosa. Nature 
343(6256): 364-366. 
Dryja TP, Finn JT, Peng YW, McGee TL, Berson EL (1995): Mutations in 
the gene encoding the a-subunit of the rod cGMP-gated channel 
in autosomal recessive retinitis pigmentosa. Proc Natl Acad Sci 
USA 92: 10177-10181. 
Dryja TP, Li T (1995): Molecular genetics of retinitis pigmentosa. Hum 
Mol Genet 4: 1739-1743. 
Dryja TP, Hahn LB, Reboul T, Arnaud B (1996): Missense mutati0I1:·in 











Nougaret form of congenital stationary night blindness. Nat Genet 
1996 13(3): 358-360. 
Faktorovich EG, Steinberg RH, Yasumura D, Matthes MT, LaVail MM 
(1990): Photoreceptor degeneration in inherited retinal dystrophy 
delayed by basic fibroblast growth factor. Nature 347: 83-86. 
Farrar GJ, Jordan SA, Kenna P, Humphries MM, Kumar-Singh R, 
McWilliam P, Allamand V, Sharp E, Humphries P (1991): 
Autosomal dominant retinitis pigmentosa: localization of a 
disease gene (RP6) to the short arm of chromosome 6. Genomics 
11(4): 870-874. 
Farrer LA, Grundfast KM, Amos J, Arnos KS, Asher JH Jr, Beighton P, 
DiehlSR, FexJ, Foy C, Friedman TB, et a1. (1992): Waardenburg 
syndrome (WS) type I is caused by defects at multiple loci, one of 
which is near ALPP on chromosome 2: first report of the WS 
consortium. Am J Hum Genet 50(5): 902-913. 
Finckh U, Xu S, Kumaramanickavel G, Schurmann M, Mukkadan JK, 
Fernandez ST, John S, Weber JL, Denton MJ, Gal A (1998): 
Homozygosity mapping of autosomal recessive retinitis 
pigmentosa locus (RP22) on chromosome 16p12.1-p12.3. 
Genomics 48(3): 341-345. 
Fitzgibbon J, Pilz A, Gayther S, Appukuttan B, Dulai KS, Delhanty JD, 
Helmkamp GM Jr, Yarbrough LR, Hunt DM (1994): Localization 
of the gene encoding human phosphatidylinositol transfer protein 
(PITPN) to 17p13.3: a gene showing homology to the Drosophila 
retinal degeneration B gene (rdgB). Cytogenet Cell Genet 67(3): 
205-207. 
Fowles C, Akhtar M, Cohen P (1989): Interplay of phosphorylation 'and 











outer segments. Biochemistry 28(24): 9385-9391. 
Fuchs S, Nakazawa M, Maw M, Tamai M, Oguchi Y, Gal A (1995): A 
homozygous I-base pair deletion in the arrestin gene is a 
frequent cause of Oguchi disease in Japanese. Nat Genet 10(3}: 
360-262. 
Gal A, Orth U, Baehr W, Schwinger E, Rosenberg T (1994): 
Heterozygous missense mutation in the rod cGMP 
phosphodiesterase ~-subunit gene in autosomal dominant 
stationary night blindness. Nat Genet 7: 64-68. 
Gal A, Apfelstedt-Sylla E, Janecke AR, Zrenner E (1997): Rhodospin 
mutations in inherited retinal dystrophies and dysfunctions. Prog 
Ret Eye Res 16(1): 51-79. 
Glass lA, Good P, Coleman MP, Fullwood P, Giles MG, Lindsay S, 
Nemeth AH, Davies KE, Willshaw HA, Fielder A, et al (1993): 
Genetic mapping of a cone and rod dysfunction (Aland Island eye 
disease) to the proximal short arm of the human X chromosome. 
J Med Genet 30(12): 1044-1050. 
Goldberg AF, Molday RS (1996): Defective subunit assembly underlies a 
digenic form of retinitis pigmentosa linked to mutations in 
peripherinJrds and ROM-I. Proc Natl Acad Sci USA 93(24): 
13726-13730. 
Goliath R, Shugart Y, Janssens P, Weissenbach J, Beighton P, Ramasar 
R, Greenberg J (1995): Fine localization of the locus for autosomal 
dominant retinitis pigmentosa on chromosome 17p. Am J Hum 
Genet 57(4): 962-964. 
Goliath R, Tombran-Tink J, Rodriquez IR, Chader G, Ramesar R, ' 











a prime candidate for retinitis pigmentosa and is tightly linked to" 
the RP13 locus on chromosome 17pI3.3. Mol Vis 2: 96004. 
Greenberg J, Babaya M, Ramesar R, Beighton P (1992) Retinitis 
pigmentosa, AD type I: exclusion of linkage to D3S47 (C 17) in a 
large South African family of British origin. Clin. Genet. 41: 322­
325. 
Greenberg J, Bartman L, Ramesar R, Beighton P (1993) Retinitis 
pigmentosan in Southern Africa. Clin. Genet. 44: 232-235. 
Greenberg J, Ramesar R, Beighton P (1994a) Genetic mapping of 
retinitis pigmentosa-the implications for South African patients. 
S.·Afri. Med. J. 84:410-412. 
Greenberg J, Goliath R, Beighton P, Ramesar R (1994b) A new locus for 
autosomal dominant retinitis pigmentosa on the short arm of 
chromosome 17. Hum. Mol. Genet. 3: 915-918. 
Greenberg J and Peters A (1995) Genetic blindness: macular 
dystrophies and retinitis pigmentosa S. Afri. Med. J. 85: 6492­
6493. 
Greenberg J, Beatty S, Soltau H, Bryer A (1996): Huntington disease 
and late onset spinocerebellar ataxias: A predictive testing service 
in Cape Town. CME 16: 1364-1367. 
Gregory-Evans K, Kelsell RE, Gregory-Evans CY, Downes SM, Fitzke 
FW, Holder GE, Simunovic M, Mollon JD, Taylor R, Hunt DM, et 
al. (2000): Autosomal dominant cone-rod retinal dystrophy 
(CORD6) from heterozygous mutation of GUCY2D, which encodes 
retinal guanylate cyclase. Ophthalmology 107(1): 55-61. 











acids. Nat Genet 5(2): 111-117. 
Gu SM, Thompson DA, Srikumari CR, Lorenz B, Finckh U, Nicoletti A, 
Murthy KR, Rathmann M, Kumaramanickavel G, Denton MJ, Gal 
A (1997): Mutations in RPE65 cause autosomal recessive 
childhood-onset severe retinal dystrophy. Nat Genet 17(2): 194­
197. 
Gu S, Kumaramanickavel G, Srikumari CR, Denton MJ, Gal A (1999): 
Autosomal recessive retinitis pigmentosa locus RP28 maps 
between D2S1337 and D2S286 on chromosome 2p11-p15 in an 
Indian family. J Med Genet 36(9): 705-707. 
Guillonneau X, Piriev NI, Danciger M, Kozak CA, Cideciyan AV, 
Jacobson SG, Farber DB (1999): A nonsense mutation in a novel 
gene is associated with retinitis pigmentosa in a family linked to 
the RP1locus. Hum Mol Genet 8(8): 1541-1546. 
Gyapay G, Morissette J, Vignal A, Dib C, Fizames C, Millasseau P, Marc 
S, Bernardi G, Lathrop M, Weissenbach J (1994): The 1993-94 
Genethon human genetic linkage map. Nat Genet 7: 246-339. 
Hagstrom SA, North MA, Nishina PL, Berson EL, Dryja (1998): 
Recessive mutations in the gene encoding the tubby-like protein 
TULP1 in patients with retinitis pigmentosa. Nat Genet 18(2): 
174-176. 
Hameed A, Khaliq S, Ismail M, Anwar K, Ebenezer ND, Jordan T, Mehdi 
SQ, Payne AM, Bhattacharya SS (2000): A novel locus for Leber 
congenital amaurosis (LCA4) with anterior keratoconus 




















Hardcastle AJ, David-Gray ZK, Jay M, Bird AC, Bhattacharya SS 
(1997): Localization of CSNBX (CSNB4) between the retinitis 
pigmentosa loci RP2 and RP3 on proximal Xp. Invest Ophthalmol 
Vis Sci 38 (13): 2750-2755. 
Hmani M, Ghorbel A, Boulila-Elgaied A, Ben Zina Z, Kammoun W, Drira 
M, Chaabouni M, Petit C, Ayadi H (1999): A novel locus for Usher 
syndrome type II, USH2B, maps to chromosome 3 at p23-24.2. 
Eur J Hum Genet 7(3): 363-367. 
Hotta Y, Benzer S (1970): Genetic dissection of the Drosophila nervous 
system by means of mosaics. Proc Natl Acad Sci 67(3): 1156-63. 
Huang SH, Pittler SJ, Huang X, Oliveira L, Berson E, Dryja TP (1995): 
Autosomal recessive retinitis pigmentosa caused by mutations in 
the a-subunit of rod cGMP phosphodiesterase. Nat Genet 11: 
468-471. 
Humayun M, Propst R, de Juan E Jr, McCormick K, Hickingbotham D 
(1994): Bipolar surface electrical stimulation of the vertibrate 
retina. Arch Ophthalmol112: 110-11'6. 
Hurley JB, Dizhoor AM, Ray S, Stryer L (1993): Recoverin's 
role:conclusion withdrawn. Science 260 (5109): 740. 
Ingelhearn CF, Carter SA, Keen TJ, Lindsey J, Stephenson AM, Bashir 
R, AI-Maghtheh M, Moore AT, Jay M, Bird AC, et al. (1993): A new 
locus for autosomal dominant retinitis pigmentosa on 
, 
chromosome 7p. Nature Genet. 4: 51-58. 
Inglehearn CF (1998): Molecular genetics of human retinal dystrophies. 











Jansen GA, Ofman R, Ferdinandusse S, Ijlst L, Muijsers AO, Skjeldal 
OH, Stokke 0, Jakobs C, Besley GT, Wraith JE, Wanders RJ 
(1997): Refsum disease is caused by mutations in the phytanoyl­
CoA hydroxylase gene. Nat Genet 17(2}: 190-193. 
Jay M (1982): On the heredity of retinitis pigmentosa. Br J Ophthalmol 
66: 405-416. 
Jay M, Jay B (1982): Families with retinitis pigmentosa: problems in the 
analysis of sporadic, simplex and multiplex cases. 
Ophthalmologica 185(2): 61-64. 
Jay M, Evans K (1996): Retinal dystrophies and genetic counselling. 
Acta Ophthalmol 219: 5-7. 
Jordan SA, Farrar GJ, Kenna P, Humphries MM, Sheils DM, Kumar­
Singh R, Sharp EM, Soriano N, Ayuso C, Benitez J, et al. (1993): 
Localiization of an autosomal dominant retinitis pigmentosa gene 
• to chromosome 7q. Na~ure Genet. 4: 54-58. 
Kajiwara K, Berson EL, Dryja TP (1994): Digenic retinitis pigmentosa 
due to the mutation at the unlinked peripherin/RDS and ROMI 
loci. Science 264: 1604-1608. 
Kaplan J, Gerber S, Bonneau D, Rozet JM, Delrieu 0, Briard ML, 
Dollfus H, Ghazi I, Dufier JL, Frezal J, et al. (1992): A gene for 
Usher syndrome type I (USHIA) maps to chromosome 14q. 
Genomics 14(4}: 979-987. 
Kaplan J, Gerber S, Larget-Piet D, Rozet JM, Dollfus H, Dufier JL, 
Odent S, Postel-Vinay A, Janin N, Briard ML, et aI., (1993): A 
gene for Stargardt's disease (fundus flavimaculatus) maps to the 











Kelsell RE, Evans K, Gregory CY, Moore AT, Bird AC, Hunt DM (1997): 
Localisation of a gene for dominant cone-rod dystrophy (CORD6) 
to chromosome 17p. Hum Mol Genet 6 (4):597-600. 
Kelsell RE, Gregory-Evans K, Payne AM, Perrault I, Kaplan J, Yang RB, 
Garbers DL, Bird AC, Moore AT, Hunt DM (1998): Mutations in 
the retinal guanylate cyclase (RETGC-1) gene in dominant cone­
rod dystrophy. Hum Mol Genet 7(7): 1179-84. 
Kimberling WJ, Weston MD, Moller C, Davenport SL, Shugart YY, 
Priluck lA, Martini A, Milani M, Smith RJ (1990): Localization of 
Usher syndrome type II to chromosome 1q. Genomics 7(2): 245­
249. 
Kimberling WJ, Moller CG, Davenport S, Priluck lA, Beighton PH, 
Greenberg J, Reardon W, Weston MD, Kenyon JB, Grunkemeyer 
JA, et aI. (1992): Linkage of Usher syndrome type I gene (USH1B) 
to the long arm of chromosome 11. Genomics 14(4): 988-994. 
Kimberling WJ, Orten D, Pieke-Dahl S (2000): Genetic heterogeneity of 
Usher syndrome. Adv Otorhinolaryngol 56: 11-18. 
Knowles JA, Shugart Y, Banerjee P, Gilliam TC, Lewis CA, Jacobson SG, 
Ott J (1994). Identification of a locus, distinct from RDS­
peripherin, for autosomal recessive reinitis pigmentosa on 
chromosome 6p. Hum Mol Genet 3: 1401-1403. 
Kojis TL, Heinzmann C, Flodman P, Ngo JT, Sparkes RS, Spence MA, 
Bateman JB, Heckenlively JR (1996): Map refinement of locus 
RP13 to human chromosome 17p13.3 in a second family with 












Krumpaszky HG, Klauss V (1996): Epidemiology of blindness and eye 
disease. Ophthalmologica 210(1): 1-84. 
Kumar R, Chen S, Scheurer D, Wang QL, Duh E, Sung CH, Rehemtulla 
A, Swaroop A, Adler R, Zack DJ (1996): The bZIP transcription 
factor Nrl stimulates rhodopsin promoter activity in primary 
retinal cell cultures. J BioI Chern 271(47): 29612-8. 
Kumar-Singh R, Farrar GJ, Mansergh F, Kenna P, Bhattacharya S, Gal 
A, Humphries P (1993): Exclusion of the involvement of all known 
Retinitis Pigmentosa loci in the disease present in a family of Irish 
origin provides evidence for a sixth autosomal dominant locus 
(RP8). Hum. Mol. Genet. 2: 875-878. 
Kwitek-Black AE, Carmi R, Duyk GM, Buetow KH, Elbedour K, Parvari 
R, Yandava CN, Stone EM, Sheffield VC (1993): Linkage of 
Bardet-Biedl syndrome to chromosome 16q and evidence for non­
allelic genetic heterogeneity. Nat Genet 5(4): 392-396. 
Lathrop GM, Lalouel JM (1984): Easy calculations of Lod scores and 
genetic risks on small computers. Am. J. Hum. Genet. 36: 460­
465. 
LaVail MM, Yasumura D, Matthes MT, Lau-Villacorta C, Unoki K, Sung 
CH, Steinberg RH (1998): Protection of mouse photoreceptors by 
survival factors in retinal degenerations. Invest Ophthalmol Vis 
Sci 39(3): 592-602. 
Leppert M, Baird L, Anderson KL, Otterud B, Lupski JR, Lewis RA 
(1994): Bardet-Biedl syndrome is linked to DNA markers on 














Lese CM, Fantes JA, Riethman HC, Ledbetter DH (1999): 
Characterization of physical gap sizes at human telomeres. 
Genome Res 9(9): 888-894. 
Lester DH, Inglehearn CF, Bashir R, Ackford H, Esakowitz L, Jay M, 
Bird AC, Wright AF, Papiha SS, Bhattacharya SS (1990): Linkage 
to D3S47 (C 17) in one large autosomal dominant retinitis
• 	 pigmentosa family and exclusion in another: confirmation of 
genetic heterogeneity. Am J Hum Genet 47(3): 536-541. 
Leutelt J, Oehlmann R, Younus F, Vandenborn LI, Weber JL, Denton 
MN, Mehdi SQ, Gal A (1995): Autosomal recessive reitinits 
pigmentosa lcus maps on chromosome 1q in a large 
consanguineous family from Pakistan. Clin Genet 47: 122-124. 
Liou GI, Fong SL, Gosden J, van Tuinen P, Ledbetter DH, Christie S, 
Rout D, Bhattacharya S, Cook RG, Li Y, et al (1987): Human 
interstitial retinol-binding protein (IRBP): cloning, partial 
sequence, and chromosomal localization. Somat Cell Mol Genet 
13(4): 315-323. 
Liu X, Ondek B, Williams DS (1998): Mutant myosin VIla causes 
defective melanosome distribution in the RPE of shaker-1 mice. 
Nat Genet 19: 117-118. 
Liu XZ, Hope C, Liang CY, Zou JM, Xu LR, Cole T, Mueller RF, Bundey 
S, Nance W, Steel KP, Brown SD.(1999): A mutation (2314delG) in 
the Usher syndrome type IIA gene: high prevalence and 
phenotypic variation. Am J Hum Genet 64(4): 1221-1225. 
Lohmann D, Horsthemke B, Gillessen-Kaesbach G, Stefani FH, Hofler H 
(1992): Detection of small RBI gene deletions in retinoblastomp. 
by mUltiplex PCR and high-resolution gel electrophoresis. Hum 











Lotery AJ, Ennis KT, Silvestri G, Nicholl S, McGibbon D, Collins AD, 
Hughes AE (1996): Localisation of a gene for central areolar 
choroidal dystrophy to chromosome 17p. Hum Mol Genet 5(5): 
705-708. 
Loyer M, Pina AL, EI-Hilahl H, Vallelado A, Lee Y, Zhu D, Maumenee I, 
Koekenkoop R (1998): Novel mutations in the retinal guanylyl 
cyclase gene in new populations of patients with leber's 
congenital amaurosis. IOVS 39(4): S295. 
Lyness AL, Ernst W, Quinlan MP, Clover GM, Arden GB, Carter RM, 
Bird AC, Parker JA (1985): A clinical, psychophysical, and 
electroretinographic survey of patients with autosomal dominant 
retinitis pigmentosa. Br J OphthalmoI69(5): 326-339. 
Martens UM, Zijlmans JM, Poon SS, Dragowska W, Yui J, Chavez EA, 
,ward RK, Lansdorp PM (1998): Short telomeres on human 
chromosome 17p. Nat Genet 18(1): 76-80. 
Martinez-Mir A, Paloma E, Allikmets R, Ayuso C, del Rio T, Dean M, 
Vilageliu L, Gonzalez-Duarte R, Ba1cells S (1998): Retinitis 
pigmentosa caused by a homozygous mutation in the Stargardt 
disease gene ABCR. Nat Genet 18(1): 11-12. 
Massof RW, Finkelstein D (1981): Two forms of autosomal dominant 
primary retinitis pigmentosa. Doc Ophthalmol 51: 289-346. 
Matsumoto-Suzuki E, Hirosawa K, Hotta Y (1989): Structure of the 
subrhabdomeric cisternae in the photoreceptor cells of Drosophila 
melanogaster. J NeurocytoI18(1): 87-93. 
Maw MA, Kennedy B, Knight A, Bridges R, Roth KE, Mani EJ, 











Mutation of the gene encoding cellular retinaldehyde-binding 
protein in autosomal recessive retinitis pigmentosa. Nature Genet 
17: 198- 200. 
McLaughlin ME, Sandberg MA, Berson EL, Dryja TP (1993): Recessive 
mutations in the gene encoding the beta-subunit of rod 
phosphodiesterase in patients with retinitis pigmentosa. Nat 
Genet 4(2): 130-134. 
McLaughlin ME, Ehrhart TL, Berson EL, Dryja TP (1995). Mutation 
spectrum of the gene encoding the beta subunit of rod 
phosophodiesterase among patients with autosomal recessive 
retinitis pigmentosa. Proc Natl Acad Sci USA 92: 3249-3253. 
McWilliam P, Farrar GJ, Kenna P, Bradley DG, Humphries MM, Sharp 
EM, McConnell, DJ, Lawler M, Sheils D, Ryan C, Stevens K, 
Daiger SP, Humphries P (1989): Autosomal dominant retinitis 
, pigmentosa (ADRP): localization of an ADRP gene to the long arm 
of chromosome 3. Genomics 5 (3): 619-622. 
Meindl A, Dry K, Herrmann K, Manson F, Ciccodicola A, Edgar A, 
Carvalho MRS, Achatz H, Hellebrand H, Lennon A, Migliaccio C, 
Porter K, Zrenner E, Bird A, Jay M, Lorenz B, Wittwer B, D'Urso 
M, Meitinger T, Wright A (1996): A gene (RPGR) with homology to 
the RCC1.guanine nucleotide exchange factor is mutated in X­
linked retinitis pigmentosa (RP3). Nature Genet 13: 35-42. 
Meire FM, Bergen AA, De Rouck A, Leys M, Delleman JW (1994): X 
linked progressive cone dystrophy. Localisation of the gene locus 
to Xp21-p11.1 by linkage analysis. Br J Ophthalmol 78(2): 103­
108. 
Molday R, Hicks D, Molday L (1987): Peripherin. A rim-specific 











Vis Sci 28:50-60. 
Murakami A, Yajima T, Inana G (1992): Isolation of human retinal 
genes: recoverin cDNA and gene. Biochem Biophys Res Commun 
187( 1): 234-244. 
Nakazawa M, Wada Y, Tarnai M (1998): Arrestin gene mutations in 
autosomal recessive retinitis pigmentosa. Arch Ophthalmol 
116(4): 498-501. 
Naylor HM, Newcomer ME (1999): The structure of human retinol­
binding protein (RBP) with its carrier protein transthyretin reveals 
an interaction with the carboxy terminus of RBP. Biochemistry 
38(9): 2647-2653. 
Ngo JT, Klisak I, Sparkes RS, Mohandas T, Yamaki K, Shinohara T, 
Bateman JB (1990): Assignment of the S-antigen gene (SAG) to 
human chromosome 2q24-q37. Genomics 7(1): 84-87. 
Ngo JT, Bateman JB, Klisak I, Mohandas T, Van Dop C, Sparkes RS 
(1993): Regional mapping of a human rod alpha-transducin 
(GNAT1) gene to chromosome 3p22. Genomics 18(3): 724-725. 
Nichols, BE, Sheffield, VC, Vandenburgh K, Drack, AV, Kimura AE, 
Stone EM (1993): Butterfly-shaped pigment dystrophy of the fovea 
caused by a point mutation in codon 167 of the RDS gene. Nature 
Genet 3: 202-207. 
Nickerson JM, Li GR, Lin ZY, Takizawa N, Si JS, Gross EA (1998): 
Structure-function relationships in the four repeats of human 











Oliveira L, Miniou P, Viegas-Pequignot E, Rozet JM, Dollfus H, Pittler SJ 
(1994): Human retinal guanylate cyclase (GUC2D) maps to 
chromosome 17p13.1. Genomics 22: 478-81. 
Oswald AH, GoldblattJ, Sampson G, Clokie R, Beighton P (1985): 
Retinitis pigmentosa in South Africa. S Afri Med J 68: 863-866. 
Ott J, Bhattacharya SS, Chen JD, Denton MJ, Donald J, Dubay' C, 
Farrar GJ, Fishman GA, Frey D, GalA, Humphries P, Jay B, Jay 
M, Litt M, Machler M, Musarella M, Neugebauer M, Wright AF 
(1990): Localizing multiple X chromosome-linked retinitis 
pigmentosa loci using multilocus homogeneity tests. Proc Natl 
Acad Sci USA 2: 701-704 .. 
Perrault I, Rozet JM, Calvas P, Gerber S, Camuzat A, Dollfus H, 
Chatelin S, Souied E, Ghazi I, Leowski C, Bonnemaison M, Le 
Paslier D, Frezal J, Dufier JL, Pittler S, Munnich A, Kaplan J 
(1996): Retinal-specific guanylate cyclase gene mutations in 
Leber's congenital amaurosis. Nat Genet 14(4): 461-4. 
Perrault I, Rozet JM, Gerber S, Kelsell RE, Souied E, Cabot A, Hunt DM, 
Munnich A, Kaplan J (1998): A retGC-1 mutation in autosomal 
dominant cone-rod dystrophy. Am J Hum Genet 63(2): 651-654. 
Phelan JK, Bok D (2000): A brief review of retinitis pigmentosa and the 
identified retinitis pigmentosa genes. Mol Vis 6: 116-124. 
Picoult-Newberg L, Ideker TE, Pohl MG, Taylor SL, Donaldson MA, 
Nickerson DA, Boyce-Jacino M (1999): Mining SNPs from EST 
databases.Genome Res 9(2): 167-174. 
Pieke-Dahl S, Moller CG, Kelley PM, Astuto LM, Cremers CW, Gorin. 











syndrome type II: localisation to chromosome 5q.. J Med Genet 
37(4): 256-262. 
Pittler SJ, Baehr W, Wasmuth JJ, McConnell DG, Champagne MS, 
vanTuinen P, Ledbetter D, Davis RL (1990): Molecular 
characterization of human and bovine rod photoreceptor cGMP 
phosphodiesterase alpha-subunit and chromosomal localization 
of the human gene. Genomics 6(2): 272-283 . 
Riley J, Butler R, Ogilvie D, Finniear R, Jenner D, Powell S, Anand R, 
Smith JC, Markham AF (1990): A novel, rapid method for the 
isolation of terminal sequences from yeast artificial chromosome 
(YAC) clones. Nucl Acids Res 18: 2887-2890. 
Rocchi M, Covone A, Romeo G, Faraonio R, Colantuoni V (1989): 
Regional mapping of RBP4 to 10q23-q24 and RBPI to 3q21-q22 
in man. Somat. Cell Molec Genet 15: 185-190. 
Rogers GR, Rizzo WB, Zlotogorski A, Hashem N, Lee M, Compton JG, 
Bale SJ (1995): Genetic homogeneity in Sjogren-Larsson 
syndrome: linkage to chromosome 17p in families of different 
non-Swedish ethnic origins. Am J Hum Genet 57(5): 1123-1129. 
Rosenfeld PJ, Cowley GS, McGee TL, Sandberg MA, Berson EL, Dryja TP 
(1992). A null mutation in the rhodopsin gene causes rod 
photoreceptor dysfunction and autosomal recessive retinitis 
pigmentosa. Nat Genet 1: 209-213. 
Ross MH, Romrell W (1989): Histology: a text and atlas. Williams and 
Wilken, Baltimore, USA. 
Ruiz A, Borrego S, Marcos I, Antinolo G (1998): A major locus for 
autosomal recessive retinitis pigmentosa on 6q, determined by 











gamma-aminobutyric acid-receptor clusters. Am J Hum Genet 
62(6): 1452-1459. 
Sambrook J, Fritsch EF, Maniatis T (1989): Molecular cloning: A 
laboratory manual. Cold Spring Harbour, New York, USA. 
Sankila EM, Pakarinen L, Kaariainen IH, Aittomaki K, Karjalainen S, 
Sistonen P, de la Chapelle A (1995): Assignment of an Usher 
syndrome type III (USH3) gene to chromosome 3q. Hum Mol 
Genet 4: 93-98. 
Shastry BS (1994): Retinitis pigmentosa and related disorders: 
phenotypes of rhodopsin and peripherinjRDS mutations. Am J 
Med Genet 52: 467-474. 
Shastry BS (1997): Signal transduction in the retina and inherited 
retinopathies. Cell Mol Life Sci 53: 419-429. 
Sheedlo HJ, Li LX, Turner JE. (1989): Functional and structural 
characteristics of photoreceptor cells rescued in RPE-cell grafted 
retinas of RCS dystrophic rats. Exp Eye Res 48: 841-854. 
Sheffield VC, Carmi R, Kwitek-Black A, Rokhlina T, Nishimura D, Duyk 
GM, Elbedour K, Sunden SL, Stone EM (1994): Identification of a 
Bardet-Biedl syndrome locus on chromosome 3 and evaluation of 
an efficient approach to homozygosity mapping. Hum Mol Genet 
3: 1331-1335. 
Shyjan AW, de Sauvage FJ, Gillett NA, Goeddel DV,.Lowe DG (1992): 
Molecular cloning of a retina-specific membrane guanylyl cyclase. 
Neuron 9(4): 727-37. 
Small KW, Syrquin M, Mullen L, Gehrs K (1996): Mapping of autosomal 











Lee EC, Kimberling WJ, Daiger SP, Pelias MZ, Keats BJ, Jay M, 

Bird A, Reardon W, Guest M, et al. (1992): Localization of two 

genes for Usher syndrome type I to chromosome 11. 

Genomics 14(4): 995-1002. 

Smith RJ, Lee EC, Kimberling WJ, Daiger SP, Pelias MZ, Keats BJ, Jay 
M, Bird A, Reardon W, Guest M, et al. (1992): Localization of two 
genes for Usher syndrome type I to chromosome 11. Genomics 
14(4): 995-1002. 
Smith RJ, Berlin CI, Hejtmancik JF, Keats BJB, Kimberling WJ, Lewis 
RA, Moller CG, Pelias MZ, Tranebjaerg (1994): Clinical diagnosis 
of the Usher syndromes. Amer J Med Genet 50: 32-38. 
Sohocki MM, Sullivan LS, Mintz-Hittner HA, Birch D, Heckenlively JR, 
Freund CL, McInnes RR, Daiger SP (1998): A range of clinical 
phenotypes associated with mutations in CRX, a photoreceptor 
transcription-factor gene. Am J Hum Genet 63(5): 1307-1315. 
Sohocki MM, Malone KA, Sullivan LS, Daiger SP (1999): Localisation of 
retina/pineal-expressed sequences: identification of novel 
candidate genes for inherited retinal disorders. Genomic 58: 29­
33. 
Souied EH, Sales MJ, Soubrane G, Coscas G, Bigorie B, Kaplan J, 
Munnich A, Rotig A (1998): Macular dystrophy, diabetes, and 
deafness associated with a large mitochondrial DNA deletion. Am 
J Ophthalmol 125(1): 100-103. 
Stack M, Jones D, White G, Liscia DS, Venesio T, Casey G, Crichton D, 
Varley J, Mitchell E, Heighway J, et al. (1995): Detailed mapping 
and loss of heterozygosity analysis suggests a suppressor lotus 
involved in sporadic breast cancer within a distal region of .. 











Steele FR, Chader GJ, Johnson LV, Tombran-Tink J (1993): Pigment 
epithelium-derived factor: neurotrophic activity and identification 
as a member of the serine protease inhibitor gene family. Proc 
Natl Acad Sci 90(4): 1526-1530. 
Stone EM, Nichols BE, Streb LM, Kimura AE, Sheffield VC (1992): 
Genetic linkage of vitelliform macular degeneration (Best's 
disease) to chromosome 11q13. Nat Genet 1: 246-250. 
Stone EM, Nichols BE, Kimura AE, Weingeist TA, Drack A, Sheffield VC 
(1994): Clinical features of a Stargardt's-like domimant 
progressive macular dystrophy with gentic linkage to'chromosome 
6q. Arch Ophthlmol 112: 765-772. 
Strachan T and Read AP (1996) Human Molecular Genetics (First 
edition) BIOS Scientific Publishers Ltd. 
Stryer L (1988): Molecular basis of visual excitation. Cold Spring 
Harbour Symposia on Quantitative Biology, vol LUI. 
Stryer L (1991): Visual excitation and recovery. J BioI Chern 266(17): 
10711-10714. 
Sullivan LS, Heckenlively JR, Bowne SJ, Zuo J, Hide WA, Gal A, Denton 
M, Inglehearn CF, Blanton SH, Daiger SP (1999): Mutations in a . 
novel retina-specific gene cause autosomal dominant retinitis 
pigmentosa. Nat Genet 22(3): 255-259. 
Tarttelin EE, Plant C, Weissenbach J, Bird AC, Bhaatacharya SS, 
Ingelhearn CF (1996): A new family linked to the RP13 locus for 
autosomal dominant retinitis pigmentosa on distal 17p. J Med 











Teague ~W, Aldred MA, Jay M, Dempster M, Harrison C, Carothers AD. 
Hardwick W, Evans HJ, Strain L, Brock DJH, Bubdey S, Jay B, 
Bird AC, Bhattacharya SS, Wright AF (1994): Heterogeneity 
analysis in 40 X-linked retinitis pigmentosa families. Am J Hum 
Genet 55: 105-111. 
Terwilliger JD, Ott J, (1994): Handbook of human genetic linkage. John 
Hopkins University press. Baltimore, USA. 
Tombran-Tink J, Johnson LV (1989): Neuronal differentiation of 
retinoblastoma cells induced by medium conditioned by human 
RPE cells. Invest Ophthalmol Vis Sci 30(8): 1700-1707. 
Tombran-Tink J, Pawar H, Swaroop A, Rodriguez I, Chader GJ (1994): 
Localization of the gene for pigment epithelium-derived factor 
(PEDF) to chromosome 17p13.1 and expression in cultured 
human retinoblastoma cells. Genomics 19(2): 266-272. 
Tombran-Tink J, Shivaram SM, Chader GJ, Johnson LV, Bok D (1995): 
Expression, secretion, and age-related downregulation of pigment 
epithelium-derived factor, a serpin with neurotrophic activity. 
Neurosci 15(7): 4992-5003. 
Travis GH, Bren an MB, Danielson PE, Kozak CA, Sutcliffe JG (1989): 
Identification of a photoreceptor-specific mRNA encoded by the 
gene responsible for retinal degeneration slow (rds). Nature 
338(6210): 70-73. 
Valverde D, Solans T, Grinberg D, Ba1cells S, Vilageliu L, Bayes M, 
Chivelet P, Besmond C, Goossen M, Gonalez Duarte R, Baiget M 
(1996). A novel mutation in exon 17 of the beta-subunit of rod 
phosophodiesterase in two RP sisters of a consanguineous family. 











Valverde D, Vazquez-Gundin F, del Rio E, Calaf M, Fernandez JL, 
Baiget M (1998): Analysis of the IRBP gene as a cause of RP in 45 
ARRP Spanish families. Autosomal recessive retinitis pigmentosa. 
Interstitial retinol binding protein. Spanish Multicentric and 
Multidisciplinary Group for Research into Retinitis Pigmentosa. 
Ophthalmic Genet 19(4): 197-202. 
van Soest S, te Nijenhuis S, van den Born LI, Bleeker-Wagemakers EM, . 
Sharp E, Sandkuijl LA, Westerveld A, Bergen AA (1996): Fine 
mapping of the autosomal recessive retinitis pigmentosa locus 
(RP12) on chromosome 1q; exclusion of the phosducin gene 
(PDC). Cytogenet Cell Genet 73(1-2): 81-85. 
Vandenplas S, Wiid I, Grobler:-Rabie A, Brebner K, Ricketts M, Wallis G, 
Bester A, Boyd C, Mathew C (1984): Blot hybridization analysis of 
genomic DNA. J Med Genet 21: 164-172. 
Vihtelic TS, Goebl M, Milligan S, O'Tousa JE, Hyde DR (1993): 
Localization of Drosophila retinal degeneration B, a membrane­
associated phosphatidylinositol transfer protein. J Cell BioI 
122(5): 1013-22 . 
Wayne S, Der Kaloustian VM, Schloss M, Polomeno R, Scott DA, 
HejtmancikJF, Sheffield VC, Smith RJ (1996): Localization of the 
Usher syndrome type ID gene (Ush1D) to chromosome 10. Hum 
Mol Genet 5(10): 1689-1692. 
Weber B, Riess 0, Hutchinson G, Collins C, Lin BY, Kowbel D, Andrew 
S, Schappert K, Hayden MR (1991): Genomic organization and 
complete sequence of the human gene encoding the beta-subunit 
of the cGMP phosphodiesterase and its localisation to 4p 16.3. 











Weber BHF, Vogt G, Pruett RC, Stohr H, Felbor U (1994): Mutations in 
the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients 
with Sorsby's fundus dystrophy. Nature Genet 8: 352-356. 
Wei! D, Blanchard S, Kaplan J, Guilford P, Gibson F, Walsh J, Mburu 
P, Varela A, Levilliers J, Weston MD, et al. (1995): Defective 
myosin VIlA gene responsible for Usher syndrome type lB. 
Nature 374(6517): 60-61. 
Weleber RG, Carr RE, Murphy WH, Sheffield VC, Stone EM (1993): 
Phenotypic variation including retinitis pigmentosa, pattern 
dystrophy, and fundus flavimaculatus in a single family with a 
deletion of codon 153 or 154 of the peripherinjRDS gene. Arch 
Ophthalmol 111: 1531-1542. 
Wells J, Wroblewski J, Keen J, Inglehearn C, Jubb C, Eckstein A 
(1993): Mutations in the human retinal degeneration slow (rds) 
gene can cause either retinitis pigmentosa or macular dystrophy. 
Nature Genet 3: 213-217. 
Wiechmann AF, Hammarback JA (1993): Expression of recoverin mRNA 
in the human retina: localization by in situ hybridization. Exp 
Eye Res 57(6): 763-9. 
Wiechmann AF, Akots G, Hammarback JA, Pettenati MJ, Rao PN, 
Bowden DW (1994a): Genetic and physical mapping of human 
recoverin: a gene expressed in retinal photoreceptors. Invest Oph 
Vis Sci 35(2): 325-331. 
Wiechmann AF, Haro KC, Bowden DW (1994b): Three microsatellite 
polymorphisms at the recoverin locus on chromosome 17. Hum 











Wilson CJ, Applebury ML (1993): Arresting G-protein coupled receptor 
activity. Curr BioI 3: 683-686. 
Wyllie AH, Kerr JFK, Currie AR (1980): Cell death: the significance of 
apoptosis. Int Rev Cytol 68: 251-306. 
Xiang M, Ge T, Tomlinson CR, Klein WH (1991): Structure and 
promoter activity of the LpS 1 genes of Lytechinus pictus. 
Duplicated exons account for LpS 1 proteins with eight calcium 
binding domains. J BioI Chern 266(16):10524-33. 
Xu S, Yu Schartz M, Rosenberg T, Gal A (1996): A ninth locus (RP18) for 
autosomal dominant retinitis pigmentosa maps in the pericentric 
region of chromosome 1. Hum Mol Genet 5: 1193-1197. 
Yamamoto S, Sippel KC, Berson EL, Dryja TP (1997): Defects in the 
rhodopsin kinase gene in the Oguchi form of stationary night 
blindness. Nat Genet 15(2): 175-178. 
Yang RB, Foster DC, Garbers DL, Fulle HJ (1995): Two membrane 
forms of guanylyl cyclase found in the eye. Proc Natl Acad Sci 92: 
602-606. 
Yang RB, Fulle HJ, Garbers DL (1996): Chromosomal localisation and 
genomic organisation of genes encoding guanylyl cyclase 
receptors expressed in olfactory sensory neurons and retina. 
Genomics 31: 367-372. 
Yang-Feng TL, Swaroop A (1992): Neural retina-specific leucine zipper 
gene NRL (D 14S46E) maps to human chromosome 14q11.1­











Yau K (1994): Phototransduction mechanisms in retinal rods and cones. 
Invest Ophthalmol Vis Sci 35(1): 9-30. 
Zhang K, Bither PP, Park R, Donoso LA, Seidman JG, Seidman CE 
(1994): A dominant Stargardt's macular dystrophy locus maps to 
chromosome 13q34. Arch Ophthalmol 112: 759-764. 
Zhang K, Nguyen TE, Crandall A, Donoso LA (1995): Genetic and 
molecular studies of macular dystophies: recent developments. 
Surv Ophthalmol 40 (1): 51-61. 
190 
